Project Name,Region,Country,Site ID,Subject ID,Latest Visit (SV) (Source: Rave EDC: BO4),Subject Status (Source: PRIMARY Form),Input files,,,,,,,,,CPMD,,,,,,,,,,,,,,,,,,,,,,SSM,,,,,
,,,,,,,Missing Visits,Missing Page,# Coded terms,# Uncoded Terms,# Open issues in LNR,# Open Issues reported for 3rd party reconciliation in EDRR,Inactivated forms and folders,# eSAE dashboard review for DM,# eSAE dashboard review for safety,Visit status,Page status (Source: (Rave EDC : BO4)),,,,,Queries status (Source:(Rave EDC : BO4)),,,,,,,,Page Action Status (Source: (Rave EDC : BO4)),,,,,,Protocol Deviations (Source:(Rave EDC : BO4)),,PI Signatures (Source: (Rave EDC : BO4)),,,,,
,,,,,,,,,,,,,,,,# Expected Visits (Rave EDC : BO4),# Pages Entered,# Pages with Non-Conformant data,# Total CRFs with queries & Non-Conformant data,# Total CRFs without queries & Non-Conformant data,% Clean Entered CRF,# DM Queries,# Clinical Queries,# Medical Queries,# Site Queries,# Field Monitor Queries,# Coding Queries,# Safety Queries,#Total Queries,# CRFs Require Verification (SDV),# Forms Verified,# CRFs Frozen,# CRFs Not Frozen,# CRFs Locked,# CRFs Unlocked,# PDs Confirmed,# PDs Proposed,# CRFs Signed,CRFs overdue for signs within 45 days of Data entry,CRFs overdue for signs between 45 to 90 days of Data entry,CRFs overdue for signs beyond 90 days of Data entry,Broken Signatures,CRFs Never Signed
Responsible LF for action,,,,,,,,,,,,,,,,,,Site/CRA,,,,DM,CSE/CDD,CDMD/Medical Lead,Site/CRA,CRA,Coder,Safety Team,,CRA,,,DM,,,CD LF,,Investigator,,,,,
Study 4,ASIA,KOR,Site 1,Subject 1,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,326,0,,,,1,0,0,0,0,0,0,1,17,264,0,0,0,0,1,0,279,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 169,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 752,Cycle 3 Week 3 (1),Discontinued,,,,,,,,,,13,113,0,,,,0,0,0,0,0,0,0,0,5,26,0,0,0,0,1,0,91,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 753,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 754,Post CYCLE 6 Visit 2 (1),Discontinued,,,,,,,,,,29,217,0,,,,0,0,0,0,0,0,0,0,1,54,0,0,0,0,4,0,185,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 755,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,305,0,,,,0,0,0,0,0,0,0,0,8,84,0,4,0,0,1,0,261,5,0,0,1,4
Study 4,ASIA,KOR,Site 1,Subject 756,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,286,0,,,,0,0,0,0,0,0,0,0,9,82,0,0,0,0,1,0,240,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 757,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,287,0,,,,0,0,0,0,0,0,0,0,7,71,0,0,0,0,1,0,246,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 758,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,295,0,,,,0,0,0,0,0,0,0,0,14,83,0,0,0,0,2,0,246,1,0,0,1,0
Study 4,ASIA,KOR,Site 1,Subject 759,Unplanned Visit (7),Discontinued,,,,,,,,,,29,248,0,,,,0,0,0,0,0,0,0,0,3,64,0,0,0,0,1,0,201,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 760,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,288,0,,,,0,0,0,0,0,0,0,0,10,88,0,0,0,0,1,0,242,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 761,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,0,13,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 762,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,276,0,,,,0,0,0,0,0,0,0,0,11,69,0,0,0,0,1,0,237,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 763,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,268,2,,,,0,0,0,0,0,0,0,0,9,70,0,0,0,0,1,0,228,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 764,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,251,0,,,,0,0,0,0,0,0,0,0,7,61,0,0,0,0,1,0,214,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 765,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,258,0,,,,0,0,0,0,0,0,0,0,9,70,0,0,0,0,1,0,222,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 766,Screening,Screen Failure,,,,,,,,,,1,18,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,0,16,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 767,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,307,0,,,,0,0,0,0,0,0,0,0,17,70,8,0,0,0,2,0,252,4,0,0,0,4
Study 4,ASIA,KOR,Site 1,Subject 768,EOT1 (1),Discontinued,,,,,,,,,,14,103,0,,,,0,0,0,0,0,0,0,0,1,20,0,0,0,0,1,0,86,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 769,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,270,0,,,,0,0,0,0,0,0,0,0,13,56,0,0,0,0,3,0,230,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 770,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,253,0,,,,0,0,0,0,0,0,0,0,14,68,0,0,0,0,1,0,217,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 771,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,264,0,,,,0,0,0,0,0,0,0,0,9,69,0,0,0,0,1,0,228,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 772,Screening,Screen Failure,,,,,,,,,,1,19,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,0,16,0,0,0,0,0
Study 4,ASIA,KOR,Site 1,Subject 773,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,263,0,,,,0,0,0,0,0,0,0,0,8,63,0,0,0,0,1,0,227,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 6,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,314,0,,,,1,0,0,0,0,0,0,1,3,265,0,1,0,0,1,0,271,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 7,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,301,0,,,,0,0,0,0,0,0,0,0,3,98,0,0,0,0,0,0,254,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 8,Post CYCLE 6 Visit 1 (1),Discontinued,,,,,,,,,,28,209,0,,,,0,0,0,0,0,0,0,0,1,41,0,0,0,0,0,0,175,1,0,0,1,0
Study 4,ASIA,KOR,Site 3,Subject 102,EOT1 (1),Discontinued,,,,,,,,,,29,227,0,,,,0,2,0,0,0,0,0,2,3,57,0,1,0,0,0,0,187,1,0,0,1,0
Study 4,ASIA,KOR,Site 3,Subject 103,EOT1 (1),Discontinued,,,,,,,,,,23,204,0,,,,0,0,0,0,0,0,0,0,9,60,0,0,0,0,0,0,150,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 104,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 774,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,304,0,,,,1,0,0,0,0,0,0,1,4,106,0,2,0,0,0,0,265,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 775,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,295,0,,,,0,0,0,0,0,0,0,0,1,86,172,1,0,0,0,0,255,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 776,Cycle 4 Week 3_CO (1),On Trial,,,,,,,,,,54,375,0,,,,1,0,0,0,0,0,0,1,11,92,0,0,0,0,1,0,310,3,0,0,3,0
Study 4,ASIA,KOR,Site 3,Subject 777,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,328,0,,,,0,0,0,0,0,0,0,0,7,110,0,0,0,0,0,0,271,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 778,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,323,0,,,,0,0,0,0,0,0,0,0,5,114,0,0,0,0,0,0,269,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 779,Week 48 (1),Discontinued,,,,,,,,,,30,203,0,,,,0,0,0,0,0,0,0,0,4,44,0,3,0,0,0,0,164,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 780,30-DAY SAFETY FOLLOW UP_CO (1),Survival,,,,,,,,,,58,404,0,,,,0,0,0,0,0,0,0,0,9,106,0,0,0,0,0,0,329,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 781,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,300,0,,,,0,0,0,0,0,0,0,0,5,107,0,0,0,0,0,0,253,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 782,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,298,0,,,,0,0,0,0,0,0,0,0,7,116,0,0,0,0,0,0,242,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 783,Week 24 (1),Discontinued,,,,,,,,,,29,196,0,,,,0,0,0,0,0,0,0,0,1,37,0,0,0,0,0,0,165,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 784,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,267,0,,,,0,0,0,0,0,0,0,0,3,78,0,0,0,0,0,0,225,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 785,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,284,0,,,,0,0,0,0,0,0,0,0,19,96,0,0,0,0,0,0,219,0,0,0,0,0
Study 4,ASIA,KOR,Site 3,Subject 786,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 9,Cycle 6 Week 6 (1),Discontinued,,,,,,,,,,27,189,0,,,,0,0,0,0,0,0,0,0,3,147,0,0,0,0,1,0,151,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 10,Week 24 (1),Follow-Up,,,,,,,,,,39,319,0,,,,0,0,0,0,0,0,0,0,33,137,0,0,0,0,1,0,278,1,0,0,1,0
Study 4,ASIA,KOR,Site 4,Subject 105,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 106,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 787,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,303,0,,,,0,0,0,0,0,0,0,0,18,92,0,0,0,0,1,0,263,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 788,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,303,0,,,,0,0,0,0,0,0,0,0,18,85,0,0,0,0,1,0,264,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 789,Week 24 (1),Discontinued,,,,,,,,,,32,233,0,,,,0,0,0,0,0,0,0,0,1,54,0,0,0,0,1,0,199,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 790,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,287,0,,,,0,0,0,0,0,0,0,0,10,81,0,0,0,0,1,0,243,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 791,Unplanned Visit (2),Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,0,13,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 792,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,306,0,,,,0,0,0,0,0,0,0,0,18,77,0,0,0,0,1,0,266,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 793,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,287,0,,,,0,0,0,0,0,0,0,0,20,75,0,0,0,0,2,0,234,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 794,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 795,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,284,0,,,,0,0,0,0,0,0,0,0,16,85,0,0,0,0,1,0,234,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 796,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,311,0,,,,0,0,0,0,0,0,0,0,10,95,0,0,0,0,1,0,261,4,0,0,0,4
Study 4,ASIA,KOR,Site 4,Subject 797,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,269,0,,,,0,0,0,0,0,0,0,0,18,69,100,0,0,0,1,0,233,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 798,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,61,407,0,,,,5,2,0,0,0,0,0,7,12,91,0,0,0,0,1,0,338,7,0,0,5,2
Study 4,ASIA,KOR,Site 4,Subject 799,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,257,0,,,,0,0,0,0,0,0,0,0,17,68,0,0,0,0,1,0,222,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 800,Post CYCLE 6 Visit 1 (1),Discontinued,,,,,,,,,,28,218,0,,,,0,0,0,0,0,0,0,0,10,56,0,0,0,0,3,0,172,0,0,0,0,0
Study 4,ASIA,KOR,Site 4,Subject 801,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,34,274,0,,,,0,0,0,0,0,0,0,0,8,73,0,0,0,0,1,0,234,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 170,EOT 2 (1),Follow-Up,,,,,,,,,,45,361,0,,,,7,0,0,1,0,0,0,8,64,249,0,0,0,0,0,0,288,4,0,0,4,0
Study 4,ASIA,TWN,Site 43,Subject 171,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 172,Week 48 (1),Survival,,,,,,,,,,35,253,0,,,,0,0,0,0,0,0,0,0,3,55,0,0,0,0,1,0,218,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 802,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 803,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,291,0,,,,0,0,0,0,0,0,1,1,8,95,0,0,0,0,0,0,233,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 804,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,299,0,,,,0,0,0,0,0,0,0,0,6,107,0,0,0,0,0,0,247,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 805,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,289,0,,,,1,0,0,0,0,0,0,1,19,79,0,0,0,0,1,0,222,9,0,0,7,2
Study 4,ASIA,TWN,Site 43,Subject 806,Unplanned Visit_CO (4),Discontinued,,,,,,,,,,35,253,0,,,,1,0,0,0,0,0,0,1,5,50,0,0,0,0,0,0,204,0,0,0,0,0
Study 4,ASIA,TWN,Site 43,Subject 807,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,284,2,,,,0,0,0,0,0,0,0,0,9,97,0,0,0,0,0,0,230,1,0,0,1,0
Study 4,ASIA,TWN,Site 108,Subject 808,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 809,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,425,0,,,,0,0,0,0,0,0,0,0,15,256,0,0,0,0,2,0,361,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 810,Unplanned Visit (38),On Trial,,,,,,,,,,39,518,0,,,,4,0,0,0,0,0,0,4,9,105,0,0,0,0,1,0,433,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 811,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,384,0,,,,0,0,0,0,0,0,0,0,8,110,0,0,0,0,3,0,333,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 812,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 813,Screening,Discontinued,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,0,10,0,0,0,0,0,0,22,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 814,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,374,0,,,,0,0,0,0,0,0,0,0,21,265,0,0,0,0,0,0,310,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 815,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,311,0,,,,0,0,0,0,0,0,0,0,3,85,0,1,0,0,0,0,267,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 816,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,320,0,,,,0,0,0,0,0,0,0,0,16,114,0,0,0,0,0,0,265,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 817,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,292,0,,,,0,0,0,0,0,0,0,0,4,85,0,0,0,0,0,0,243,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 818,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,319,0,,,,0,0,0,0,0,0,0,0,15,91,0,0,0,0,1,0,265,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 819,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 820,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,362,0,,,,0,0,0,0,0,0,0,0,18,87,0,0,0,0,1,0,310,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 821,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 822,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,292,0,,,,1,0,0,0,0,0,0,1,14,96,0,0,0,0,0,0,246,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 823,Week 48 (1),Survival,,,,,,,,,,37,300,0,,,,0,0,0,0,0,0,0,0,9,108,0,0,0,0,0,0,246,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 824,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 825,Cycle 3 Week 1_CO (1),Discontinued,,,,,,,,,,39,370,0,,,,0,0,0,0,0,0,0,0,18,101,0,0,0,0,0,0,268,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 826,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,312,0,,,,0,0,0,0,0,0,0,0,11,82,0,0,0,0,1,0,268,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 827,Long term FU 2 (1),Discontinued,,,,,,,,,,27,191,0,,,,0,0,0,0,0,0,0,0,4,54,0,0,0,0,0,0,159,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 828,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,29,250,0,,,,0,0,0,0,0,0,0,0,8,51,0,0,0,0,0,0,201,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 829,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,291,0,,,,0,0,0,0,0,0,0,0,9,106,0,0,0,0,1,0,234,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 830,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,279,0,,,,0,0,0,0,0,0,0,0,17,79,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 831,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 832,EOT 2 (1),Discontinued,,,,,,,,,,42,389,0,,,,0,0,0,0,0,0,0,0,16,65,0,0,0,0,0,0,307,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 833,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,280,0,,,,0,0,0,0,0,0,0,0,10,75,0,0,0,0,0,0,242,0,0,0,0,0
Study 4,ASIA,TWN,Site 108,Subject 834,Unplanned Visit (4),Screen Failure,,,,,,,,,,1,19,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 190,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,341,0,,,,0,0,0,0,0,0,0,0,23,275,0,3,0,0,1,0,284,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 191,EOT1 (1),Discontinued,,,,,,,,,,28,210,0,,,,0,0,0,0,0,0,0,0,3,49,0,0,0,0,1,0,172,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 192,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,282,0,,,,0,0,0,0,0,0,0,0,11,126,0,0,0,0,0,0,238,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 193,Unplanned Visit (2),On Trial,,,,,,,,,,34,338,0,,,,0,0,0,0,0,0,0,0,33,109,0,1,0,0,0,0,268,3,0,0,3,0
Study 4,ASIA,SGP,Site 47,Subject 194,EOT1 (1),Discontinued,,,,,,,,,,20,169,0,,,,0,0,0,0,0,0,0,0,4,43,0,0,0,0,0,0,134,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 195,Week 24 (1),Follow-Up,,,,,,,,,,57,369,0,,,,0,0,0,0,0,0,0,0,6,71,0,0,0,0,0,0,295,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 196,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,273,0,,,,0,0,0,0,0,0,0,0,15,86,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 197,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 198,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,286,0,,,,0,0,0,0,0,0,0,0,13,71,0,0,0,0,1,0,236,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 199,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,260,0,,,,0,0,0,0,0,0,0,0,8,67,0,0,0,0,0,0,225,0,0,0,0,0
Study 4,ASIA,SGP,Site 47,Subject 200,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,271,0,,,,0,0,0,0,0,0,0,0,13,73,0,0,0,0,1,0,222,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 835,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,38,331,0,,,,0,0,0,0,0,0,0,0,9,280,4,1,0,0,0,0,282,1,0,0,1,0
Study 4,ASIA,SGP,Site 109,Subject 836,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 837,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 838,Post CYCLE 6 Visit 4 (1),Discontinued,,,,,,,,,,31,258,0,,,,0,0,0,0,0,0,0,0,3,62,0,0,0,0,1,0,209,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 839,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 840,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 841,Long term FU 2 (1),Discontinued,,,,,,,,,,36,312,0,,,,0,0,0,0,0,0,0,0,3,96,11,0,0,0,1,0,265,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 842,EOT1 (1),Follow-Up,,,,,,,,,,37,321,0,,,,3,0,0,0,0,0,0,3,31,91,0,0,0,0,0,0,269,1,0,0,1,0
Study 4,ASIA,SGP,Site 109,Subject 843,Week 48 (1),Survival,,,,,,,,,,35,294,0,,,,0,0,0,0,0,0,0,0,8,69,0,0,0,0,0,0,239,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 844,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,260,0,,,,0,0,0,0,0,0,0,0,7,65,0,0,0,0,0,0,223,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 845,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,277,0,,,,0,0,0,0,0,0,0,0,8,75,0,0,0,0,0,0,239,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 846,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,308,0,,,,0,0,0,0,0,0,0,0,7,89,0,1,0,0,1,0,258,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 847,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 848,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 849,Week 24 (1),Discontinued,,,,,,,,,,30,211,0,,,,0,0,0,0,0,0,0,0,3,54,0,0,0,0,0,0,171,0,0,0,0,0
Study 4,ASIA,SGP,Site 109,Subject 850,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,247,0,,,,0,0,0,0,0,0,0,0,7,57,0,0,0,0,1,0,211,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 17,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 18,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,329,0,,,,1,0,0,0,0,0,0,1,25,94,0,0,0,0,1,0,271,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 19,Post CYCLE 6 Visit 11 (1),Survival,,,,,,,,,,38,341,0,,,,0,0,0,0,0,0,0,0,8,281,0,1,0,0,1,0,291,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 851,EOT 2 (1),Discontinued,,,,,,,,,,55,438,0,,,,0,0,0,0,0,0,0,0,17,141,0,0,0,0,0,0,349,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 852,Post CYCLE 6 Visit 1 (1),Discontinued,,,,,,,,,,28,262,0,,,,0,0,0,0,0,0,0,0,22,82,0,0,0,0,0,0,184,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 853,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 854,Week 48 (1),Survival,,,,,,,,,,36,290,0,,,,1,0,0,0,0,0,0,1,10,83,0,0,0,0,0,0,233,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 855,Week 24 (1),Survival,,,,,,,,,,36,299,0,,,,0,0,0,0,0,0,0,0,7,92,0,0,0,0,0,0,249,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 856,Unplanned Visit_CO (1),On Trial,,,,,,,,,,39,373,0,,,,1,0,0,1,0,0,0,2,41,126,0,0,0,0,1,0,301,2,0,0,2,0
Study 4,EMEA,AUT,Site 10,Subject 857,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 858,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 859,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 860,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,309,0,,,,0,0,0,0,0,0,0,0,17,105,0,0,0,0,0,0,254,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 861,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,266,0,,,,0,0,0,0,0,0,0,0,8,91,0,0,0,0,2,0,219,0,0,0,0,0
Study 4,EMEA,AUT,Site 10,Subject 862,Unplanned Recist (1),Discontinued,,,,,,,,,,10,116,0,,,,0,0,0,0,0,0,0,0,7,32,0,0,0,0,1,0,89,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 627,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,29,345,0,,,,0,0,0,1,0,0,0,1,17,281,0,1,0,0,1,0,282,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 628,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,41,358,0,,,,0,0,0,0,0,0,0,0,23,140,0,0,0,0,1,0,294,8,0,0,3,5
Study 4,EMEA,AUT,Site 87,Subject 629,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,40,346,0,,,,0,0,0,0,0,0,0,0,10,108,0,0,0,0,0,0,293,5,0,0,0,5
Study 4,EMEA,AUT,Site 87,Subject 630,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,362,0,,,,0,1,0,0,0,0,0,1,10,121,0,0,0,0,0,0,306,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 631,Unplanned Visit (2),Discontinued,,,,,,,,,,55,370,0,,,,0,0,0,0,0,0,0,0,12,72,0,0,0,0,2,0,302,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 863,EOT 2 (1),Discontinued,,,,,,,,,,43,335,0,,,,0,0,0,0,0,0,0,0,14,92,1,1,0,0,1,0,282,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 864,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 865,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 866,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,331,0,,,,0,0,0,0,0,0,0,0,2,115,0,0,0,0,0,0,287,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 867,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,37,334,0,,,,0,0,0,0,0,0,0,0,2,116,0,0,0,0,1,0,292,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 868,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,13,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 869,Screening,Screen Failure,,,,,,,,,,1,19,0,,,,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,17,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 870,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,306,0,,,,0,0,0,0,0,0,0,0,8,93,0,0,0,0,2,0,256,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 871,Unplanned Recist (1),Discontinued,,,,,,,,,,32,267,0,,,,0,0,0,0,0,0,0,0,2,79,1,0,0,0,2,0,232,1,0,0,1,0
Study 4,EMEA,AUT,Site 87,Subject 872,EOT1 (1),Discontinued,,,,,,,,,,27,204,0,,,,0,0,0,0,0,0,0,0,1,39,0,0,0,0,2,0,170,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 873,Cycle 3 Week 1 (1),Discontinued,,,,,,,,,,12,118,0,,,,0,0,0,3,0,0,0,3,5,31,0,0,0,0,2,0,95,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 874,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,328,0,,,,0,0,0,0,0,0,0,0,5,103,0,0,0,0,0,0,279,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 875,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,317,0,,,,0,0,0,0,0,0,0,0,10,106,0,0,0,0,0,0,262,4,0,0,4,0
Study 4,EMEA,AUT,Site 87,Subject 876,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,314,0,,,,0,0,0,0,0,0,0,0,12,92,0,0,0,0,0,0,264,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 877,Screening,Discontinued,,,,,,,,,,1,45,1,,,,0,0,0,0,0,0,0,0,1,11,0,0,0,0,2,0,41,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 878,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,303,0,,,,0,0,0,0,0,0,0,0,10,84,0,0,0,0,1,0,264,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 879,Long term FU 1 (1),Discontinued,,,,,,,,,,25,208,0,,,,0,0,0,1,0,0,0,1,13,53,0,0,0,0,0,0,162,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 880,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,305,0,,,,0,0,0,0,0,0,0,0,12,84,0,0,0,0,0,0,260,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 881,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,276,0,,,,0,0,0,0,0,0,0,0,12,74,0,0,0,0,0,0,232,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 882,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,291,0,,,,0,0,0,0,0,0,0,0,10,84,0,0,0,0,0,0,247,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 883,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,29,246,0,,,,0,0,0,0,0,0,0,0,8,64,0,0,0,0,1,0,199,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 884,Week 48 (1),Survival,,,,,,,,,,30,235,0,,,,0,0,0,0,0,0,0,0,9,66,0,1,0,0,1,0,191,1,0,0,1,0
Study 4,EMEA,AUT,Site 87,Subject 885,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,313,0,,,,0,0,0,0,0,0,0,0,12,112,0,0,0,0,0,0,254,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 886,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,33,308,1,,,,0,0,0,0,0,0,0,0,19,103,0,0,0,0,0,0,235,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 887,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,294,0,,,,0,0,0,0,0,0,0,0,4,92,0,0,0,0,1,0,252,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 888,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,265,0,,,,0,0,0,4,0,0,0,4,20,57,0,0,0,0,0,0,228,1,0,0,1,0
Study 4,EMEA,AUT,Site 87,Subject 889,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,290,0,,,,0,0,0,0,0,0,0,0,7,97,0,0,0,0,0,0,235,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 890,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,265,0,,,,0,0,0,0,0,0,0,0,13,73,0,0,0,0,0,0,219,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 891,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,269,0,,,,0,0,0,0,0,0,0,0,7,72,0,0,0,0,2,0,229,0,0,0,0,0
Study 4,EMEA,AUT,Site 87,Subject 892,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,268,0,,,,0,0,0,0,0,0,0,0,10,74,0,0,0,0,1,0,219,5,0,0,1,4
Study 4,EMEA,AUT,Site 110,Subject 893,Cycle 1 Week 6 (1),Discontinued,,,,,,,,,,7,85,0,,,,0,0,0,2,0,0,0,2,5,67,0,0,0,0,4,0,51,13,1,5,15,4
Study 4,EMEA,AUT,Site 110,Subject 894,Screening,Screen Failure,,,,,,,,,,1,21,0,,,,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,17,3,0,0,3,0
Study 4,EMEA,AUT,Site 110,Subject 895,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,AUT,Site 110,Subject 896,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,28,256,0,,,,0,0,0,0,1,0,0,1,27,92,0,0,0,0,1,0,135,39,4,25,38,30
Study 4,EMEA,BEL,Site 111,Subject 897,Long term FU 7 (1),Survival,,,,,,,,,,25,206,0,,,,0,0,0,1,0,0,0,1,5,176,174,1,0,0,3,0,173,1,0,0,1,0
Study 4,EMEA,BEL,Site 112,Subject 898,Post CYCLE 6 Visit 9 (1),Survival,,,,,,,,,,35,469,0,,,,0,0,0,0,0,0,0,0,1,413,0,0,0,0,0,0,357,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 899,Week 48 (1),Survival,,,,,,,,,,34,326,0,,,,0,0,0,1,0,0,0,1,1,117,0,2,0,0,2,0,265,1,0,0,1,0
Study 4,EMEA,BEL,Site 112,Subject 900,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,394,0,,,,0,0,0,1,0,0,0,1,0,175,0,0,0,0,0,0,309,1,0,0,1,0
Study 4,EMEA,BEL,Site 112,Subject 901,Week 48 (1),Survival,,,,,,,,,,39,321,0,,,,0,0,0,1,0,0,0,1,1,88,0,0,0,0,1,0,265,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 902,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 903,Screening,Discontinued,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,5,0,2,0,0,0,0,11,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 904,Post CYCLE 6 Visit 11 (1),Survival,,,,,,,,,,38,359,0,,,,1,0,0,0,0,0,0,1,3,129,0,0,0,0,1,0,299,5,0,0,5,0
Study 4,EMEA,BEL,Site 112,Subject 905,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,39,330,0,,,,0,0,0,1,0,0,0,1,1,117,0,0,0,0,0,0,257,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 906,Week 24 (1),Discontinued,,,,,,,,,,31,207,0,,,,0,0,0,0,0,0,0,0,1,41,0,0,0,0,0,0,175,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 907,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,30,226,0,,,,0,0,0,0,0,0,0,0,1,54,0,1,0,0,1,0,188,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 908,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,282,0,,,,0,0,0,0,0,0,0,0,1,92,192,0,0,0,2,0,234,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 909,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,BEL,Site 112,Subject 910,Unplanned Visit (3),On Trial,,,,,,,,,,33,288,0,,,,0,0,0,1,0,0,0,1,17,93,0,0,0,0,0,0,218,7,0,0,4,3
Study 4,EMEA,DNK,Site 113,Subject 911,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,300,0,,,,0,0,0,0,0,0,0,0,1,259,0,0,0,0,0,0,211,44,0,0,44,0
Study 4,EMEA,DNK,Site 113,Subject 912,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,311,0,,,,0,0,0,0,0,0,0,0,1,117,0,0,0,0,0,0,217,50,0,0,47,3
Study 4,EMEA,DNK,Site 113,Subject 913,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,DNK,Site 113,Subject 914,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,DNK,Site 113,Subject 915,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,311,0,,,,0,0,0,0,0,0,0,0,6,104,0,0,0,0,0,0,206,54,0,0,43,11
Study 4,EMEA,DNK,Site 113,Subject 916,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,319,0,,,,0,0,0,0,0,0,0,0,2,123,0,0,0,0,1,0,213,46,0,0,46,0
Study 4,EMEA,DNK,Site 113,Subject 917,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 114,Subject 918,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,40,450,0,,,,0,0,0,1,0,0,0,1,45,350,0,1,0,0,3,0,303,63,0,0,51,12
Study 4,EMEA,FRA,Site 114,Subject 919,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,FRA,Site 114,Subject 920,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,2,1,0,2,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,FRA,Site 114,Subject 921,Screening,Discontinued,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,7,2,0,0,2,0
Study 4,EMEA,FRA,Site 114,Subject 922,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,38,374,0,,,,0,2,0,2,0,0,0,4,23,85,0,0,0,0,2,0,264,51,0,0,46,5
Study 4,EMEA,FRA,Site 114,Subject 923,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,31,369,0,,,,1,0,0,5,0,0,1,7,60,76,0,1,0,0,2,0,232,61,0,0,49,12
Study 4,EMEA,FRA,Site 114,Subject 924,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,394,0,,,,0,0,0,0,0,0,0,0,53,96,0,0,0,0,1,0,263,54,0,0,54,0
Study 4,EMEA,FRA,Site 114,Subject 925,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,386,0,,,,0,0,0,0,0,0,0,0,84,68,0,0,0,0,1,0,246,60,0,0,49,11
Study 4,EMEA,FRA,Site 114,Subject 926,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 114,Subject 927,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 114,Subject 928,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 114,Subject 929,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,30,346,0,,,,0,0,0,2,0,0,0,2,62,81,0,0,0,0,4,0,218,57,0,0,45,12
Study 4,EMEA,FRA,Site 114,Subject 930,EOT 2 (1),Discontinued,,,,,,,,,,44,320,0,,,,0,0,0,0,0,0,0,0,9,50,0,0,0,0,2,0,212,52,1,0,53,0
Study 4,EMEA,FRA,Site 114,Subject 931,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 114,Subject 932,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,333,0,,,,0,0,0,0,0,0,0,0,46,71,0,0,0,0,1,0,223,42,0,0,42,0
Study 4,EMEA,FRA,Site 114,Subject 933,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,27,270,0,,,,0,1,0,0,0,0,0,1,45,46,0,0,0,0,0,0,177,45,0,0,45,0
Study 4,EMEA,FRA,Site 115,Subject 934,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,39,347,0,,,,0,0,0,0,1,0,0,1,17,276,0,0,0,0,1,0,219,50,7,25,42,40
Study 4,EMEA,FRA,Site 115,Subject 935,Long term FU 15 (1),Follow-Up,,,,,,,,,,37,319,0,,,,0,0,0,0,0,0,0,0,32,114,0,0,0,0,0,0,196,45,0,35,54,26
Study 4,EMEA,FRA,Site 115,Subject 936,Long term FU 12 (1),Follow-Up,,,,,,,,,,36,321,2,,,,0,0,0,3,0,0,0,3,13,124,0,0,0,0,1,0,194,39,6,31,54,22
Study 4,EMEA,FRA,Site 115,Subject 937,Unplanned Visit_CO (1),Discontinued,,,,,,,,,,45,345,0,,,,0,0,0,3,0,0,0,3,16,95,0,0,0,0,1,0,208,54,5,5,64,0
Study 4,EMEA,FRA,Site 115,Subject 938,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,8,91,0,,,,0,0,0,0,0,0,0,0,1,20,0,0,0,0,4,0,63,15,0,1,16,0
Study 4,EMEA,FRA,Site 115,Subject 939,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,330,0,,,,0,0,0,0,0,0,0,0,1,116,0,0,0,0,3,0,217,44,7,22,43,30
Study 4,EMEA,FRA,Site 115,Subject 940,Week 48 (1),Follow-Up,,,,,,,,,,49,393,0,,,,0,0,0,2,0,0,0,2,15,108,0,0,0,0,0,0,254,59,11,3,60,13
Study 4,EMEA,FRA,Site 115,Subject 941,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 115,Subject 942,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,288,0,,,,0,0,0,0,0,0,0,0,3,87,0,0,0,0,1,0,171,47,1,28,39,37
Study 4,EMEA,FRA,Site 115,Subject 943,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,321,0,,,,0,0,0,0,0,0,0,0,9,95,0,0,0,0,1,0,201,44,8,25,43,34
Study 4,EMEA,FRA,Site 115,Subject 944,Week 48 (1),Follow-Up,,,,,,,,,,41,361,0,,,,0,0,0,1,0,0,0,1,60,93,0,0,0,0,1,0,201,56,8,15,54,25
Study 4,EMEA,FRA,Site 115,Subject 945,Screening,Screen Failure,,,,,,,,,,1,15,1,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 115,Subject 946,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,20,147,0,,,,0,0,0,0,0,0,0,0,5,23,0,0,0,0,1,0,97,24,0,3,27,0
Study 4,EMEA,FRA,Site 115,Subject 947,Long term FU 1 (1),Follow-Up,,,,,,,,,,36,296,1,,,,1,0,0,1,0,0,0,2,7,87,0,0,0,0,1,0,175,36,10,30,40,36
Study 4,EMEA,FRA,Site 115,Subject 948,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,277,0,,,,0,0,0,1,0,0,0,1,36,41,0,0,0,0,0,0,166,45,1,14,40,20
Study 4,EMEA,FRA,Site 115,Subject 949,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,360,0,,,,0,0,0,0,1,0,0,1,26,119,0,0,0,0,0,0,212,42,12,17,43,28
Study 4,EMEA,FRA,Site 115,Subject 950,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,296,0,,,,0,0,0,0,0,0,0,0,12,64,0,0,0,0,0,0,188,45,3,15,39,24
Study 4,EMEA,FRA,Site 115,Subject 951,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,2,1,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,FRA,Site 115,Subject 952,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,2,1,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,FRA,Site 116,Subject 953,Long term FU 1 (1),Survival,,,,,,,,,,4,77,0,,,,1,0,0,0,0,0,0,1,3,38,0,0,0,0,1,0,62,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 954,EOT 2 (1),Discontinued,,,,,,,,,,35,286,0,,,,0,0,0,0,0,0,0,0,7,71,0,1,0,0,1,0,221,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 955,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,38,359,0,,,,0,0,0,0,0,0,0,0,3,314,0,0,0,0,0,0,316,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 956,Unplanned Recist (2),Survival,,,,,,,,,,4,96,0,,,,0,0,0,0,0,0,0,0,5,45,0,0,0,0,1,0,84,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 957,Week 24 (1),Discontinued,,,,,,,,,,27,207,1,,,,0,0,0,0,0,0,0,0,1,45,0,0,0,0,1,0,178,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 958,Week 24 (1),Discontinued,,,,,,,,,,26,203,1,,,,0,0,0,0,0,0,0,0,1,45,0,0,0,0,0,0,174,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 959,EOT1 (1),Discontinued,,,,,,,,,,2,46,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,2,0,43,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 960,Post CYCLE 6 Visit 14 (1),Discontinued,,,,,,,,,,36,357,0,,,,0,0,0,0,0,0,0,0,18,132,0,0,0,0,2,0,308,1,0,0,1,0
Study 4,EMEA,FRA,Site 116,Subject 961,Unplanned Visit (1),Discontinued,,,,,,,,,,31,253,0,,,,0,0,0,0,0,0,0,0,3,74,0,0,0,0,2,0,210,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 962,Week 48 (1),Discontinued,,,,,,,,,,60,398,1,,,,0,0,0,0,0,0,0,0,5,95,0,0,0,0,2,0,332,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 963,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 964,Week 48 (1),Follow-Up,,,,,,,,,,37,308,0,,,,0,0,0,0,0,0,0,0,4,89,0,0,0,0,2,0,261,1,0,0,1,0
Study 4,EMEA,FRA,Site 116,Subject 965,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 966,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 967,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,349,0,,,,0,0,0,0,0,0,0,0,11,114,0,0,0,0,0,0,304,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 968,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,21,0,,,,0,0,0,0,0,0,0,0,2,9,0,1,0,0,0,0,15,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 969,Unplanned Visit_CO (1),Discontinued,,,,,,,,,,43,354,0,,,,0,0,0,0,0,0,0,0,5,101,0,0,0,0,1,0,289,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 970,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,326,0,,,,0,0,0,0,0,0,0,0,4,123,0,1,0,0,2,0,278,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 971,Week 24 (1),Discontinued,,,,,,,,,,28,194,0,,,,0,0,0,0,0,0,0,0,4,34,0,0,0,0,1,0,163,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 972,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,322,0,,,,0,0,0,0,0,0,0,0,5,96,0,0,0,0,3,0,273,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 973,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,333,0,,,,0,0,0,0,0,0,0,0,9,125,0,0,0,0,1,0,275,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 974,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 975,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,305,0,,,,0,0,0,0,0,0,0,0,13,96,0,0,0,0,0,0,252,1,0,0,1,0
Study 4,EMEA,FRA,Site 116,Subject 976,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,385,0,,,,0,0,0,0,0,0,0,0,17,150,0,0,0,0,1,0,316,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 977,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 978,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 979,Post CYCLE 6 Visit 8 (1),Discontinued,,,,,,,,,,35,321,0,,,,0,0,0,0,0,0,0,0,7,108,0,0,0,0,1,0,264,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 980,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,342,1,,,,0,0,0,0,0,0,0,0,5,117,0,0,0,0,1,0,291,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 981,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 982,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 983,EOT1 (1),Discontinued,,,,,,,,,,24,164,0,,,,0,1,0,0,0,0,0,1,2,34,0,0,0,0,1,0,137,1,0,0,1,0
Study 4,EMEA,FRA,Site 116,Subject 984,Cycle 6 Week 6 (1),Discontinued,,,,,,,,,,27,195,0,,,,0,0,0,0,0,0,0,0,4,38,0,0,0,0,2,0,158,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 985,Cycle 1 Week 6 (1),Discontinued,,,,,,,,,,6,83,0,,,,0,0,0,0,0,0,0,0,5,20,0,0,0,0,0,0,68,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 986,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,265,0,,,,0,0,0,0,0,0,0,0,4,87,0,0,0,0,0,0,223,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 987,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,268,0,,,,0,0,0,0,0,0,0,0,10,82,0,0,0,0,1,0,220,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 988,Post CYCLE 6 Visit 2 (1),Discontinued,,,,,,,,,,29,241,0,,,,1,1,0,0,0,0,0,2,9,64,0,0,0,0,1,0,194,3,0,0,3,0
Study 4,EMEA,FRA,Site 116,Subject 989,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 990,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,38,293,0,,,,0,0,0,0,0,0,0,0,9,57,0,0,0,0,1,0,236,0,0,0,0,0
Study 4,EMEA,FRA,Site 116,Subject 991,Cycle 1 Week 1_CO (1),On Trial,,,,,,,,,,36,296,0,,,,11,4,0,0,0,0,0,15,30,72,0,0,0,0,0,0,229,13,0,0,13,0
Study 4,EMEA,FRA,Site 117,Subject 992,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 117,Subject 993,Long term FU 4 (1),Discontinued,,,,,,,,,,40,286,0,,,,1,0,0,0,6,0,0,7,10,237,0,0,0,0,2,0,191,44,11,0,55,0
Study 4,EMEA,FRA,Site 117,Subject 994,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,279,0,,,,0,0,0,0,0,0,0,0,9,88,0,0,0,0,1,0,151,51,24,6,76,5
Study 4,EMEA,FRA,Site 117,Subject 995,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,34,286,0,,,,1,0,0,0,0,0,0,1,20,78,0,0,0,0,0,0,177,50,13,0,49,14
Study 4,EMEA,FRA,Site 117,Subject 996,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,8,3,0,0,3,0
Study 4,EMEA,FRA,Site 117,Subject 997,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,20,0,,,,0,0,0,0,0,0,0,0,2,3,0,1,0,0,0,0,14,3,0,0,3,0
Study 4,EMEA,FRA,Site 117,Subject 998,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,2,1,0,1,0,0,0,0,9,2,0,0,2,0
Study 4,EMEA,FRA,Site 117,Subject 999,Week 24 (1),Follow-Up,,,,,,,,,,37,268,0,,,,3,4,0,0,7,0,0,14,15,58,0,0,0,0,1,0,149,47,27,6,57,23
Study 4,EMEA,FRA,Site 118,Subject 1000,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,38,340,0,,,,1,1,0,0,0,0,0,2,21,276,0,1,0,0,2,0,247,47,0,0,47,0
Study 4,EMEA,FRA,Site 118,Subject 1001,Week 48 (1),Discontinued,,,,,,,,,,59,355,0,,,,0,1,0,0,0,0,0,1,6,68,0,1,0,0,1,0,226,69,0,0,69,0
Study 4,EMEA,FRA,Site 118,Subject 1002,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,372,0,,,,0,0,0,0,0,0,0,0,23,124,1,8,0,0,0,0,265,50,0,0,50,0
Study 4,EMEA,FRA,Site 118,Subject 1003,Week 24 (1),Discontinued,,,,,,,,,,37,293,0,,,,0,0,0,0,0,0,0,0,2,88,0,0,0,0,1,0,213,42,0,0,42,0
Study 4,EMEA,FRA,Site 118,Subject 1004,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,32,262,0,,,,0,0,0,0,0,0,0,0,13,79,203,2,0,0,0,0,170,40,0,0,40,0
Study 4,EMEA,FRA,Site 118,Subject 1005,Cycle 1 Week 1_CO (1),On Trial,,,,,,,,,,37,350,0,,,,3,0,0,0,0,0,0,3,37,96,0,0,0,0,3,0,244,57,0,0,51,6
Study 4,EMEA,FRA,Site 118,Subject 1006,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,346,0,,,,0,0,0,0,0,0,0,0,28,106,0,1,0,0,1,0,239,49,0,0,49,0
Study 4,EMEA,FRA,Site 118,Subject 1007,Week 48 (1),Discontinued,,,,,,,,,,53,365,0,,,,3,1,0,0,0,0,0,4,26,75,294,0,0,0,1,0,220,73,0,0,73,0
Study 4,EMEA,FRA,Site 118,Subject 1008,Week 24 (1),Follow-Up,,,,,,,,,,60,426,0,,,,0,3,0,0,0,0,0,3,32,95,299,1,0,0,1,0,274,72,0,0,72,0
Study 4,EMEA,FRA,Site 118,Subject 1009,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,331,0,,,,0,0,0,0,0,0,0,0,38,103,244,1,0,0,1,0,216,47,0,0,47,0
Study 4,EMEA,FRA,Site 118,Subject 1010,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,310,0,,,,0,1,0,0,0,0,0,1,30,82,224,0,0,0,1,0,210,52,0,2,41,13
Study 4,EMEA,FRA,Site 118,Subject 1011,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 118,Subject 1012,Cycle 1 Week 5 (1),Discontinued,,,,,,,,,,6,87,0,,,,0,3,0,0,0,0,0,3,9,26,74,1,0,0,0,0,54,13,0,0,13,0
Study 4,EMEA,FRA,Site 118,Subject 1013,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,48,307,0,,,,0,0,0,0,0,0,0,0,9,60,256,1,0,0,0,0,197,57,0,0,57,0
Study 4,EMEA,FRA,Site 118,Subject 1014,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,298,0,,,,0,0,0,0,0,0,0,0,34,81,215,0,0,0,0,0,204,43,0,0,43,0
Study 4,EMEA,FRA,Site 118,Subject 1015,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,FRA,Site 118,Subject 1016,Week 24 (1),Follow-Up,,,,,,,,,,43,336,0,,,,0,0,0,0,0,0,0,0,33,71,256,0,0,0,0,0,209,60,0,0,60,0
Study 4,EMEA,FRA,Site 118,Subject 1017,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,27,247,0,,,,0,0,0,0,0,0,0,0,21,59,207,0,0,0,0,0,147,40,0,0,40,0
Study 4,EMEA,FRA,Site 118,Subject 1018,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,250,0,,,,0,0,0,0,0,0,0,0,24,57,178,0,0,0,0,0,166,40,0,0,40,0
Study 4,EMEA,FRA,Site 119,Subject 1019,Unplanned Visit (4),Survival,,,,,,,,,,31,315,0,,,,0,0,0,0,0,0,0,0,13,258,0,0,0,0,2,0,208,37,0,10,45,2
Study 4,EMEA,FRA,Site 119,Subject 1020,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,37,438,1,,,,0,0,0,0,0,0,0,0,25,117,0,0,0,0,1,0,255,65,4,37,50,56
Study 4,EMEA,FRA,Site 119,Subject 1021,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,34,405,0,,,,0,0,0,0,0,0,0,0,14,97,0,0,0,0,1,0,238,70,3,25,51,47
Study 4,EMEA,FRA,Site 119,Subject 1022,EOT 2 (1),Discontinued,,,,,,,,,,39,272,1,,,,1,0,0,0,0,0,0,1,26,36,0,0,0,0,1,0,169,48,1,3,52,0
Study 4,EMEA,FRA,Site 119,Subject 1023,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,468,0,,,,4,0,0,0,0,0,0,4,51,128,0,0,0,0,2,0,263,70,27,21,80,38
Study 4,EMEA,FRA,Site 119,Subject 1024,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 119,Subject 1025,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,453,1,,,,0,0,0,0,0,0,0,0,64,125,0,0,0,0,0,0,237,90,8,25,81,42
Study 4,EMEA,FRA,Site 119,Subject 1026,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,31,236,0,,,,2,0,0,0,0,0,0,2,33,31,0,0,0,0,2,0,144,40,4,4,48,0
Study 4,EMEA,FRA,Site 119,Subject 1027,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,1,0,4,0
Study 4,EMEA,FRA,Site 119,Subject 1028,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,10,3,0,1,4,0
Study 4,EMEA,FRA,Site 119,Subject 1029,Unplanned Visit (2),Survival,,,,,,,,,,14,206,1,,,,0,2,0,0,0,0,0,2,3,25,0,0,0,0,0,0,145,21,0,5,23,3
Study 4,EMEA,FRA,Site 120,Subject 1030,Post CYCLE 6 Visit 3 (1),Discontinued,,,,,,,,,,29,307,0,,,,2,0,0,0,0,0,0,2,17,242,0,0,0,0,3,0,184,43,0,0,43,0
Study 4,EMEA,FRA,Site 120,Subject 1031,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,66,589,1,,,,0,2,0,1,0,0,0,3,19,137,0,0,0,0,0,0,394,77,15,0,74,18
Study 4,EMEA,FRA,Site 120,Subject 1032,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,39,360,0,,,,0,0,0,0,0,0,0,0,3,138,0,0,0,0,1,0,264,47,1,0,48,0
Study 4,EMEA,FRA,Site 120,Subject 1033,Unplanned Recist (1),Discontinued,,,,,,,,,,32,402,0,,,,0,0,0,0,0,0,0,0,17,139,0,0,0,0,3,0,265,46,0,0,46,0
Study 4,EMEA,FRA,Site 120,Subject 1034,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,FRA,Site 120,Subject 1035,Unplanned Visit_CO (15),Discontinued,,,,,,,,,,55,493,0,,,,0,0,0,0,0,0,0,0,12,130,0,0,0,0,0,0,332,66,2,0,68,0
Study 4,EMEA,FRA,Site 120,Subject 1036,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,331,0,,,,0,0,0,0,0,0,0,0,5,125,0,0,0,0,0,0,233,47,0,0,47,0
Study 4,EMEA,FRA,Site 120,Subject 1037,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,46,392,1,,,,0,0,0,0,0,0,0,0,14,95,0,0,0,0,2,0,265,55,2,0,57,0
Study 4,EMEA,FRA,Site 120,Subject 1038,Week 24 (1),Discontinued,,,,,,,,,,32,290,0,,,,0,0,0,0,0,0,0,0,14,92,0,0,0,0,2,0,185,48,1,0,49,0
Study 4,EMEA,FRA,Site 120,Subject 1039,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,37,443,1,,,,1,0,0,1,0,0,0,2,10,130,0,0,0,0,1,0,307,52,0,0,47,5
Study 4,EMEA,FRA,Site 120,Subject 1040,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 120,Subject 1041,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,420,0,,,,2,0,0,0,0,0,0,2,8,112,0,0,0,0,1,0,287,57,0,0,46,11
Study 4,EMEA,FRA,Site 120,Subject 1042,Unplanned Visit (25),Discontinued,,,,,,,,,,29,329,0,,,,0,0,0,0,0,0,0,0,10,60,0,0,0,0,1,0,220,36,2,0,38,0
Study 4,EMEA,FRA,Site 120,Subject 1043,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 120,Subject 1044,EOT1 (1),Follow-Up,,,,,,,,,,33,396,0,,,,0,1,0,1,0,0,0,2,12,98,0,0,0,0,0,0,263,47,4,0,48,3
Study 4,EMEA,FRA,Site 120,Subject 1045,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,21,221,0,,,,0,0,0,0,0,0,0,0,3,34,0,0,0,0,0,0,153,27,0,0,27,0
Study 4,EMEA,FRA,Site 120,Subject 1046,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,396,0,,,,0,0,0,0,0,0,0,0,9,113,0,0,0,0,0,0,266,57,0,0,44,13
Study 4,EMEA,FRA,Site 121,Subject 1047,Week 48 (1),Follow-Up,,,,,,,,,,56,438,0,,,,0,0,0,0,0,0,0,0,11,336,0,0,0,0,5,0,288,74,0,0,74,0
Study 4,EMEA,FRA,Site 121,Subject 1048,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,8,3,0,0,3,0
Study 4,EMEA,FRA,Site 121,Subject 1049,Post CYCLE 6 Visit 7 (1),Discontinued,,,,,,,,,,32,261,0,,,,0,0,0,0,0,0,0,0,7,67,0,1,0,0,0,0,176,40,0,0,40,0
Study 4,EMEA,FRA,Site 121,Subject 1050,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,36,329,0,,,,0,0,0,0,0,0,0,0,3,103,0,1,0,0,2,0,243,44,0,0,44,0
Study 4,EMEA,FRA,Site 121,Subject 1051,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,316,0,,,,0,0,0,0,0,0,0,0,3,97,0,0,0,0,1,0,221,43,0,0,43,0
Study 4,EMEA,FRA,Site 121,Subject 1052,Unplanned Visit (2),Discontinued,,,,,,,,,,1,56,0,,,,0,0,0,0,0,0,0,0,2,10,0,1,0,0,3,0,45,5,0,0,5,0
Study 4,EMEA,FRA,Site 121,Subject 1053,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 121,Subject 1054,Screening,Discontinued,,,,,,,,,,0,13,0,,,,0,0,0,0,0,0,0,0,1,5,0,1,0,0,0,0,8,3,0,0,3,0
Study 4,EMEA,FRA,Site 122,Subject 1055,Unplanned Recist (1),On Trial,,,,,,,,,,42,344,0,,,,0,0,0,0,0,0,0,0,9,289,0,0,0,0,0,0,245,44,5,0,46,3
Study 4,EMEA,FRA,Site 122,Subject 1056,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,370,0,,,,0,0,0,0,0,0,0,0,8,110,0,0,0,0,2,0,257,50,7,0,48,9
Study 4,EMEA,FRA,Site 122,Subject 1057,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 122,Subject 1058,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,9,131,0,,,,0,0,0,0,0,0,0,0,7,42,0,1,0,0,1,0,85,17,0,0,17,0
Study 4,EMEA,FRA,Site 122,Subject 1059,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,FRA,Site 122,Subject 1060,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,41,332,0,,,,0,0,0,1,0,0,0,1,7,89,0,0,0,0,1,0,225,56,5,0,47,14
Study 4,EMEA,FRA,Site 122,Subject 1061,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,26,191,0,,,,0,0,0,0,0,0,0,0,1,31,0,0,0,0,0,0,131,31,0,0,31,0
Study 4,EMEA,FRA,Site 122,Subject 1062,Unplanned Visit_CO (2),Discontinued,,,,,,,,,,36,269,0,,,,0,0,0,3,0,0,0,3,8,59,0,1,0,0,0,0,166,47,3,0,50,0
Study 4,EMEA,FRA,Site 122,Subject 1063,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,276,0,,,,0,0,0,0,0,0,0,0,7,71,0,0,0,0,0,0,186,46,4,0,41,9
Study 4,EMEA,FRA,Site 123,Subject 1064,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,FRA,Site 123,Subject 1065,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,FRA,Site 123,Subject 1066,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,267,0,,,,0,0,0,0,0,0,0,0,26,147,0,0,0,0,0,0,212,0,0,0,0,0
Study 4,EMEA,DEU,Site 124,Subject 1067,Cycle 3 Week 3_CO (1),Discontinued,,,,,,,,,,43,342,0,,,,0,0,0,0,0,0,0,0,1,284,0,0,0,0,1,0,269,0,0,1,1,0
Study 4,EMEA,DEU,Site 124,Subject 1068,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,306,0,,,,12,0,0,0,0,0,0,12,1,119,0,0,0,0,1,0,256,0,0,0,0,0
Study 4,EMEA,DEU,Site 124,Subject 1069,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,DEU,Site 124,Subject 1070,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,35,297,0,,,,0,0,0,0,0,0,0,0,1,95,0,0,0,0,2,0,247,0,0,0,0,0
Study 4,EMEA,DEU,Site 124,Subject 1071,EOT1 (1),Discontinued,,,,,,,,,,32,288,0,,,,0,0,0,0,0,0,0,0,1,93,0,0,0,0,0,0,237,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1072,Week 24 (1),Discontinued,,,,,,,,,,39,301,0,,,,2,0,0,0,0,0,0,2,4,256,0,0,0,0,1,0,250,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1073,Week 24 (1),Discontinued,,,,,,,,,,32,259,1,,,,0,0,0,0,0,0,0,0,4,73,0,0,0,0,1,0,213,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1074,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,34,281,0,,,,0,0,0,0,0,0,0,0,1,67,0,0,0,0,1,0,239,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1075,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,302,0,,,,0,0,0,0,0,0,0,0,1,97,0,0,0,0,0,0,264,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1076,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,295,0,,,,2,0,0,0,0,0,0,2,1,81,0,0,0,0,1,0,257,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1077,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1078,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,30,272,0,,,,5,0,0,0,0,0,0,5,1,80,0,0,0,0,0,0,226,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1079,Screening,Screen Failure,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,1,8,0,1,0,0,0,0,20,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1080,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1081,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,273,0,,,,0,0,0,0,0,0,0,0,1,91,0,0,0,0,0,0,233,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1082,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,31,267,0,,,,0,0,0,0,0,0,0,0,1,94,0,0,0,0,0,0,218,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1083,Week 24 (1),Survival,,,,,,,,,,13,128,0,,,,1,0,0,0,0,0,0,1,1,36,0,0,0,0,0,0,106,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1084,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,255,0,,,,1,0,0,0,0,0,0,1,1,73,0,0,0,0,0,0,218,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1085,Unplanned Recist (1),Survival,,,,,,,,,,28,237,0,,,,1,1,0,0,0,0,0,2,2,74,0,0,0,0,0,0,197,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1086,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1087,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,26,233,0,,,,0,0,0,0,0,0,0,0,1,67,0,0,0,0,0,0,206,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1088,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,29,239,0,,,,0,0,0,0,0,0,0,0,2,54,0,1,0,0,0,0,205,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1089,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,DEU,Site 125,Subject 1090,Week 24 (1),Discontinued,,,,,,,,,,39,276,0,,,,0,0,0,0,0,0,0,0,3,53,0,0,0,0,2,0,235,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1091,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,30,346,0,,,,1,0,0,0,0,0,0,1,39,271,0,0,0,0,2,0,279,1,0,0,1,0
Study 4,EMEA,DEU,Site 126,Subject 1092,EOT1 (1),Discontinued,,,,,,,,,,29,235,0,,,,0,0,0,0,0,0,0,0,5,71,0,0,0,0,0,0,192,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1093,Unplanned Visit (3),Discontinued,,,,,,,,,,22,192,1,,,,0,0,0,0,0,0,0,0,5,40,0,0,0,0,0,0,151,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1094,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,306,0,,,,0,0,0,0,0,0,0,0,10,99,0,0,0,0,0,0,257,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1095,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,337,0,,,,0,0,0,0,0,0,0,0,15,109,0,0,0,0,3,0,279,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1096,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,350,0,,,,1,0,0,0,0,0,0,1,13,99,0,1,0,0,2,0,292,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1097,Unplanned Recist_CO (3),Discontinued,,,,,,,,,,43,357,1,,,,0,0,0,0,0,0,0,0,11,95,0,2,0,0,0,0,287,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1098,Unplanned Visit (4),Discontinued,,,,,,,,,,32,270,0,,,,0,0,0,0,0,0,0,0,5,71,0,0,0,0,1,0,228,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1099,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,301,0,,,,0,0,0,0,0,0,0,0,5,96,0,0,0,0,1,0,248,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1100,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,312,1,,,,0,0,0,0,0,0,0,0,9,83,0,0,0,0,1,0,260,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1101,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,369,1,,,,0,0,0,1,0,0,0,1,31,126,0,0,0,0,0,0,298,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1102,EOT1 (1),Discontinued,,,,,,,,,,13,115,0,,,,0,0,0,0,0,0,0,0,3,27,0,0,0,0,1,0,92,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1103,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,322,0,,,,0,0,0,0,0,0,0,0,16,95,0,0,0,0,0,0,276,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1104,Screening,Discontinued,,,,,,,,,,1,43,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,1,0,39,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1105,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,33,359,0,,,,0,0,0,0,0,0,0,0,13,130,0,2,0,0,0,0,286,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1106,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1107,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,33,360,0,,,,0,0,0,0,0,0,0,0,36,108,0,1,0,0,2,0,273,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1108,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,305,0,,,,0,0,0,0,0,0,0,0,12,82,0,0,0,0,0,0,257,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1109,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,360,0,,,,1,0,0,0,0,0,0,1,26,108,0,0,0,0,0,0,291,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1110,Cycle 2 Week 1_CO (1),On Trial,,,,,,,,,,42,343,0,,,,6,1,0,0,0,0,0,7,30,85,0,0,0,0,0,0,278,2,0,0,2,0
Study 4,EMEA,DEU,Site 126,Subject 1111,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,327,0,,,,1,0,0,0,0,0,0,1,28,84,0,0,0,0,2,0,270,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1112,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,30,276,0,,,,0,0,0,0,0,0,0,0,16,90,0,0,0,0,0,0,230,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1113,Unplanned Visit (5),Discontinued,,,,,,,,,,30,260,0,,,,0,0,0,0,0,0,0,0,3,57,0,0,0,0,0,0,215,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1114,EOT1 (1),Discontinued,,,,,,,,,,29,260,1,,,,0,0,0,0,0,0,0,0,16,62,0,2,0,0,0,0,206,0,0,0,0,0
Study 4,EMEA,DEU,Site 126,Subject 1115,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,291,0,,,,0,1,0,0,0,0,0,1,31,94,0,0,0,0,1,0,232,1,0,0,1,0
Study 4,EMEA,DEU,Site 126,Subject 1116,EOT1 (1),Survival,,,,,,,,,,31,326,0,,,,2,0,0,0,0,0,0,2,37,101,0,0,0,0,1,0,237,1,0,0,1,0
Study 4,EMEA,DEU,Site 127,Subject 1117,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,DEU,Site 127,Subject 1118,Unplanned Visit (3),Discontinued,,,,,,,,,,7,73,0,,,,0,0,0,0,0,0,0,0,1,43,0,0,0,0,1,0,60,0,0,0,0,0
Study 4,EMEA,DEU,Site 127,Subject 1119,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,297,0,,,,0,0,0,0,0,0,0,0,3,231,0,1,0,0,2,0,253,0,0,0,0,0
Study 4,EMEA,DEU,Site 127,Subject 1120,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,286,0,,,,0,0,0,0,0,0,0,0,13,81,0,0,0,0,1,0,241,0,0,0,0,0
Study 4,EMEA,DEU,Site 128,Subject 1121,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,30,247,0,,,,0,0,0,0,0,0,0,0,25,187,0,0,0,0,1,0,190,0,0,0,0,0
Study 4,EMEA,DEU,Site 128,Subject 1122,Screening,Screen Failure,,,,,,,,,,1,25,0,,,,0,0,0,0,0,0,0,0,1,7,23,1,0,0,0,0,23,0,0,0,0,0
Study 4,EMEA,DEU,Site 128,Subject 1123,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,328,0,,,,0,0,0,0,0,0,0,0,42,94,0,0,0,0,0,0,257,6,0,0,5,1
Study 4,EMEA,DEU,Site 129,Subject 1124,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,335,0,,,,1,0,0,0,0,0,0,1,14,276,0,0,0,0,0,0,274,1,0,0,1,0
Study 4,EMEA,NLD,Site 11,Subject 20,Post CYCLE 6 Visit 6 (1),Discontinued,,,,,,,,,,33,319,0,,,,0,0,0,0,0,0,0,0,16,262,0,0,0,0,0,0,248,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 21,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,40,383,0,,,,1,0,0,0,0,0,0,1,18,121,0,0,0,0,1,0,310,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1125,EOT1 (1),Survival,,,,,,,,,,39,334,0,,,,0,0,0,0,0,0,0,0,9,105,0,0,0,0,2,0,281,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1126,Week 48 (1),Discontinued,,,,,,,,,,50,357,0,,,,0,0,0,0,0,0,0,0,6,89,0,0,0,0,1,0,289,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1127,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,6,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1128,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,300,0,,,,0,0,0,0,0,0,0,0,4,97,0,1,0,0,0,0,253,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1129,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,26,248,0,,,,0,0,0,0,0,0,0,0,14,74,0,0,0,0,2,0,192,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1130,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,346,0,,,,0,0,0,0,0,0,0,0,16,119,0,0,0,0,1,0,277,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1131,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,29,265,0,,,,0,0,0,0,0,0,0,0,17,68,0,0,0,0,1,0,201,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1132,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,38,320,0,,,,0,0,0,0,0,0,0,0,4,85,0,0,0,0,1,0,268,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1133,Long term FU 4 (1),Follow-Up,,,,,,,,,,36,304,0,,,,0,0,0,0,0,0,0,0,4,109,0,0,0,0,0,0,261,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1134,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,292,0,,,,0,0,0,0,0,0,0,0,1,82,0,0,0,0,1,0,253,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1135,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,44,319,0,,,,0,0,0,0,0,0,0,0,1,85,0,0,0,0,1,0,272,0,0,0,0,0
Study 4,EMEA,NLD,Site 11,Subject 1136,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,34,284,0,,,,0,0,0,0,0,0,0,0,8,81,0,0,0,0,0,0,236,0,0,0,0,0
Study 4,EMEA,NLD,Site 130,Subject 1137,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,NLD,Site 130,Subject 1138,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,390,0,,,,0,0,0,0,0,0,0,0,52,289,0,1,0,0,2,0,232,44,12,18,48,26
Study 4,EMEA,NLD,Site 130,Subject 1139,EOT1 (1),Survival,,,,,,,,,,12,162,0,,,,1,0,0,0,0,0,0,1,11,50,0,1,0,0,2,0,103,21,0,1,22,0
Study 4,EMEA,NLD,Site 130,Subject 1140,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,NLD,Site 130,Subject 1141,Long term FU 3 (1),Follow-Up,,,,,,,,,,38,329,0,,,,1,0,0,0,0,0,0,1,16,92,0,4,0,0,0,0,198,40,9,20,42,27
Study 4,EMEA,NLD,Site 130,Subject 1142,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,331,0,,,,0,0,0,0,1,0,0,1,13,76,0,0,0,0,1,0,205,49,6,15,45,25
Study 4,EMEA,NLD,Site 130,Subject 1143,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,13,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,NLD,Site 130,Subject 1144,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,301,0,,,,0,0,0,0,0,0,0,0,7,72,0,0,0,0,0,0,186,40,5,15,46,14
Study 4,EMEA,NLD,Site 131,Subject 1145,EOT1 (1),Discontinued,,,,,,,,,,15,117,0,,,,0,0,0,0,0,0,0,0,1,99,0,0,0,0,3,0,99,0,0,0,0,0
Study 4,EMEA,NLD,Site 131,Subject 1146,Cycle 1 Week 1 (1),Discontinued,,,,,,,,,,2,55,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,1,0,49,0,0,0,0,0
Study 4,EMEA,NLD,Site 131,Subject 1147,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,386,0,,,,0,0,0,0,0,0,0,0,51,120,0,0,0,0,1,0,295,0,0,0,0,0
Study 4,EMEA,NLD,Site 132,Subject 1148,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,298,0,,,,0,0,0,1,0,0,0,1,33,213,0,2,0,0,1,0,172,46,1,27,47,27
Study 4,EMEA,NLD,Site 132,Subject 1149,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,279,0,,,,0,0,0,0,0,0,0,0,14,78,0,0,0,0,1,0,163,39,5,20,42,22
Study 4,EMEA,NLD,Site 132,Subject 1150,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,252,0,,,,0,0,0,0,0,0,0,0,8,64,0,0,0,0,0,0,143,39,12,16,44,23
Study 4,EMEA,NLD,Site 132,Subject 1151,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,NLD,Site 132,Subject 1152,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,260,0,,,,0,0,0,0,0,0,0,0,10,61,0,0,0,0,1,0,152,41,3,19,40,23
Study 4,EMEA,NLD,Site 132,Subject 1153,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,278,0,,,,0,0,0,0,0,0,0,0,27,67,0,0,0,0,0,0,152,41,6,27,40,34
Study 4,EMEA,NLD,Site 132,Subject 1154,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,259,0,,,,0,0,0,0,0,0,0,0,37,46,0,3,0,1,2,0,136,47,3,13,42,21
Study 4,EMEA,POL,Site 133,Subject 1155,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,9,2,0,0,2,0
Study 4,EMEA,POL,Site 133,Subject 1156,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,404,0,,,,0,0,0,0,0,0,0,0,9,337,0,0,0,0,2,0,287,47,0,0,47,0
Study 4,EMEA,POL,Site 133,Subject 1157,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,403,0,,,,1,0,0,0,0,0,0,1,1,112,0,0,0,0,0,0,306,42,0,0,42,0
Study 4,EMEA,POL,Site 133,Subject 1158,Week 48 (1),Discontinued,,,,,,,,,,32,340,0,,,,1,0,0,0,0,0,0,1,3,62,0,0,0,0,1,0,243,41,0,0,41,0
Study 4,EMEA,POL,Site 133,Subject 1159,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,POL,Site 133,Subject 1160,EOT1 (1),Survival,,,,,,,,,,16,141,1,,,,1,0,0,0,0,0,0,1,1,34,0,0,0,0,1,0,99,21,0,0,21,0
Study 4,EMEA,POL,Site 133,Subject 1161,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,POL,Site 133,Subject 1162,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,331,0,,,,1,0,0,0,0,0,0,1,5,110,0,0,0,0,1,0,232,43,0,0,43,0
Study 4,EMEA,POL,Site 133,Subject 1163,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,POL,Site 133,Subject 1164,Week 24 (1),Discontinued,,,,,,,,,,46,322,0,,,,0,1,0,0,0,0,0,1,11,75,0,0,0,0,1,0,201,56,0,0,56,0
Study 4,EMEA,POL,Site 133,Subject 1165,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,POL,Site 133,Subject 1166,Week 24 (1),Discontinued,,,,,,,,,,42,314,0,,,,0,0,0,0,0,0,0,0,7,73,0,0,0,0,1,0,206,51,0,0,51,0
Study 4,EMEA,POL,Site 133,Subject 1167,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,63,462,0,,,,1,0,0,3,2,0,0,6,1,106,0,0,0,0,1,0,314,79,0,0,72,7
Study 4,EMEA,POL,Site 133,Subject 1168,Post CYCLE 6 Visit 7 (1),Discontinued,,,,,,,,,,34,330,0,,,,0,1,0,0,0,0,0,1,16,90,0,0,0,0,0,0,230,46,0,0,43,3
Study 4,EMEA,POL,Site 133,Subject 1169,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,292,0,,,,0,0,0,0,0,0,0,0,1,82,0,0,0,0,3,0,213,41,0,0,41,0
Study 4,EMEA,POL,Site 133,Subject 1170,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,299,0,,,,0,0,0,0,0,0,0,0,7,99,0,0,0,0,0,0,203,43,0,0,43,0
Study 4,EMEA,POL,Site 133,Subject 1171,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,POL,Site 133,Subject 1172,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,339,0,,,,0,0,0,0,0,0,0,0,1,89,0,0,0,0,1,0,252,41,0,0,41,0
Study 4,EMEA,POL,Site 133,Subject 1173,Week 24 (1),Follow-Up,,,,,,,,,,61,394,0,,,,0,4,0,0,0,0,0,4,1,68,0,0,0,0,2,0,261,68,0,0,68,0
Study 4,EMEA,POL,Site 133,Subject 1174,Week 24 (1),Discontinued,,,,,,,,,,31,217,0,,,,0,0,0,0,0,0,0,0,3,45,0,0,0,0,1,0,142,37,0,0,37,0
Study 4,EMEA,POL,Site 133,Subject 1175,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,328,0,,,,0,0,0,0,0,0,0,0,4,103,0,0,0,0,0,0,234,42,0,0,42,0
Study 4,EMEA,POL,Site 133,Subject 1176,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,POL,Site 133,Subject 1177,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,272,0,,,,0,0,0,0,0,0,0,0,1,64,0,0,0,0,1,0,178,53,0,0,38,15
Study 4,EMEA,POL,Site 133,Subject 1178,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,249,0,,,,0,0,0,0,0,0,0,0,1,77,0,0,0,0,1,0,177,37,0,0,37,0
Study 4,EMEA,POL,Site 134,Subject 1179,Unplanned Visit (8),Discontinued,,,,,,,,,,40,369,0,,,,3,1,0,0,0,0,0,4,18,296,0,0,0,0,1,0,221,39,4,39,46,36
Study 4,EMEA,POL,Site 134,Subject 1180,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,327,0,,,,1,0,0,0,0,0,0,1,4,112,0,1,0,0,0,0,205,41,9,28,48,30
Study 4,EMEA,POL,Site 134,Subject 1181,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,320,0,,,,2,0,0,0,0,0,0,2,13,87,0,0,0,0,2,0,201,46,7,15,44,24
Study 4,EMEA,POL,Site 134,Subject 1182,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,53,344,0,,,,1,1,0,0,0,0,0,2,6,66,0,0,0,0,0,0,216,60,4,3,65,2
Study 4,EMEA,POL,Site 134,Subject 1183,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,POL,Site 134,Subject 1184,EOT1 (1),Discontinued,,,,,,,,,,21,137,0,,,,0,0,0,0,0,0,0,0,1,24,0,0,0,0,0,0,89,25,0,0,25,0
Study 4,EMEA,POL,Site 135,Subject 1185,EOT1 (1),Discontinued,,,,,,,,,,18,135,0,,,,0,1,0,0,0,0,0,1,1,109,0,0,0,0,0,0,114,0,0,0,0,0
Study 4,EMEA,POL,Site 135,Subject 1186,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,369,0,,,,1,0,0,0,0,0,0,1,45,213,0,0,0,0,3,0,276,1,0,0,1,0
Study 4,EMEA,POL,Site 135,Subject 1187,EOT1 (1),Discontinued,,,,,,,,,,32,260,0,,,,0,0,0,0,0,0,0,0,3,81,0,0,0,0,1,0,218,0,0,0,0,0
Study 4,EMEA,POL,Site 135,Subject 1188,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,22,159,0,,,,0,0,0,0,0,0,0,0,2,21,0,0,0,0,0,0,136,0,0,0,0,0
Study 4,EMEA,POL,Site 135,Subject 1189,Unplanned Visit (2),Discontinued,,,,,,,,,,18,154,0,,,,0,0,0,0,0,0,0,0,1,25,0,0,0,0,0,0,132,0,0,0,0,0
Study 4,EMEA,POL,Site 135,Subject 1190,EOT1 (1),Discontinued,,,,,,,,,,27,199,0,,,,0,0,0,0,0,0,0,0,1,33,0,0,0,0,0,0,168,0,0,0,0,0
Study 4,EMEA,POL,Site 135,Subject 1191,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,268,0,,,,1,0,0,0,0,0,0,1,9,65,0,0,0,0,0,0,231,1,0,0,1,0
Study 4,EMEA,POL,Site 135,Subject 1192,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,33,255,0,,,,1,0,0,0,0,0,0,1,9,63,0,0,0,0,0,0,218,1,0,0,1,0
Study 4,EMEA,POL,Site 135,Subject 1193,EOT1 (1),Survival,,,,,,,,,,29,215,0,,,,0,0,0,4,0,0,0,4,3,44,0,0,0,0,0,0,181,1,0,0,1,0
Study 4,EMEA,POL,Site 135,Subject 1194,Unplanned Recist (1),Discontinued,,,,,,,,,,14,127,0,,,,0,0,0,0,0,0,0,0,4,28,0,0,0,0,0,0,103,0,0,0,0,0
Study 4,EMEA,ESP,Site 136,Subject 1195,Post CYCLE 6 Visit 6 (1),Discontinued,,,,,,,,,,31,273,0,,,,2,0,0,0,0,0,0,2,10,218,0,1,0,0,6,0,220,1,0,0,1,0
Study 4,EMEA,ESP,Site 136,Subject 1196,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,301,1,,,,0,0,0,1,0,0,0,1,40,38,0,0,0,0,2,0,239,14,0,0,12,2
Study 4,EMEA,ESP,Site 136,Subject 1197,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 136,Subject 1198,Long term FU 7 (1),Follow-Up,,,,,,,,,,21,184,2,,,,0,2,0,4,0,0,0,6,47,107,0,0,0,0,2,0,167,0,0,0,0,0
Study 4,EMEA,ESP,Site 136,Subject 1199,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,262,0,,,,1,0,0,1,0,0,0,2,29,41,0,0,0,0,0,0,217,0,0,0,0,0
Study 4,EMEA,ESP,Site 136,Subject 1200,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,12,103,0,,,,1,0,0,0,0,0,0,1,4,20,0,0,0,0,2,0,86,1,0,0,2,0
Study 4,EMEA,ESP,Site 136,Subject 1201,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,29,270,0,,,,13,4,0,0,0,0,0,17,24,48,0,0,0,0,3,0,228,0,0,0,0,0
Study 4,EMEA,ESP,Site 136,Subject 1202,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,251,0,,,,0,0,0,1,0,0,0,1,26,40,0,0,0,0,1,0,198,8,0,0,0,8
Study 4,EMEA,ESP,Site 136,Subject 1203,Week 24 (1),Discontinued,,,,,,,,,,32,225,0,,,,0,0,0,0,0,0,0,0,12,44,0,0,0,0,3,0,187,0,0,0,0,0
Study 4,EMEA,ESP,Site 136,Subject 1204,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,14,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1205,Cycle 1 Week 1 (1),Discontinued,,,,,,,,,,2,74,0,,,,0,0,0,0,0,0,0,0,3,62,0,0,0,0,0,0,56,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1206,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1207,Cycle 4 Week 5 (1),Discontinued,,,,,,,,,,18,161,0,,,,0,0,0,0,0,0,0,0,3,103,136,0,0,0,1,0,129,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1208,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,39,379,0,,,,0,0,0,0,0,0,0,0,13,218,0,0,0,0,0,0,314,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1209,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,39,394,0,,,,0,0,0,0,0,0,0,0,26,146,0,3,0,0,0,0,312,3,0,0,1,2
Study 4,EMEA,ESP,Site 137,Subject 1210,Screening,Screen Failure,,,,,,,,,,1,20,0,,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,18,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1211,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,36,303,0,,,,1,0,0,0,0,0,0,1,8,91,0,0,0,0,1,0,263,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1212,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1213,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,39,387,0,,,,0,0,0,0,0,0,0,0,28,126,0,1,0,0,0,0,323,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1214,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,31,225,0,,,,0,0,0,0,0,0,0,0,3,47,0,0,0,0,1,0,187,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1215,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 137,Subject 1216,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,306,0,,,,0,0,0,0,0,0,0,0,18,106,12,0,0,0,1,0,232,9,0,0,4,5
Study 4,EMEA,ESP,Site 137,Subject 1217,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 138,Subject 1218,Unplanned Visit (22),Discontinued,,,,,,,,,,33,378,0,,,,0,0,0,0,0,0,0,0,6,312,0,0,0,0,2,0,273,40,0,0,40,0
Study 4,EMEA,ESP,Site 138,Subject 1219,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,41,431,0,,,,0,0,0,0,0,0,0,0,16,131,0,0,0,0,1,0,294,56,0,0,48,8
Study 4,EMEA,ESP,Site 138,Subject 1220,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,ESP,Site 138,Subject 1221,Unplanned Visit (21),Discontinued,,,,,,,,,,31,410,0,,,,0,0,0,0,0,0,0,0,13,90,0,1,0,0,2,0,291,40,0,0,40,0
Study 4,EMEA,ESP,Site 138,Subject 1222,Unplanned Visit (17),On Trial,,,,,,,,,,36,433,0,,,,0,0,0,0,0,0,0,0,24,115,0,0,0,0,4,0,286,65,0,0,50,15
Study 4,EMEA,ESP,Site 138,Subject 1223,Unplanned Visit (8),On Trial,,,,,,,,,,38,374,0,,,,0,0,0,0,0,0,0,0,10,93,0,1,0,0,3,0,260,55,0,0,45,10
Study 4,EMEA,ESP,Site 138,Subject 1224,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,ESP,Site 138,Subject 1225,Week 48 (1),Discontinued,,,,,,,,,,32,305,0,,,,0,0,0,0,0,0,0,0,1,65,0,0,0,0,2,0,217,40,0,0,40,0
Study 4,EMEA,ESP,Site 138,Subject 1226,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,14,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,ESP,Site 138,Subject 1227,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,ESP,Site 138,Subject 1228,Unplanned Visit (15),On Trial,,,,,,,,,,37,426,0,,,,0,0,0,0,0,0,0,0,20,114,200,0,0,0,0,0,290,57,0,0,47,10
Study 4,EMEA,ESP,Site 138,Subject 1229,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,ESP,Site 138,Subject 1230,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,3,11,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,ESP,Site 138,Subject 1231,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,ESP,Site 138,Subject 1232,Unplanned Visit_CO (23),Discontinued,,,,,,,,,,51,593,0,,,,0,0,0,0,1,0,0,1,17,116,0,3,0,0,1,0,399,65,0,0,65,0
Study 4,EMEA,ESP,Site 138,Subject 1233,Unplanned Visit (6),On Trial,,,,,,,,,,35,320,0,,,,0,0,0,0,0,0,0,0,8,98,100,0,0,0,0,0,215,46,0,0,43,3
Study 4,EMEA,ESP,Site 138,Subject 1234,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,6,4,0,0,4,0
Study 4,EMEA,ESP,Site 138,Subject 1235,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,606,0,,,,0,0,0,0,0,0,0,0,11,113,1,1,0,0,1,0,439,53,0,0,44,9
Study 4,EMEA,ESP,Site 138,Subject 1236,Unplanned Visit (64),Survival,,,,,,,,,,31,659,0,,,,0,0,0,0,0,0,0,0,22,126,0,2,0,0,2,0,468,46,0,0,46,0
Study 4,EMEA,ESP,Site 138,Subject 1237,Week 48 (1),Discontinued,,,,,,,,,,31,348,0,,,,0,0,0,0,0,0,0,0,7,62,0,1,0,0,1,0,238,41,0,0,41,0
Study 4,EMEA,ESP,Site 138,Subject 1238,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,437,0,,,,0,0,0,0,0,0,0,0,29,164,201,0,0,0,1,0,252,68,0,0,54,14
Study 4,EMEA,ESP,Site 138,Subject 1239,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,391,0,,,,0,0,0,0,0,0,0,0,7,76,0,1,0,0,0,0,261,57,0,0,42,15
Study 4,EMEA,ESP,Site 138,Subject 1240,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,324,0,,,,0,0,0,0,0,0,0,0,9,99,0,0,0,0,0,0,211,41,0,4,41,4
Study 4,EMEA,ESP,Site 139,Subject 1241,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,374,0,,,,0,0,0,0,0,0,0,0,10,319,0,0,0,0,1,0,232,49,22,20,61,30
Study 4,EMEA,ESP,Site 139,Subject 1242,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1243,Cycle 6 Week 3 (1),Discontinued,,,,,,,,,,23,232,0,,,,0,0,0,0,0,0,0,0,22,69,0,2,0,0,1,0,119,38,0,2,40,0
Study 4,EMEA,ESP,Site 139,Subject 1244,Week 24 (1),Follow-Up,,,,,,,,,,66,497,0,,,,0,0,0,1,0,0,0,1,19,136,0,1,0,0,0,0,305,77,1,14,80,12
Study 4,EMEA,ESP,Site 139,Subject 1245,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,367,0,,,,0,0,0,1,0,0,0,1,16,119,0,1,0,0,2,0,227,51,12,20,54,29
Study 4,EMEA,ESP,Site 139,Subject 1246,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1247,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1248,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1249,Unplanned Visit (3),Discontinued,,,,,,,,,,23,185,0,,,,0,0,0,0,0,0,0,0,4,30,0,1,0,0,1,0,115,28,1,4,33,0
Study 4,EMEA,ESP,Site 139,Subject 1250,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,39,365,0,,,,0,0,0,0,0,0,0,0,1,112,0,0,0,0,2,0,232,43,13,29,60,25
Study 4,EMEA,ESP,Site 139,Subject 1251,Post CYCLE 6 Visit 4 (1),Discontinued,,,,,,,,,,29,266,0,,,,0,0,0,1,0,0,0,1,5,60,0,0,0,0,1,0,175,38,7,0,45,0
Study 4,EMEA,ESP,Site 139,Subject 1252,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,40,357,0,,,,0,0,0,0,0,0,0,0,20,121,0,0,0,0,0,0,235,49,10,6,50,15
Study 4,EMEA,ESP,Site 139,Subject 1253,Long term FU 14 (1),Follow-Up,,,,,,,,,,25,239,0,,,,1,0,0,1,0,0,0,2,15,94,0,0,0,0,0,0,165,29,13,12,40,14
Study 4,EMEA,ESP,Site 139,Subject 1254,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,11,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1255,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,40,363,0,,,,0,0,0,0,0,0,0,0,5,132,0,0,0,0,0,0,233,47,11,18,46,30
Study 4,EMEA,ESP,Site 139,Subject 1256,Cycle 6 Week 1_CO (1),On Trial,,,,,,,,,,60,468,0,,,,1,0,0,2,0,0,0,3,3,124,0,0,0,0,1,0,269,66,22,37,58,67
Study 4,EMEA,ESP,Site 139,Subject 1257,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,386,0,,,,0,0,0,0,0,0,0,0,26,132,0,0,0,0,1,0,242,58,3,9,52,18
Study 4,EMEA,ESP,Site 139,Subject 1258,Unplanned Visit (3),Discontinued,,,,,,,,,,27,233,0,,,,0,0,0,0,0,0,0,0,4,44,0,1,0,0,1,0,148,37,0,7,44,0
Study 4,EMEA,ESP,Site 139,Subject 1259,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,334,0,,,,0,0,0,0,0,0,0,0,16,99,0,0,0,0,1,0,215,44,9,6,46,13
Study 4,EMEA,ESP,Site 139,Subject 1260,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,309,0,,,,0,0,0,0,0,0,0,0,11,86,0,0,0,0,1,0,201,43,10,11,50,14
Study 4,EMEA,ESP,Site 139,Subject 1261,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,358,0,,,,0,0,0,0,0,0,0,0,12,98,0,0,0,0,2,0,241,43,11,8,46,16
Study 4,EMEA,ESP,Site 139,Subject 1262,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,336,0,,,,1,0,0,1,0,0,0,2,20,99,1,1,0,0,2,0,205,55,0,10,48,17
Study 4,EMEA,ESP,Site 139,Subject 1263,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,36,317,0,,,,0,0,0,0,0,0,0,0,6,87,0,0,0,0,1,0,190,41,6,23,48,22
Study 4,EMEA,ESP,Site 139,Subject 1264,EOT1 (1),Discontinued,,,,,,,,,,3,56,0,,,,0,0,0,0,0,0,0,0,2,11,0,1,0,0,2,0,40,7,2,1,9,1
Study 4,EMEA,ESP,Site 139,Subject 1265,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1266,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,307,0,,,,1,0,0,2,0,0,0,3,12,89,0,0,0,0,0,0,189,46,7,15,42,26
Study 4,EMEA,ESP,Site 139,Subject 1267,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,307,0,,,,0,0,0,0,0,0,0,0,3,112,0,0,0,0,0,0,187,43,10,22,41,34
Study 4,EMEA,ESP,Site 139,Subject 1268,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,328,0,,,,0,0,0,0,0,0,0,0,7,125,0,0,0,0,0,0,178,42,21,31,60,34
Study 4,EMEA,ESP,Site 139,Subject 1269,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,296,0,,,,0,0,0,0,0,0,0,0,1,89,0,0,0,0,0,0,179,47,5,23,44,31
Study 4,EMEA,ESP,Site 139,Subject 1270,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,346,0,,,,0,0,0,0,0,0,0,0,10,106,0,0,0,0,0,0,195,48,3,41,61,31
Study 4,EMEA,ESP,Site 139,Subject 1271,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,330,0,,,,0,0,0,0,0,0,0,0,1,85,0,0,0,0,1,0,192,45,0,48,66,27
Study 4,EMEA,ESP,Site 139,Subject 1272,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,316,0,,,,0,0,0,0,0,0,0,0,7,79,0,0,0,0,1,0,194,46,9,13,46,22
Study 4,EMEA,ESP,Site 139,Subject 1273,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,304,0,,,,0,0,0,0,0,0,0,0,18,78,0,0,0,0,1,0,194,39,12,15,44,22
Study 4,EMEA,ESP,Site 139,Subject 1274,Week 48 (1),Discontinued,,,,,,,,,,36,310,0,,,,0,0,0,0,0,0,0,0,21,76,0,0,0,0,1,0,191,39,1,26,47,19
Study 4,EMEA,ESP,Site 139,Subject 1275,Cycle 1 Week 6_CO (1),On Trial,,,,,,,,,,40,336,0,,,,1,0,0,5,0,0,0,6,16,66,0,0,0,0,1,0,150,51,35,37,63,60
Study 4,EMEA,ESP,Site 139,Subject 1276,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,263,0,,,,0,0,0,0,0,0,0,0,14,52,0,0,0,0,1,0,160,38,10,11,41,18
Study 4,EMEA,ESP,Site 139,Subject 1277,Week 24 (1),Discontinued,,,,,,,,,,19,163,0,,,,0,0,0,1,0,0,0,1,6,39,0,0,0,0,1,0,101,25,0,10,34,1
Study 4,EMEA,ESP,Site 139,Subject 1278,Week 24 (1),Discontinued,,,,,,,,,,42,323,0,,,,0,0,0,2,0,0,0,2,1,77,0,0,0,0,0,0,211,48,0,15,63,0
Study 4,EMEA,ESP,Site 139,Subject 1279,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,301,0,,,,0,0,0,0,0,0,0,0,17,83,0,0,0,0,1,0,165,44,0,39,65,18
Study 4,EMEA,ESP,Site 139,Subject 1280,Long term FU 5 (1),Follow-Up,,,,,,,,,,37,278,0,,,,0,0,0,2,0,0,0,2,11,60,0,0,0,0,0,0,174,39,14,8,46,15
Study 4,EMEA,ESP,Site 139,Subject 1281,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,297,0,,,,0,0,0,0,0,0,0,0,16,74,0,1,0,0,0,0,177,46,0,18,50,14
Study 4,EMEA,ESP,Site 139,Subject 1282,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,288,0,,,,0,0,0,0,0,0,0,0,20,75,0,0,0,0,0,0,177,37,10,14,41,20
Study 4,EMEA,ESP,Site 139,Subject 1283,EOT 2 (1),Discontinued,,,,,,,,,,36,292,0,,,,0,0,0,0,0,0,0,0,8,61,0,0,0,0,1,0,187,47,0,7,52,2
Study 4,EMEA,ESP,Site 139,Subject 1284,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,269,0,,,,0,0,0,0,0,0,0,0,16,59,0,0,0,0,0,0,168,37,9,11,38,19
Study 4,EMEA,ESP,Site 139,Subject 1285,Unplanned Visit (4),Discontinued,,,,,,,,,,31,279,0,,,,0,0,0,0,0,0,0,0,12,65,0,0,0,0,2,0,177,37,16,4,44,13
Study 4,EMEA,ESP,Site 139,Subject 1286,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,30,289,0,,,,0,0,0,0,0,0,0,0,21,85,0,0,0,0,0,0,176,47,11,7,42,23
Study 4,EMEA,ESP,Site 139,Subject 1287,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,30,241,0,,,,0,0,0,0,0,0,0,0,18,59,0,0,0,0,1,0,138,42,9,8,40,19
Study 4,EMEA,ESP,Site 139,Subject 1288,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,247,0,,,,0,0,0,0,0,0,0,0,7,53,0,0,0,0,1,0,150,37,9,13,39,20
Study 4,EMEA,ESP,Site 139,Subject 1289,Unplanned Recist (6),Survival,,,,,,,,,,29,295,0,,,,0,0,0,2,0,0,0,2,6,106,0,0,0,0,1,0,178,43,19,15,47,30
Study 4,EMEA,ESP,Site 139,Subject 1290,Week 24 (1),Discontinued,,,,,,,,,,56,354,0,,,,0,0,0,1,0,0,0,1,2,59,0,0,0,0,2,0,216,61,2,14,67,10
Study 4,EMEA,ESP,Site 139,Subject 1291,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,267,0,,,,0,0,0,0,0,0,0,0,3,63,0,0,0,0,1,0,159,50,5,9,42,22
Study 4,EMEA,ESP,Site 139,Subject 1292,Unplanned Recist (1),Screen Failure,,,,,,,,,,1,20,0,,,,0,0,0,0,0,0,0,0,0,9,0,2,0,0,0,0,16,3,0,0,3,0
Study 4,EMEA,ESP,Site 139,Subject 1293,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,1,0,7,2,0,0,2,0
Study 4,EMEA,ESP,Site 140,Subject 1294,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1295,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,434,0,,,,0,0,0,0,0,0,0,0,37,349,0,4,0,0,0,0,345,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1296,EOT1 (1),Discontinued,,,,,,,,,,29,243,0,,,,0,0,0,0,0,0,0,0,7,67,0,0,0,0,2,0,194,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1297,Long term FU 2 (1),Discontinued,,,,,,,,,,34,343,0,,,,0,0,0,0,0,0,0,0,5,97,0,3,0,0,2,0,291,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1298,Long term FU 1 (1),Discontinued,,,,,,,,,,23,231,0,,,,0,0,0,0,0,0,0,0,18,79,182,0,0,0,0,0,173,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1299,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,339,0,,,,0,0,0,0,0,0,0,0,10,115,0,0,0,0,1,0,289,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1300,Unplanned Visit_CO (3),Discontinued,,,,,,,,,,41,366,0,,,,0,0,0,0,0,0,0,0,12,98,2,0,0,0,2,0,296,6,0,0,6,0
Study 4,EMEA,ESP,Site 140,Subject 1301,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,37,340,0,,,,0,0,0,0,0,0,0,0,8,98,0,1,0,0,1,0,279,11,0,0,1,10
Study 4,EMEA,ESP,Site 140,Subject 1302,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,35,357,0,,,,0,0,0,0,0,0,0,0,13,118,0,0,0,0,2,0,294,1,0,0,1,0
Study 4,EMEA,ESP,Site 140,Subject 1303,Week 24 (1),Discontinued,,,,,,,,,,45,412,0,,,,0,0,0,0,0,0,0,0,10,102,0,0,0,0,3,0,333,0,0,0,0,0
Study 4,EMEA,ESP,Site 141,Subject 1304,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,36,300,0,,,,0,0,0,0,0,0,0,0,9,84,0,0,0,0,2,0,250,3,0,0,3,0
Study 4,EMEA,ESP,Site 140,Subject 1305,Screening,Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,15,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1306,Post CYCLE 6 Visit 1 (1),Survival,,,,,,,,,,23,215,0,,,,0,0,0,0,0,0,0,0,7,49,0,0,0,0,2,0,167,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1307,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,33,335,0,,,,0,0,0,0,0,0,0,0,19,113,0,1,0,0,1,0,272,4,0,0,4,0
Study 4,EMEA,ESP,Site 140,Subject 1308,Long term FU 9 (1),Follow-Up,,,,,,,,,,34,319,0,,,,0,0,0,0,0,0,0,0,9,106,0,0,0,0,2,0,269,1,0,0,1,0
Study 4,EMEA,ESP,Site 140,Subject 1309,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,296,0,,,,0,0,0,0,0,0,0,0,8,82,224,0,0,0,0,0,253,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1310,Screening,Screen Failure,,,,,,,,,,1,19,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,17,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1311,Long term FU 8 (1),Discontinued,,,,,,,,,,22,378,0,,,,0,0,0,0,0,0,0,0,37,206,0,1,0,0,2,0,268,2,0,0,2,0
Study 4,EMEA,ESP,Site 140,Subject 1312,Week 24 (1),Follow-Up,,,,,,,,,,34,306,0,,,,0,0,0,0,0,0,0,0,7,93,0,2,0,0,2,0,260,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1313,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,32,259,0,,,,0,0,0,0,0,0,0,0,7,60,0,0,0,0,2,0,221,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1314,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1315,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,315,0,,,,0,0,0,0,0,0,1,1,24,107,0,0,0,0,0,0,241,8,0,0,8,0
Study 4,EMEA,ESP,Site 140,Subject 1316,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1317,Cycle 6 Week 5_CO (1),On Trial,,,,,,,,,,53,400,0,,,,6,1,0,0,0,0,0,7,14,80,0,1,0,0,1,0,314,16,0,0,6,10
Study 4,EMEA,ESP,Site 140,Subject 1318,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,14,0,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1319,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1320,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,248,0,,,,0,0,0,0,0,0,0,0,9,69,0,0,0,0,1,0,212,0,0,0,0,0
Study 4,EMEA,ESP,Site 140,Subject 1321,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,31,267,0,,,,0,0,0,0,0,0,0,0,14,73,0,0,0,0,0,0,225,2,0,0,2,0
Study 4,EMEA,ESP,Site 142,Subject 1322,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,40,396,0,,,,0,0,0,0,0,0,0,0,10,325,0,1,0,0,3,0,332,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1323,Unplanned Visit (4),Discontinued,,,,,,,,,,28,312,0,,,,0,0,0,0,0,0,0,0,28,104,0,0,0,0,1,0,228,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1324,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,32,401,0,,,,0,0,0,0,0,0,0,0,50,143,0,1,0,0,0,0,290,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1325,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,378,0,,,,0,0,0,0,0,0,0,0,10,123,0,0,0,0,1,0,311,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1326,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,410,0,,,,0,0,0,0,0,0,0,0,26,133,0,3,0,0,3,0,330,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1327,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,38,377,0,,,,0,0,0,0,0,0,0,0,45,102,0,0,0,0,1,0,304,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1328,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,404,0,,,,0,0,0,0,0,0,0,0,40,121,0,0,0,0,1,0,317,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1329,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,37,379,0,,,,0,0,0,0,0,0,0,0,22,141,0,0,0,0,0,0,294,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1330,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,36,357,0,,,,0,0,0,0,0,0,0,0,17,128,0,0,0,0,0,0,287,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1331,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,34,292,0,,,,0,0,0,0,0,0,0,0,23,66,0,0,0,0,1,0,246,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1332,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,9,0,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1333,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 142,Subject 1334,EOT1 (1),Follow-Up,,,,,,,,,,34,269,0,,,,0,0,0,0,0,0,0,0,10,61,0,0,0,0,1,0,226,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1335,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,40,400,0,,,,0,0,0,2,0,0,0,2,16,330,0,0,0,0,1,0,321,5,0,0,1,4
Study 4,EMEA,ESP,Site 143,Subject 1336,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1337,EOT1 (1),Discontinued,,,,,,,,,,32,270,0,,,,0,0,0,0,0,0,0,0,1,62,0,0,0,0,2,0,228,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1338,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,36,299,0,,,,0,0,0,0,0,0,0,0,1,101,0,0,0,0,3,0,257,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1339,EOT1 (1),Discontinued,,,,,,,,,,13,121,0,,,,0,0,0,0,0,0,0,0,1,24,0,0,0,0,3,0,102,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1340,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,2,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1341,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,12,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1342,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,369,0,,,,0,0,0,0,0,0,0,0,21,115,0,0,0,0,3,0,291,3,0,0,1,2
Study 4,EMEA,ESP,Site 143,Subject 1343,Unplanned Visit (4),Discontinued,,,,,,,,,,30,309,0,,,,0,0,0,0,0,0,0,0,7,96,139,0,0,0,0,0,247,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1344,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1345,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,30,312,0,,,,0,0,0,0,0,0,0,0,12,90,0,0,0,0,5,0,259,2,0,0,2,0
Study 4,EMEA,ESP,Site 143,Subject 1346,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1347,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1348,Cycle 4 Week 1 (1),Discontinued,,,,,,,,,,15,121,0,,,,0,0,0,0,0,0,0,0,6,22,0,0,0,0,1,0,96,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1349,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1350,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 143,Subject 1351,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,272,0,,,,0,0,0,0,0,0,0,0,7,79,0,0,0,0,2,0,219,0,0,0,0,0
Study 4,EMEA,ESP,Site 141,Subject 1352,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,47,424,0,,,,1,0,0,0,0,0,0,1,15,334,0,0,0,0,5,0,345,8,0,0,8,0
Study 4,EMEA,ESP,Site 141,Subject 1353,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,36,367,0,,,,1,0,0,0,0,0,0,1,6,99,0,0,0,0,5,0,310,0,0,0,0,0
Study 4,EMEA,ESP,Site 141,Subject 1354,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,11,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1355,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,30,263,0,,,,0,0,0,0,0,0,0,0,2,218,0,0,0,0,2,0,223,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1356,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1357,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1358,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1359,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1360,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,396,0,,,,0,0,0,0,0,0,0,0,1,119,0,0,0,0,2,0,345,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1361,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1362,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1363,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 144,Subject 1364,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1365,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,41,348,0,,,,0,0,0,0,0,0,0,0,15,286,0,1,0,0,1,0,305,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1366,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,309,0,,,,0,0,0,0,0,0,0,0,3,90,0,0,0,0,0,0,266,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1367,EOT 2 (1),Discontinued,,,,,,,,,,28,192,0,,,,0,0,0,0,0,0,0,0,2,37,0,0,0,0,0,0,162,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1368,Week 24 (1),Discontinued,,,,,,,,,,32,245,0,,,,0,0,0,0,0,0,0,0,6,58,0,8,0,0,0,0,201,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1369,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,59,402,0,,,,0,1,0,0,0,0,0,1,19,84,0,0,0,0,0,0,324,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1370,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,270,0,,,,0,1,0,0,0,0,0,1,12,82,0,0,0,0,0,0,220,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1371,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 145,Subject 1372,EOT1 (1),Discontinued,,,,,,,,,,26,166,0,,,,0,0,0,0,0,0,0,0,1,27,0,0,0,0,0,0,138,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1373,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,416,0,,,,1,0,0,0,0,0,0,1,28,336,0,1,0,0,2,0,335,3,0,0,3,0
Study 4,EMEA,ESP,Site 146,Subject 1374,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1375,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1376,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,32,328,0,,,,0,0,0,0,0,0,0,0,15,90,0,0,0,0,3,0,262,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1377,Week 48 (1),Discontinued,,,,,,,,,,46,308,0,,,,0,0,0,0,0,0,0,0,1,67,0,0,0,0,1,0,258,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1378,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1379,Week 48 (1),Survival,,,,,,,,,,36,283,0,,,,0,0,0,0,0,0,0,0,5,69,0,0,0,0,1,0,235,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1380,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,350,0,,,,0,0,0,0,0,0,0,0,10,125,0,0,0,0,1,0,294,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1381,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1382,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,11,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1383,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,258,0,,,,0,0,0,0,0,0,0,0,12,69,0,0,0,0,0,0,214,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1384,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1385,Long term FU 1 (1),Follow-Up,,,,,,,,,,36,324,0,,,,0,0,0,0,0,0,0,0,16,87,0,0,0,0,1,0,265,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1386,Screening,Screen Failure,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,3,9,0,2,0,0,0,0,16,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1387,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,ESP,Site 146,Subject 1388,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,SWE,Site 147,Subject 1389,Unplanned Visit (2),Discontinued,,,,,,,,,,31,264,0,,,,0,0,0,0,0,0,0,0,5,223,0,0,0,0,0,0,184,38,0,0,38,0
Study 4,EMEA,SWE,Site 147,Subject 1390,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,244,0,,,,0,0,0,2,0,0,0,2,1,66,0,0,0,0,0,0,169,39,0,0,39,0
Study 4,EMEA,SWE,Site 147,Subject 1391,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,267,0,,,,0,0,0,0,0,0,0,0,1,84,0,0,0,0,0,0,191,40,0,0,40,0
Study 4,EMEA,SWE,Site 147,Subject 1392,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,293,0,,,,0,0,0,1,0,0,0,1,4,96,0,0,0,0,0,0,207,43,0,0,43,0
Study 4,EMEA,SWE,Site 148,Subject 1393,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,39,401,0,,,,0,0,0,0,0,0,0,0,18,327,0,0,0,0,1,0,246,45,4,34,46,37
Study 4,EMEA,SWE,Site 148,Subject 1394,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,368,0,,,,0,0,0,1,0,0,0,1,10,130,0,0,0,0,1,0,231,43,5,31,49,30
Study 4,EMEA,SWE,Site 148,Subject 1395,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,27,197,0,,,,0,0,0,0,0,0,0,0,1,35,0,0,0,0,0,0,128,33,0,5,38,0
Study 4,EMEA,SWE,Site 148,Subject 1396,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,299,0,,,,0,0,0,1,0,0,0,1,5,89,0,0,0,0,0,0,178,45,1,26,50,22
Study 4,EMEA,SWE,Site 148,Subject 1397,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,EMEA,SWE,Site 148,Subject 1398,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,264,0,,,,0,0,0,1,0,0,0,1,5,80,0,0,0,0,0,0,154,37,11,16,38,26
Study 4,EMEA,SWE,Site 148,Subject 1399,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,SWE,Site 148,Subject 1400,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,32,344,0,,,,0,2,0,5,0,0,0,7,20,99,0,0,0,0,2,0,180,39,23,35,50,47
Study 4,EMEA,SWE,Site 149,Subject 1401,EOT1 (1),Survival,,,,,,,,,,31,347,0,,,,0,0,0,0,0,0,0,0,11,287,0,0,0,0,0,0,241,40,1,4,42,3
Study 4,EMEA,SWE,Site 149,Subject 1402,EOT 2 (1),Discontinued,,,,,,,,,,46,383,0,,,,0,0,0,0,0,0,0,0,5,77,0,0,0,0,1,0,252,56,0,2,58,0
Study 4,EMEA,SWE,Site 149,Subject 1403,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,27,221,0,,,,0,0,0,0,0,0,0,0,3,46,0,0,0,0,0,0,139,33,0,5,38,0
Study 4,EMEA,SWE,Site 149,Subject 1404,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,308,0,,,,1,0,0,0,0,0,1,2,7,99,0,0,0,0,1,0,205,40,17,0,43,14
Study 4,EMEA,SWE,Site 149,Subject 1405,EOT1 (1),On Trial,,,,,,,,,,36,313,0,,,,12,0,0,0,0,0,0,12,22,85,0,1,0,0,1,0,173,59,12,5,42,34
Study 4,EMEA,SWE,Site 149,Subject 1406,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,325,0,,,,0,0,0,0,0,0,0,0,5,82,0,0,0,0,0,0,214,45,9,5,41,18
Study 4,EMEA,SWE,Site 149,Subject 1407,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,284,0,,,,0,0,0,0,0,0,0,0,7,93,0,2,0,0,0,0,175,43,9,6,41,17
Study 4,EMEA,CHE,Site 150,Subject 1408,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,320,0,,,,0,0,0,0,0,0,0,0,16,266,0,0,0,0,0,0,182,43,11,20,47,27
Study 4,EMEA,CHE,Site 150,Subject 1409,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,377,0,,,,0,0,0,0,0,0,0,0,27,162,0,0,0,0,2,0,204,59,6,14,54,25
Study 4,EMEA,CHE,Site 150,Subject 1410,Week 48 (1),Survival,,,,,,,,,,43,387,0,,,,0,0,0,0,0,0,0,0,18,144,0,0,0,0,1,0,227,56,4,9,64,5
Study 4,EMEA,CHE,Site 150,Subject 1411,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,342,0,,,,0,0,0,0,0,0,0,0,25,148,0,0,0,0,1,0,177,49,5,26,47,33
Study 4,EMEA,CHE,Site 151,Subject 1412,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,7,0,1,0,0,0,0,11,0,0,0,0,0
Study 4,EMEA,CHE,Site 151,Subject 1413,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,302,0,,,,0,0,0,2,0,0,0,2,12,241,175,0,0,0,0,0,257,0,0,0,0,0
Study 4,EMEA,CHE,Site 151,Subject 1414,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,268,0,,,,0,0,0,0,0,0,0,0,3,97,201,0,0,0,0,0,228,0,0,0,0,0
Study 4,EMEA,CHE,Site 151,Subject 1415,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,289,1,,,,0,0,0,0,0,0,0,0,6,91,10,0,0,0,0,0,244,0,0,0,0,0
Study 4,EMEA,CHE,Site 152,Subject 1416,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,8,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,EMEA,GBR,Site 153,Subject 1417,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,273,0,,,,1,3,0,4,0,0,0,8,8,211,0,1,0,0,1,0,151,47,3,31,42,39
Study 4,EMEA,GBR,Site 153,Subject 1418,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,260,0,,,,0,0,0,0,0,0,0,0,1,80,0,0,0,0,1,0,147,50,14,14,39,39
Study 4,EMEA,GBR,Site 153,Subject 1419,Screening,Screen Failure,,,,,,,,,,0,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,GBR,Site 153,Subject 1420,EOT1 (1),Discontinued,,,,,,,,,,2,44,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,1,0,36,3,1,1,5,0
Study 4,EMEA,GBR,Site 154,Subject 1421,Week 24 (1),Discontinued,,,,,,,,,,47,316,0,,,,0,0,0,0,0,0,0,0,2,263,266,0,0,0,2,0,264,0,0,0,0,0
Study 4,EMEA,GBR,Site 154,Subject 1422,Screening,Screen Failure,,,,,,,,,,1,25,0,,,,0,0,0,0,0,0,0,0,1,8,0,2,0,0,0,0,23,0,0,0,0,0
Study 4,EMEA,GBR,Site 154,Subject 1423,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,45,332,0,,,,0,0,0,0,0,0,0,0,4,85,3,1,0,0,1,0,274,0,0,0,0,0
Study 4,EMEA,GBR,Site 154,Subject 1424,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,31,279,0,,,,2,0,0,0,0,0,0,2,3,82,8,0,0,0,1,0,233,0,0,0,0,0
Study 4,EMEA,GBR,Site 154,Subject 1425,Week 24 (1),Discontinued,,,,,,,,,,31,287,0,,,,0,0,0,0,0,0,0,0,5,85,204,0,0,0,0,0,237,0,0,0,0,0
Study 4,EMEA,GBR,Site 154,Subject 1426,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,31,275,0,,,,0,0,0,1,0,0,0,1,4,81,221,0,0,0,1,0,239,0,0,0,0,0
Study 4,EMEA,GBR,Site 155,Subject 1427,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,253,0,,,,1,0,0,0,0,0,0,1,7,200,196,0,0,0,0,0,173,40,0,0,38,2
Study 4,EMEA,GBR,Site 155,Subject 1428,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,281,0,,,,3,0,0,0,0,0,0,3,11,77,11,0,0,0,0,0,184,45,5,0,38,12
Study 4,EMEA,GBR,Site 155,Subject 1429,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,250,0,,,,1,0,0,0,0,0,0,1,5,68,188,0,0,0,0,0,166,45,1,0,39,7
Study 4,EMEA,GBR,Site 155,Subject 1430,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,6,2,0,0,2,0
Study 4,EMEA,GBR,Site 156,Subject 1431,Unplanned Visit (19),Discontinued,,,,,,,,,,30,345,0,,,,0,2,0,0,0,0,0,2,14,265,5,0,0,0,1,0,248,38,0,0,38,0
Study 4,EMEA,GBR,Site 156,Subject 1432,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,288,0,,,,0,0,0,0,0,0,0,0,27,60,9,1,0,0,0,0,195,44,0,2,42,4
Study 4,EMEA,GBR,Site 156,Subject 1433,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,267,0,,,,1,0,0,0,0,0,0,1,17,67,10,0,0,0,0,0,184,42,0,0,42,0
Study 4,EMEA,GBR,Site 156,Subject 1434,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,14,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,GBR,Site 156,Subject 1435,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,15,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,GBR,Site 156,Subject 1436,Long term FU 2 (1),Follow-Up,,,,,,,,,,35,322,0,,,,0,2,0,0,0,0,0,2,36,101,21,2,0,0,1,0,212,44,0,0,44,0
Study 4,EMEA,GBR,Site 156,Subject 1437,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,15,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,GBR,Site 156,Subject 1438,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,1,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,GBR,Site 157,Subject 1439,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,288,0,,,,0,0,0,0,0,0,0,0,9,245,18,0,0,0,0,0,236,3,0,0,0,3
Study 4,EMEA,GBR,Site 157,Subject 1440,EOT1 (1),Discontinued,,,,,,,,,,27,231,0,,,,2,0,0,0,0,0,0,2,13,76,21,0,0,0,2,0,169,0,0,0,0,0
Study 4,EMEA,GBR,Site 157,Subject 1441,Cycle 2 Week 1_CO (1),On Trial,,,,,,,,,,43,382,0,,,,1,0,0,0,0,0,0,1,9,104,22,0,0,0,0,0,303,11,0,0,3,8
Study 4,EMEA,GBR,Site 158,Subject 1442,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,32,257,0,,,,0,1,0,9,0,0,0,10,13,200,9,2,0,0,0,0,156,36,6,13,41,14
Study 4,EMEA,GBR,Site 158,Subject 1443,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,269,0,,,,1,0,0,0,0,0,0,1,5,76,11,0,0,0,0,0,158,35,25,11,38,33
Study 4,EMEA,GBR,Site 158,Subject 1444,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,244,0,,,,0,0,0,1,0,0,0,1,2,70,181,0,0,0,0,0,133,34,30,11,42,33
Study 4,EMEA,GBR,Site 158,Subject 1445,EOT1 (1),Discontinued,,,,,,,,,,28,229,0,,,,0,0,0,0,0,0,0,0,5,51,6,0,0,0,2,0,129,38,19,1,58,0
Study 4,EMEA,GBR,Site 158,Subject 1446,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,245,0,,,,0,0,0,1,0,0,0,1,1,64,186,0,0,0,0,0,142,35,23,11,36,33
Study 4,EMEA,GBR,Site 158,Subject 1447,Cycle 1 Week 6_CO (1),Discontinued,,,,,,,,,,35,281,0,,,,1,0,0,4,0,0,0,5,12,74,22,0,0,0,0,0,171,43,8,1,49,3
Study 4,EMEA,GBR,Site 159,Subject 1448,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,10,0,0,0,0,0
Study 4,EMEA,GBR,Site 159,Subject 1449,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,267,0,,,,0,0,0,1,0,0,0,1,3,71,198,0,0,0,3,0,224,0,0,0,0,0
Study 4,EMEA,GBR,Site 159,Subject 1450,Cycle 5 Week 1 (1),Discontinued,,,,,,,,,,20,157,0,,,,0,0,0,0,0,0,0,0,3,127,1,0,0,0,1,0,126,0,0,0,0,0
Study 4,EMEA,GBR,Site 159,Subject 1451,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,251,0,,,,0,0,0,0,0,0,0,0,1,61,0,0,0,0,3,0,215,0,0,0,0,0
Study 4,EMEA,GBR,Site 159,Subject 1452,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,277,0,,,,0,0,0,1,0,0,0,1,7,93,0,0,0,0,1,0,220,0,0,0,0,0
Study 4,EMEA,GBR,Site 160,Subject 1453,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,GBR,Site 160,Subject 1454,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,33,268,0,,,,5,14,0,1,0,0,0,20,6,79,0,0,0,0,1,0,132,61,18,14,73,20
Study 4,EMEA,GBR,Site 160,Subject 1455,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,EMEA,CZE,Site 161,Subject 1456,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,268,0,,,,0,0,0,0,0,0,0,0,3,218,0,0,0,0,0,0,223,0,0,0,0,0
Study 4,EMEA,CZE,Site 161,Subject 1457,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,258,0,,,,1,0,0,0,0,0,0,1,5,70,0,0,0,0,0,0,211,0,0,0,0,0
Study 4,EMEA,CZE,Site 161,Subject 1458,EOT 2 (1),Discontinued,,,,,,,,,,45,339,0,,,,0,0,0,0,0,0,0,0,7,76,0,2,0,0,0,0,266,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1459,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,290,0,,,,0,0,0,0,0,0,0,0,3,249,0,0,0,0,0,0,247,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1460,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,244,0,,,,0,0,0,0,0,0,0,0,1,65,0,0,0,0,2,0,208,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1461,EOT 2 (1),Discontinued,,,,,,,,,,39,251,0,,,,0,0,0,0,0,0,0,0,1,46,0,0,0,0,0,0,211,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1462,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,5,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1463,EOT1 (1),Discontinued,,,,,,,,,,28,195,0,,,,0,0,0,0,0,0,0,0,1,36,0,0,0,0,0,0,165,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1464,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,269,0,,,,0,0,0,0,0,0,0,0,1,74,0,0,0,0,0,0,233,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1465,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,266,0,,,,0,0,0,0,0,0,0,0,5,80,0,0,0,0,0,0,217,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1466,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,270,0,,,,1,0,0,0,0,0,0,1,1,77,0,0,0,0,2,0,230,5,0,0,1,4
Study 4,EMEA,CZE,Site 162,Subject 1467,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,256,0,,,,0,0,0,0,0,0,0,0,1,68,0,0,0,0,0,0,221,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1468,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,270,0,,,,0,0,0,0,0,0,0,0,1,75,0,1,0,0,0,0,232,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1469,Cycle 6 Week 3_CO (1),On Trial,,,,,,,,,,58,384,0,,,,2,0,0,0,0,0,0,2,1,90,0,1,0,0,0,0,319,5,0,0,2,3
Study 4,EMEA,CZE,Site 162,Subject 1470,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,243,0,,,,0,0,0,0,0,0,0,0,1,59,0,0,0,0,0,0,206,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1471,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,264,0,,,,0,0,0,0,0,0,0,0,5,61,0,0,0,0,0,0,221,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1472,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1473,Week 24 (1),Discontinued,,,,,,,,,,27,167,0,,,,0,0,0,0,0,0,0,0,1,30,0,0,0,0,0,0,141,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1474,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,23,144,0,,,,0,0,0,0,0,0,0,0,1,18,0,0,0,0,0,0,121,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1475,Cycle 1 Week 6 (1),Discontinued,,,,,,,,,,7,81,0,,,,0,0,0,0,0,0,0,0,4,16,0,0,0,0,0,0,63,0,0,0,0,0
Study 4,EMEA,CZE,Site 162,Subject 1476,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 23,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,5,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 24,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,35,565,0,,,,0,0,0,1,0,0,0,1,1,482,0,2,0,0,1,0,413,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 637,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,368,0,,,,4,0,0,0,0,0,0,4,1,111,0,0,0,0,2,0,312,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1477,Week 48 (1),Discontinued,,,,,,,,,,31,248,0,,,,0,0,0,0,0,0,0,0,1,215,212,1,0,0,0,0,215,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1478,Week 48 (1),Discontinued,,,,,,,,,,53,363,0,,,,0,0,0,0,0,0,0,0,1,208,0,0,0,0,0,0,293,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1479,Screening,Discontinued,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,5,0,1,0,0,1,0,11,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1480,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,363,0,,,,0,0,0,0,0,0,0,0,1,154,0,0,0,0,0,0,292,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1481,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1482,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,351,0,,,,2,0,0,0,0,0,0,2,1,139,0,1,0,0,0,0,277,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1483,Week 24 (1),Discontinued,,,,,,,,,,35,277,0,,,,0,1,0,0,0,0,0,1,1,70,0,0,0,0,1,0,230,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1484,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,323,0,,,,0,1,0,6,0,0,0,7,14,120,0,0,0,0,0,0,256,0,0,0,0,0
Study 4,AMERICA,CAN,Site 13,Subject 1485,Cycle 1 Week 6_CO (1),On Trial,,,,,,,,,,37,392,0,,,,5,0,0,0,0,0,0,5,9,151,0,0,0,0,0,0,307,0,0,0,0,0
Study 4,AMERICA,CAN,Site 14,Subject 25,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,284,0,,,,0,0,0,0,0,0,0,0,3,239,0,0,0,0,1,0,237,0,0,0,0,0
Study 4,AMERICA,CAN,Site 14,Subject 26,Cycle 1 Week 1_CO (1),On Trial,,,,,,,,,,37,322,0,,,,4,1,0,0,0,0,0,5,1,105,0,0,0,0,1,0,279,0,0,0,0,0
Study 4,AMERICA,CAN,Site 14,Subject 27,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,31,232,0,,,,0,0,0,0,0,0,0,0,1,61,0,0,0,0,0,0,198,0,0,0,0,0
Study 4,AMERICA,CAN,Site 15,Subject 39,Unplanned Visit (7),On Trial,,,,,,,,,,34,310,0,,,,0,0,0,0,0,0,0,0,23,245,0,0,0,0,1,0,255,0,0,0,0,0
Study 4,AMERICA,CAN,Site 15,Subject 40,Unplanned Visit (3),On Trial,,,,,,,,,,34,269,0,,,,0,0,0,0,0,0,0,0,3,67,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,AMERICA,CAN,Site 15,Subject 41,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,1,0,8,0,0,0,0,0
Study 4,AMERICA,CAN,Site 16,Subject 55,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,276,0,,,,0,0,0,0,0,0,0,0,1,236,0,2,0,0,1,0,231,0,0,0,0,0
Study 4,AMERICA,CAN,Site 16,Subject 56,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,274,0,,,,1,0,0,0,0,0,0,1,1,71,0,1,0,0,1,0,234,0,0,0,0,0
Study 4,AMERICA,CAN,Site 16,Subject 57,Week 24 (1),Follow-Up,,,,,,,,,,46,310,0,,,,0,0,0,0,0,0,0,0,2,156,0,0,0,0,4,0,257,1,0,0,1,0
Study 4,AMERICA,CAN,Site 16,Subject 58,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,31,280,0,,,,0,0,0,0,0,0,0,0,1,75,0,0,0,0,0,0,225,0,0,0,0,0
Study 4,AMERICA,CAN,Site 16,Subject 59,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 647,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,321,0,,,,0,0,0,0,0,0,0,0,17,258,0,1,0,0,0,0,273,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 648,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,343,0,,,,0,0,0,0,0,0,0,0,12,115,0,0,0,0,1,0,295,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 649,Week 24 (1),Discontinued,,,,,,,,,,16,121,0,,,,0,0,0,0,0,0,0,0,3,29,0,0,0,0,0,0,99,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1486,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1487,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,308,0,,,,1,0,0,0,0,0,0,1,4,105,0,0,0,0,0,0,262,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1488,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,319,0,,,,0,0,0,0,0,0,0,0,7,113,0,0,0,0,0,0,259,5,0,0,1,4
Study 4,AMERICA,CAN,Site 91,Subject 1489,EOT1 (1),Discontinued,,,,,,,,,,13,109,0,,,,0,0,0,0,0,0,0,0,4,27,0,1,0,0,0,0,87,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1490,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1491,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1492,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,287,0,,,,0,0,0,0,0,0,0,0,7,87,0,0,0,0,0,0,236,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1493,Long term FU 8 (1),Follow-Up,,,,,,,,,,36,273,0,,,,0,0,0,0,0,0,0,0,4,79,0,0,0,0,2,0,233,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1494,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,CAN,Site 91,Subject 1495,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,298,0,,,,0,0,0,0,0,0,0,0,7,94,0,0,0,0,0,0,248,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 650,Post CYCLE 6 Visit 1 (1),Discontinued,,,,,,,,,,28,215,0,,,,0,0,0,0,0,0,0,0,1,175,0,0,0,0,0,0,177,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 651,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,279,0,,,,0,0,0,0,0,0,0,0,14,118,0,0,0,0,1,0,233,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 652,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,295,0,,,,0,0,0,0,0,0,0,0,1,100,0,0,0,0,0,0,257,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 653,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,282,0,,,,1,0,0,0,0,0,0,1,1,88,0,0,0,0,0,0,237,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 654,Week 24 (1),Discontinued,,,,,,,,,,32,239,0,,,,0,0,0,0,0,0,0,0,1,62,0,0,0,0,0,0,200,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 655,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,260,0,,,,0,0,0,0,0,0,0,0,7,71,0,0,0,0,2,0,221,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 656,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,10,88,0,,,,0,0,0,0,0,0,0,0,1,20,0,0,0,0,1,0,78,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 657,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 658,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,256,0,,,,0,0,0,0,0,0,0,0,1,91,0,0,0,0,0,0,214,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 659,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 660,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 661,EOT1 (1),Discontinued,,,,,,,,,,28,184,0,,,,0,0,0,0,0,0,0,0,4,39,0,0,0,0,0,0,142,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 662,Screening,Discontinued,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,0,8,0,1,0,0,0,0,12,0,0,0,0,0
Study 4,AMERICA,CAN,Site 92,Subject 663,Screening,Discontinued,,,,,,,,,,1,21,0,,,,0,0,0,0,0,0,0,0,1,11,1,2,0,0,0,0,15,0,0,0,0,0
Study 4,AMERICA,CAN,Site 163,Subject 1496,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,33,253,0,,,,0,0,0,0,0,0,0,0,1,217,0,0,0,0,0,0,212,0,0,0,0,0
Study 4,AMERICA,CAN,Site 163,Subject 1497,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,308,0,,,,0,1,0,0,0,0,0,1,4,115,0,1,0,0,2,0,246,1,0,0,1,0
Study 4,AMERICA,CAN,Site 164,Subject 1498,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,297,0,,,,0,0,0,0,0,0,0,0,9,247,0,0,0,0,0,0,176,41,4,25,44,26
Study 4,AMERICA,CAN,Site 164,Subject 1499,Week 48 (1),Survival,,,,,,,,,,36,282,0,,,,0,0,0,0,0,0,0,0,9,66,0,0,0,0,0,0,168,44,2,7,50,3
Study 4,AMERICA,CAN,Site 164,Subject 1500,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,328,0,,,,0,0,0,0,0,0,0,0,20,113,0,0,0,0,1,0,182,52,6,17,48,27
Study 4,AMERICA,CAN,Site 164,Subject 1501,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,CAN,Site 164,Subject 1502,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,17,161,0,,,,0,0,0,0,0,0,0,0,10,48,0,0,0,0,0,0,100,25,0,2,27,0
Study 4,AMERICA,CAN,Site 164,Subject 1503,EOT1 (1),Discontinued,,,,,,,,,,32,348,0,,,,0,0,0,0,0,0,0,0,28,127,0,0,0,0,1,0,204,45,6,3,49,5
Study 4,AMERICA,CAN,Site 164,Subject 1504,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,53,400,0,,,,0,0,0,0,0,0,0,0,12,99,0,0,0,0,0,0,241,69,0,8,76,1
Study 4,AMERICA,CAN,Site 164,Subject 1505,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,305,0,,,,0,0,0,0,0,0,0,0,7,102,0,0,0,0,1,0,159,44,1,47,62,30
Study 4,AMERICA,CAN,Site 164,Subject 1506,Week 48 (1),Discontinued,,,,,,,,,,34,260,0,,,,0,0,0,0,0,0,0,0,1,53,0,0,0,0,0,0,170,43,0,9,49,3
Study 4,AMERICA,CAN,Site 164,Subject 1507,Week 24 (1),Discontinued,,,,,,,,,,39,275,0,,,,0,0,0,0,0,0,0,0,8,64,0,11,0,0,1,0,157,49,1,13,63,0
Study 4,AMERICA,CAN,Site 164,Subject 1508,Week 48 (1),Survival,,,,,,,,,,35,295,0,,,,0,0,0,0,0,0,0,0,13,93,0,0,0,0,0,0,186,46,0,6,47,5
Study 4,AMERICA,CAN,Site 164,Subject 1509,Week 24 (1),Survival,,,,,,,,,,30,253,0,,,,0,0,0,0,0,0,0,0,19,82,0,0,0,0,0,0,140,42,0,9,48,3
Study 4,AMERICA,CAN,Site 164,Subject 1510,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,CAN,Site 164,Subject 1511,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,14,146,0,,,,0,0,0,0,0,0,0,0,7,45,0,0,0,0,0,0,89,22,1,2,25,0
Study 4,ASIA,CHN,Site 165,Subject 1512,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,363,0,,,,0,0,0,0,0,0,0,0,1,303,0,0,0,0,3,0,286,37,0,0,37,0
Study 4,ASIA,CHN,Site 165,Subject 1513,Screening,Discontinued,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,7,2,0,0,2,0
Study 4,ASIA,CHN,Site 166,Subject 1514,Cycle 3 Week 6_CO (1),On Trial,,,,,,,,,,48,466,0,,,,3,0,0,3,3,0,0,9,49,365,0,0,0,0,3,0,408,0,0,0,0,0
Study 4,ASIA,CHN,Site 166,Subject 1515,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,29,333,0,,,,0,0,0,0,0,0,0,0,12,75,0,1,0,0,0,0,277,0,0,0,0,0
Study 4,ASIA,CHN,Site 166,Subject 1516,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,376,0,,,,0,0,0,3,0,0,0,3,11,95,0,0,0,0,0,0,323,0,0,0,0,0
Study 4,ASIA,CHN,Site 166,Subject 1517,Post CYCLE 6 Visit 5 (1),On Trial,,,,,,,,,,32,379,0,,,,0,0,0,2,0,0,0,2,15,70,0,0,0,0,1,0,323,0,0,0,0,0
Study 4,ASIA,CHN,Site 166,Subject 1518,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,392,0,,,,5,0,0,0,0,0,0,5,25,91,0,0,0,0,0,0,327,3,0,0,3,0
Study 4,ASIA,CHN,Site 167,Subject 1519,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,353,0,,,,0,0,0,0,1,0,0,1,7,296,0,0,0,0,0,0,249,44,19,0,48,15
Study 4,ASIA,CHN,Site 168,Subject 1520,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,401,0,,,,3,0,0,0,0,0,0,3,14,336,0,0,0,0,3,0,362,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1521,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1522,Screening,Discontinued,,,,,,,,,,1,62,0,,,,0,0,0,0,0,0,0,0,4,17,0,1,0,0,0,0,51,0,0,1,1,0
Study 4,ASIA,CHN,Site 168,Subject 1523,Screening,Discontinued,,,,,,,,,,1,49,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,45,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1524,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,355,0,,,,2,0,0,0,0,0,0,2,2,65,0,1,0,0,0,0,318,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1525,Cycle 3 Week 5 (1),Discontinued,,,,,,,,,,14,159,0,,,,0,0,0,0,0,0,0,0,4,25,0,0,0,0,1,0,135,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1526,Cycle 5 Week 1 (1),Discontinued,,,,,,,,,,20,207,0,,,,0,0,0,0,0,0,0,0,1,28,0,0,0,0,2,0,183,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1527,Week 24 (1),Follow-Up,,,,,,,,,,58,513,0,,,,0,0,0,0,0,0,0,0,1,65,0,0,0,0,0,0,453,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1528,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1529,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,365,0,,,,0,0,0,2,0,0,0,2,8,69,0,0,0,0,0,0,329,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1530,Unplanned Visit (10),Discontinued,,,,,,,,,,30,374,0,,,,1,0,0,1,0,0,1,3,14,58,0,1,0,0,2,0,323,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1531,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,349,0,,,,1,0,0,0,0,0,0,1,10,72,0,0,0,0,0,4,313,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1532,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,350,0,,,,1,0,0,1,0,0,0,2,12,73,0,0,0,0,1,0,303,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1533,Unplanned Visit_CO (17),Discontinued,,,,,,,,,,43,490,0,,,,1,0,0,0,0,0,0,1,11,78,0,6,0,0,0,0,419,1,0,0,1,0
Study 4,ASIA,CHN,Site 168,Subject 1534,Cycle 5 Week 1 (1),Discontinued,,,,,,,,,,20,209,0,,,,0,0,0,0,0,0,0,0,1,25,0,0,0,0,2,0,186,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1535,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,CHN,Site 168,Subject 1536,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,CHN,Site 169,Subject 1537,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,356,0,,,,0,0,0,0,0,0,0,0,1,282,0,0,0,0,2,0,316,0,0,0,0,0
Study 4,ASIA,CHN,Site 169,Subject 1538,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1539,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,5,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1540,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,7,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1541,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,399,0,,,,0,0,0,0,3,0,0,3,9,220,0,0,0,0,0,0,347,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1542,Week 24 (1),Discontinued,,,,,,,,,,40,420,0,,,,0,0,0,0,1,0,0,1,5,194,0,0,0,0,0,0,362,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1543,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,394,0,,,,0,0,0,0,1,0,0,1,7,92,0,0,0,0,2,0,342,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1544,Long term FU 1 (1),Discontinued,,,,,,,,,,23,232,0,,,,0,0,0,0,0,0,0,0,3,39,0,0,0,0,1,0,201,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1545,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,CHN,Site 170,Subject 1546,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,39,385,0,,,,0,0,0,0,0,0,0,0,4,72,0,0,0,0,0,0,339,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1547,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,43,441,0,,,,0,0,0,0,0,0,0,0,14,359,0,0,0,0,0,0,370,4,0,0,4,0
Study 4,ASIA,CHN,Site 171,Subject 1548,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,349,0,,,,0,0,0,0,0,0,0,0,11,71,0,0,0,0,0,0,299,3,0,0,0,3
Study 4,ASIA,CHN,Site 171,Subject 1549,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,365,0,,,,0,0,0,0,0,0,0,0,5,77,0,0,0,0,0,0,317,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1550,Screening,Screen Failure,,,,,,,,,,1,24,0,,,,0,0,0,0,0,0,0,0,1,5,0,3,0,0,0,0,21,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1551,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,352,0,,,,0,0,0,0,0,0,0,0,5,81,0,0,0,0,0,0,308,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1552,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,35,369,0,,,,0,0,0,0,0,0,0,0,1,61,0,0,0,0,0,0,329,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1553,Unplanned Visit_CO (5),Discontinued,,,,,,,,,,36,391,0,,,,0,0,0,0,0,0,0,0,9,70,0,0,0,0,0,0,333,3,0,0,3,0
Study 4,ASIA,CHN,Site 171,Subject 1554,Week 48 (1),Survival,,,,,,,,,,35,311,1,,,,0,0,0,0,0,0,0,0,1,59,0,0,0,0,1,0,276,1,0,0,1,0
Study 4,ASIA,CHN,Site 171,Subject 1555,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,405,0,,,,0,0,0,0,0,0,0,0,10,99,0,0,0,0,0,0,344,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1556,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,363,0,,,,2,0,0,0,0,0,0,2,2,76,0,0,0,0,0,0,326,1,0,0,1,0
Study 4,ASIA,CHN,Site 171,Subject 1557,Screening,Screen Failure,,,,,,,,,,1,24,0,,,,0,0,0,0,0,0,0,0,0,5,0,3,0,0,0,0,22,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1558,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,386,0,,,,2,0,0,0,0,0,0,2,2,68,0,0,0,0,0,0,335,9,0,0,2,7
Study 4,ASIA,CHN,Site 171,Subject 1559,Week 48 (1),Discontinued,,,,,,,,,,32,331,0,,,,1,0,0,0,0,0,0,1,4,48,0,0,0,0,0,0,284,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1560,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,358,0,,,,0,0,0,0,0,0,0,0,1,75,0,0,0,0,0,0,320,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1561,Week 24 (1),Discontinued,,,,,,,,,,32,303,0,,,,0,1,0,0,0,0,0,1,5,52,0,0,0,0,1,0,262,1,0,0,1,0
Study 4,ASIA,CHN,Site 171,Subject 1562,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,357,0,,,,0,0,0,0,0,0,0,0,1,75,0,0,0,0,0,0,320,0,0,0,0,0
Study 4,ASIA,CHN,Site 171,Subject 1563,Cycle 1 Week 1_CO (1),On Trial,,,,,,,,,,36,376,0,,,,11,0,0,0,0,0,0,11,21,64,0,0,0,0,0,0,314,16,0,0,4,12
Study 4,ASIA,CHN,Site 171,Subject 1564,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,349,0,,,,2,0,0,0,0,0,0,2,2,75,0,0,0,0,0,0,304,9,0,0,2,7
Study 4,ASIA,CHN,Site 171,Subject 1565,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,330,0,,,,2,0,0,0,0,0,0,2,1,65,0,0,0,0,0,0,288,7,0,0,0,7
Study 4,ASIA,CHN,Site 172,Subject 1566,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,435,0,,,,0,0,0,0,0,0,0,0,7,375,0,0,0,0,0,0,376,5,0,0,3,2
Study 4,ASIA,CHN,Site 172,Subject 1567,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,405,0,,,,0,0,0,0,0,0,0,0,12,89,0,0,0,0,0,0,346,6,0,0,5,1
Study 4,ASIA,CHN,Site 172,Subject 1568,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,374,0,,,,0,0,0,1,0,0,0,1,7,74,0,0,0,0,1,0,322,4,0,0,2,2
Study 4,ASIA,CHN,Site 172,Subject 1569,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,409,0,,,,0,0,0,0,0,0,0,0,1,76,0,0,0,0,0,0,362,0,0,0,0,0
Study 4,ASIA,CHN,Site 173,Subject 1570,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,357,0,,,,0,0,0,0,0,0,0,0,17,297,0,0,0,0,0,0,305,8,0,0,3,5
Study 4,ASIA,CHN,Site 173,Subject 1571,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,382,0,,,,0,0,0,0,0,0,0,0,1,90,0,0,0,0,1,0,337,0,0,0,0,0
Study 4,ASIA,CHN,Site 173,Subject 1572,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,31,376,0,,,,1,0,0,0,0,0,0,1,5,83,1,0,0,0,2,0,330,0,0,0,0,0
Study 4,ASIA,CHN,Site 173,Subject 1573,Cycle 6 Week 6 (1),Survival,,,,,,,,,,27,308,0,,,,0,0,0,0,0,0,0,0,3,49,0,0,0,0,2,0,266,0,0,0,0,0
Study 4,ASIA,CHN,Site 173,Subject 1574,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,340,0,,,,0,0,0,0,0,0,0,0,3,67,0,0,0,0,0,0,298,0,0,0,0,0
Study 4,ASIA,CHN,Site 173,Subject 1575,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,340,0,,,,0,0,0,0,0,0,0,0,2,74,0,2,0,0,2,0,297,0,0,0,0,0
Study 4,ASIA,CHN,Site 173,Subject 1576,Unplanned Recist (2),Discontinued,,,,,,,,,,20,247,0,,,,0,0,0,0,0,0,0,0,1,45,0,0,0,0,2,0,211,0,0,0,0,0
Study 4,ASIA,CHN,Site 174,Subject 1577,Screening,Discontinued,,,,,,,,,,0,10,0,,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,CHN,Site 174,Subject 1578,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,CHN,Site 174,Subject 1579,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,475,1,,,,0,0,0,0,2,0,0,2,35,386,0,0,0,0,1,0,354,16,0,0,14,2
Study 4,ASIA,CHN,Site 174,Subject 1580,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,35,596,0,,,,0,0,0,0,5,0,0,5,10,99,0,1,0,0,0,0,491,19,0,0,7,12
Study 4,ASIA,CHN,Site 174,Subject 1581,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,354,0,,,,0,0,0,2,1,0,0,3,3,75,0,0,0,0,0,0,310,2,0,0,2,0
Study 4,ASIA,CHN,Site 174,Subject 1582,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,42,546,0,,,,2,0,0,0,3,0,0,5,27,161,0,0,0,0,0,0,428,13,0,0,12,1
Study 4,ASIA,CHN,Site 174,Subject 1583,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,351,0,,,,0,0,0,0,1,0,0,1,2,65,0,0,0,0,0,0,314,1,0,0,1,0
Study 4,ASIA,CHN,Site 174,Subject 1584,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,363,1,,,,0,0,0,0,3,0,0,3,4,76,0,0,0,0,0,0,311,5,0,0,5,0
Study 4,ASIA,CHN,Site 174,Subject 1585,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,CHN,Site 174,Subject 1586,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,421,0,,,,2,0,0,0,1,0,0,3,17,82,0,0,0,0,1,0,353,2,0,0,2,0
Study 4,ASIA,CHN,Site 174,Subject 1587,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,408,0,,,,0,0,0,0,0,0,0,0,17,98,0,0,0,0,0,0,352,1,0,0,1,0
Study 4,ASIA,CHN,Site 174,Subject 1588,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,386,0,,,,4,0,0,0,3,0,0,7,5,93,0,0,0,0,0,0,323,7,0,0,7,0
Study 4,ASIA,CHN,Site 174,Subject 1589,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,35,579,0,,,,0,0,0,0,1,0,0,1,2,83,0,0,0,0,0,0,494,1,0,0,1,0
Study 4,ASIA,CHN,Site 174,Subject 1590,Week 48 (1),Follow-Up,,,,,,,,,,43,441,1,,,,0,0,0,0,0,0,0,0,1,114,0,0,0,0,0,0,358,1,0,0,1,0
Study 4,ASIA,CHN,Site 175,Subject 1591,Post CYCLE 6 Visit 4 (1),Survival,,,,,,,,,,31,487,1,,,,2,0,0,0,0,0,0,2,42,389,0,0,0,0,1,0,378,9,0,0,9,0
Study 4,ASIA,HKG,Site 176,Subject 1592,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,8,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1593,Post CYCLE 6 Visit 7 (1),Discontinued,,,,,,,,,,34,299,0,,,,0,0,0,0,0,0,0,0,9,253,0,1,0,0,1,0,238,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1594,Unplanned Visit (35),On Trial,,,,,,,,,,35,423,0,,,,1,0,0,0,0,0,0,1,7,80,0,1,0,0,1,0,339,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1595,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,316,0,,,,0,0,0,0,0,0,0,0,4,79,0,0,0,0,0,0,261,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1596,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,291,0,,,,0,0,0,0,0,0,0,0,12,77,0,3,0,0,1,0,233,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1597,Unplanned Visit (11),On Trial,,,,,,,,,,34,285,0,,,,0,0,0,0,0,0,0,0,12,56,0,3,0,0,0,0,232,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1598,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,371,0,,,,0,0,0,0,0,0,0,0,10,105,0,0,0,0,0,0,300,0,0,0,0,0
Study 4,ASIA,JPN,Site 177,Subject 1599,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,271,0,,,,0,0,0,0,0,0,0,0,2,72,0,0,0,0,0,0,229,0,0,0,0,0
Study 4,ASIA,JPN,Site 18,Subject 63,Week 24 (1),Discontinued,,,,,,,,,,32,225,0,,,,0,0,0,0,0,0,0,0,8,176,0,0,0,0,1,0,142,38,0,0,38,0
Study 4,ASIA,JPN,Site 18,Subject 64,Week 48 (1),Survival,,,,,,,,,,32,283,0,,,,0,0,0,0,0,0,0,0,7,53,0,0,0,0,1,0,184,39,4,0,41,2
Study 4,ASIA,JPN,Site 178,Subject 1600,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,264,0,,,,0,0,0,0,0,0,0,0,1,217,0,0,0,0,0,0,174,47,6,0,42,11
Study 4,ASIA,JPN,Site 20,Subject 82,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,JPN,Site 20,Subject 1601,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,282,0,,,,0,0,0,0,0,0,0,0,1,239,0,2,0,0,1,0,235,0,0,0,0,0
Study 4,ASIA,JPN,Site 20,Subject 1602,EOT 2 (1),Discontinued,,,,,,,,,,41,303,0,,,,0,0,0,0,0,0,0,0,1,85,0,3,0,0,0,0,253,0,0,0,0,0
Study 4,ASIA,JPN,Site 20,Subject 1603,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,247,0,,,,0,0,0,0,0,0,0,0,1,74,0,0,0,0,0,0,210,0,0,0,0,0
Study 4,ASIA,JPN,Site 179,Subject 1604,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,ASIA,JPN,Site 179,Subject 1605,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,265,0,,,,0,0,0,0,0,0,0,0,3,224,0,0,0,0,0,0,226,1,0,0,1,0
Study 4,ASIA,JPN,Site 179,Subject 1606,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,263,0,,,,0,0,0,0,0,0,0,0,1,72,0,0,0,0,0,0,226,0,0,0,0,0
Study 4,ASIA,JPN,Site 179,Subject 1607,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,295,0,,,,0,1,0,0,0,0,0,1,5,96,0,0,0,0,0,0,244,1,0,0,1,0
Study 4,ASIA,JPN,Site 179,Subject 1608,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,286,0,,,,0,0,0,0,0,0,0,0,6,75,0,0,0,0,0,0,236,0,0,0,0,0
Study 4,ASIA,JPN,Site 179,Subject 1609,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,238,0,,,,0,0,0,0,0,0,0,0,1,74,0,0,0,0,0,0,204,0,0,0,0,0
Study 4,ASIA,JPN,Site 180,Subject 1610,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,268,0,,,,0,0,0,0,0,0,0,0,9,222,0,0,0,0,1,0,218,0,0,0,0,0
Study 4,ASIA,JPN,Site 180,Subject 1611,EOT1 (1),Survival,,,,,,,,,,29,290,0,,,,0,0,0,0,0,0,0,0,7,86,0,0,0,0,2,0,227,0,0,0,0,0
Study 4,ASIA,JPN,Site 180,Subject 1612,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,253,0,,,,0,0,0,0,0,0,0,0,7,60,0,0,0,0,0,0,218,0,0,0,0,0
Study 4,ASIA,JPN,Site 180,Subject 1613,Screening,Screen Failure,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,0,6,0,1,0,0,0,0,21,0,0,0,0,0
Study 4,ASIA,JPN,Site 181,Subject 1614,Cycle 6 Week 1 (1),Discontinued,,,,,,,,,,24,175,0,,,,0,0,0,0,0,0,0,0,1,143,0,0,0,0,1,0,139,0,0,0,0,0
Study 4,ASIA,JPN,Site 182,Subject 1615,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,276,0,,,,1,0,0,0,0,0,0,1,8,220,0,0,0,0,0,0,177,51,2,0,41,12
Study 4,ASIA,JPN,Site 183,Subject 1616,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,269,0,,,,0,0,0,1,0,0,0,1,4,226,0,0,0,0,0,0,223,0,0,0,0,0
Study 4,ASIA,JPN,Site 183,Subject 1617,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,260,0,,,,1,0,0,0,0,0,0,1,3,83,0,0,0,0,0,0,209,0,0,0,0,0
Study 4,ASIA,JPN,Site 183,Subject 1618,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,264,0,,,,0,0,0,0,0,0,0,0,10,85,0,0,0,0,0,0,212,0,0,0,0,0
Study 4,ASIA,JPN,Site 22,Subject 86,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,247,0,,,,0,0,0,0,0,0,0,0,1,199,0,0,0,0,0,0,210,0,0,0,0,0
Study 4,ASIA,JPN,Site 22,Subject 1619,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,254,0,,,,0,1,0,0,0,0,0,1,9,72,0,0,0,0,1,0,212,0,0,0,0,0
Study 4,ASIA,JPN,Site 22,Subject 1620,Week 24 (1),Discontinued,,,,,,,,,,30,219,0,,,,0,0,0,0,0,0,0,0,1,53,0,0,0,0,1,0,181,0,0,0,0,0
Study 4,ASIA,JPN,Site 22,Subject 1621,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,ASIA,JPN,Site 22,Subject 1622,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,245,0,,,,0,0,0,0,0,0,0,0,1,69,0,0,0,0,0,0,204,0,0,0,0,0
Study 4,ASIA,JPN,Site 22,Subject 1623,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,ASIA,JPN,Site 184,Subject 1624,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,313,0,,,,0,0,0,0,0,0,0,0,1,274,0,0,0,0,0,0,263,0,0,0,0,0
Study 4,ASIA,JPN,Site 184,Subject 1625,Long term FU 8 (1),Follow-Up,,,,,,,,,,34,263,0,,,,0,0,0,0,0,0,0,0,1,97,0,0,0,0,0,0,218,0,0,0,0,0
Study 4,ASIA,JPN,Site 184,Subject 1626,Unplanned Recist (1),Follow-Up,,,,,,,,,,35,301,0,,,,1,0,0,0,0,0,0,1,8,97,0,2,0,0,0,0,241,7,0,0,1,6
Study 4,ASIA,JPN,Site 184,Subject 1627,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,ASIA,JPN,Site 185,Subject 1628,Screening,Discontinued,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,9,0,1,0,0,0,0,11,0,0,0,0,0
Study 4,ASIA,JPN,Site 185,Subject 1629,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,305,0,,,,0,0,0,0,0,0,0,0,1,248,0,0,0,0,1,0,250,0,0,0,0,0
Study 4,ASIA,JPN,Site 185,Subject 1630,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,264,0,,,,0,0,0,0,0,0,0,0,1,72,0,0,0,0,0,0,227,0,0,0,0,0
Study 4,ASIA,JPN,Site 185,Subject 1631,Week 48 (1),Discontinued,,,,,,,,,,32,242,0,,,,0,0,0,0,0,0,0,0,1,59,0,0,0,0,0,0,200,0,0,0,0,0
Study 4,ASIA,JPN,Site 185,Subject 1632,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,290,0,,,,0,0,0,0,0,0,0,0,1,253,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,ASIA,JPN,Site 185,Subject 1633,Unplanned Recist (1),On Trial,,,,,,,,,,34,324,0,,,,0,0,0,0,0,0,0,0,1,137,0,0,0,0,0,0,239,0,0,0,0,0
Study 4,ASIA,JPN,Site 186,Subject 1634,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,248,0,,,,0,0,0,0,0,0,0,0,1,199,0,0,0,0,0,0,210,0,0,0,0,0
Study 4,ASIA,JPN,Site 187,Subject 1635,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,285,0,,,,1,0,0,0,0,0,0,1,9,219,0,0,0,0,0,0,238,0,0,0,0,0
Study 4,ASIA,JPN,Site 187,Subject 1636,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,318,0,,,,0,0,0,0,0,0,0,0,1,83,0,0,0,0,0,0,274,0,0,0,0,0
Study 4,ASIA,JPN,Site 188,Subject 1637,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,303,0,,,,0,0,0,0,0,0,0,0,15,251,0,2,0,0,0,0,228,9,0,0,6,3
Study 4,ASIA,JPN,Site 188,Subject 1638,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,283,0,,,,0,0,0,0,0,0,0,0,1,105,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,ASIA,JPN,Site 189,Subject 1639,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,335,0,,,,0,0,0,0,0,0,0,0,26,267,0,1,0,0,1,0,221,52,0,0,45,7
Study 4,ASIA,JPN,Site 189,Subject 1640,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,277,0,,,,0,1,0,0,0,0,0,1,9,80,0,0,0,0,0,0,176,41,8,0,43,6
Study 4,AMERICA,USA,Site 190,Subject 1641,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,29,234,0,,,,0,0,0,0,0,0,0,0,1,193,0,0,0,0,1,0,155,37,0,0,37,0
Study 4,AMERICA,USA,Site 190,Subject 1642,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,344,0,,,,0,0,0,0,0,0,0,0,1,123,0,0,0,0,0,0,228,51,1,7,48,11
Study 4,AMERICA,USA,Site 190,Subject 1643,Post CYCLE 6 Visit 6 (1),Discontinued,,,,,,,,,,33,338,0,,,,0,0,0,0,0,0,0,0,1,122,0,0,0,0,1,0,228,45,0,0,45,0
Study 4,AMERICA,USA,Site 190,Subject 1644,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 190,Subject 1645,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,355,0,,,,0,0,0,0,0,0,0,0,1,134,0,0,0,0,0,0,242,52,8,0,48,12
Study 4,AMERICA,USA,Site 190,Subject 1646,Post CYCLE 6 Visit 10 (1),Survival,,,,,,,,,,37,344,0,,,,1,0,0,0,0,0,0,1,2,132,0,0,0,0,1,0,243,45,0,1,45,1
Study 4,AMERICA,USA,Site 190,Subject 1647,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 190,Subject 1648,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,359,0,,,,0,0,0,0,0,0,0,0,0,126,0,0,0,0,0,0,224,50,30,6,69,17
Study 4,AMERICA,USA,Site 190,Subject 1649,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,401,0,,,,0,0,0,0,0,0,0,0,1,169,0,0,0,0,0,0,275,51,9,6,49,17
Study 4,AMERICA,USA,Site 190,Subject 1650,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 190,Subject 1651,Post CYCLE 6 Visit 1 (1),Discontinued,,,,,,,,,,28,253,0,,,,0,0,0,0,0,0,0,0,1,86,0,0,0,0,1,0,157,38,0,0,38,0
Study 4,AMERICA,USA,Site 190,Subject 1652,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,36,274,0,,,,0,0,0,0,0,0,0,0,1,81,0,0,0,0,0,0,194,41,1,0,42,0
Study 4,AMERICA,USA,Site 190,Subject 1653,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 190,Subject 1654,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 190,Subject 1655,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,20,0,,,,0,0,0,0,0,0,0,0,1,4,0,3,0,0,0,0,14,3,0,0,3,0
Study 4,AMERICA,USA,Site 190,Subject 1656,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,11,3,0,0,3,0
Study 4,AMERICA,USA,Site 190,Subject 1657,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,405,0,,,,0,0,0,0,0,0,0,0,1,176,0,0,0,0,1,0,254,63,1,11,55,20
Study 4,AMERICA,USA,Site 190,Subject 1658,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,415,0,,,,0,0,0,0,0,0,0,0,1,185,0,1,0,0,1,0,266,50,12,8,58,12
Study 4,AMERICA,USA,Site 190,Subject 1659,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,314,0,,,,0,0,0,0,0,0,0,0,1,112,0,0,0,0,0,0,208,43,4,7,44,10
Study 4,AMERICA,USA,Site 190,Subject 1660,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,326,0,,,,0,0,0,0,0,0,0,0,3,111,0,0,0,0,1,0,220,54,5,0,43,16
Study 4,AMERICA,USA,Site 190,Subject 1661,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,353,0,,,,0,0,0,0,0,0,0,0,1,132,0,0,0,0,1,0,238,45,4,9,45,13
Study 4,AMERICA,USA,Site 190,Subject 1662,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,29,236,0,,,,0,0,0,0,0,0,0,0,1,70,0,0,0,0,0,0,149,37,0,0,37,0
Study 4,AMERICA,USA,Site 190,Subject 1663,EOT1 (1),Discontinued,,,,,,,,,,14,116,0,,,,0,0,0,0,0,0,0,0,1,28,0,0,0,0,0,0,77,19,0,0,19,0
Study 4,AMERICA,USA,Site 190,Subject 1664,Unplanned Recist (3),Discontinued,,,,,,,,,,33,267,0,,,,0,0,0,0,0,0,0,0,1,68,0,0,0,0,1,0,187,39,0,0,39,0
Study 4,AMERICA,USA,Site 190,Subject 1665,Post CYCLE 6 Visit 2 (1),Survival,,,,,,,,,,29,288,0,,,,0,0,0,0,0,0,0,0,1,133,0,0,0,0,0,0,169,44,1,0,44,1
Study 4,AMERICA,USA,Site 190,Subject 1666,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,288,0,,,,0,0,0,0,0,0,0,0,0,88,0,0,0,0,0,0,186,43,6,3,40,12
Study 4,AMERICA,USA,Site 190,Subject 1667,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,264,0,,,,0,0,0,0,0,0,0,0,1,70,0,0,0,0,0,0,167,39,5,7,40,11
Study 4,AMERICA,USA,Site 191,Subject 1668,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1669,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1670,EOT1 (1),Discontinued,,,,,,,,,,12,100,0,,,,0,0,0,0,0,0,0,0,1,17,0,0,0,0,1,0,86,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1671,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,330,0,,,,0,0,0,0,0,0,0,0,2,274,0,0,0,0,0,0,288,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1672,EOT1 (1),Survival,,,,,,,,,,31,219,0,,,,0,0,0,0,0,0,0,0,1,60,0,0,0,0,1,0,186,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1673,Post CYCLE 6 Visit 4 (1),Survival,,,,,,,,,,31,281,0,,,,0,0,0,0,0,0,0,0,7,97,10,0,0,0,1,0,226,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1674,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1675,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,11,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1676,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1677,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1678,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1679,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,325,0,,,,0,0,0,0,0,0,0,0,14,96,0,0,0,0,0,0,275,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1680,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1681,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,12,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1682,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,303,0,,,,0,0,0,0,0,0,0,0,5,101,0,0,0,0,1,0,254,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1683,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,291,0,,,,0,0,0,0,0,0,0,0,5,94,0,0,0,0,1,0,248,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1684,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1685,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,316,0,,,,2,0,0,1,0,0,0,3,31,96,0,0,0,0,1,0,243,7,0,0,5,2
Study 4,AMERICA,USA,Site 191,Subject 1686,Cycle 1 Week 1_CO (1),On Trial,,,,,,,,,,36,323,0,,,,10,3,0,0,0,0,0,13,15,102,0,0,0,0,0,0,279,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1687,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 191,Subject 1688,Cycle 6 Week 6 (1),Discontinued,,,,,,,,,,27,184,0,,,,0,0,0,0,0,0,0,0,1,33,0,0,0,0,1,0,154,0,0,0,0,0
Study 4,AMERICA,USA,Site 192,Subject 1689,EOT1 (1),Follow-Up,,,,,,,,,,32,269,0,,,,1,0,0,0,0,0,0,1,6,224,0,1,0,0,2,3,224,1,0,0,1,0
Study 4,AMERICA,USA,Site 192,Subject 1690,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 192,Subject 1691,EOT1 (1),Discontinued,,,,,,,,,,12,133,0,,,,0,0,0,0,0,0,0,0,4,33,0,0,0,0,1,0,105,0,0,0,0,0
Study 4,AMERICA,USA,Site 192,Subject 1692,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 192,Subject 1693,Screening,Discontinued,,,,,,,,,,1,42,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,39,0,0,0,0,0
Study 4,AMERICA,USA,Site 25,Subject 91,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,10,125,0,,,,0,0,0,1,0,0,0,1,1,97,0,0,0,0,0,0,103,0,0,0,0,0
Study 4,AMERICA,USA,Site 25,Subject 92,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,36,325,0,,,,0,0,0,0,0,0,0,0,6,178,0,0,0,0,1,0,259,3,0,0,0,3
Study 4,AMERICA,USA,Site 25,Subject 1694,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,1,4,0,5,0,0,0,0,20,0,0,0,0,0
Study 4,AMERICA,USA,Site 25,Subject 1695,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 25,Subject 1696,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 25,Subject 1697,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 193,Subject 1698,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,25,278,0,,,,0,0,0,0,0,0,0,0,2,250,0,0,0,0,0,0,238,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1699,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,34,311,0,,,,0,0,0,0,0,0,1,1,1,270,0,0,0,0,2,0,247,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1700,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,312,0,,,,0,0,0,0,0,0,0,0,7,109,0,0,0,0,4,0,258,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1701,Week 24 (1),Discontinued,,,,,,,,,,32,251,0,,,,0,0,0,0,0,0,0,0,1,64,0,1,0,0,1,0,209,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1702,Week 24 (1),Discontinued,,,,,,,,,,33,268,0,,,,0,0,0,0,0,0,0,0,1,82,0,0,0,0,0,0,227,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1703,Week 48 (1),Follow-Up,,,,,,,,,,39,289,0,,,,0,0,0,0,0,0,0,0,1,82,0,1,0,0,0,0,243,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1704,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1705,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,316,0,,,,0,0,0,0,0,0,0,0,6,126,0,0,0,0,1,0,251,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1706,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,43,295,0,,,,0,0,0,0,0,0,0,0,1,62,0,0,0,0,3,0,241,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1707,Cycle 1 Week 1_CO (1),Discontinued,,,,,,,,,,31,239,0,,,,2,1,0,0,0,0,0,3,1,71,0,0,0,0,4,0,192,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1708,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1709,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,278,0,,,,0,0,0,0,0,0,0,0,8,101,0,0,0,0,1,0,232,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1710,Cycle 4 Week 6 (1),Discontinued,,,,,,,,,,15,143,0,,,,0,0,0,0,0,0,0,0,1,41,0,0,0,0,0,0,113,0,0,0,0,0
Study 4,AMERICA,USA,Site 194,Subject 1711,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,255,0,,,,0,0,0,0,0,0,0,0,0,95,0,0,0,0,0,0,205,0,0,0,0,0
Study 4,AMERICA,USA,Site 195,Subject 1712,EOT1 (1),Survival,,,,,,,,,,37,297,0,,,,0,0,0,0,0,0,0,0,7,251,0,2,0,0,0,0,247,0,0,0,0,0
Study 4,AMERICA,USA,Site 196,Subject 1713,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,347,0,,,,0,0,0,0,0,0,0,0,20,147,0,0,0,0,2,0,273,1,0,0,1,0
Study 4,AMERICA,USA,Site 196,Subject 1714,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,329,0,,,,0,0,0,0,0,0,0,0,3,111,0,0,0,0,1,0,276,1,0,0,1,0
Study 4,AMERICA,USA,Site 196,Subject 1715,Screening,Screen Failure,,,,,,,,,,1,22,0,,,,0,0,0,0,0,0,0,0,0,4,0,2,0,0,0,0,20,0,0,0,0,0
Study 4,AMERICA,USA,Site 196,Subject 1716,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,249,0,,,,1,0,0,0,1,0,0,2,4,66,0,3,0,0,0,0,207,1,0,0,1,0
Study 4,AMERICA,USA,Site 197,Subject 1717,Post CYCLE 6 Visit 6 (1),Survival,,,,,,,,,,33,271,0,,,,0,0,0,0,0,0,0,0,4,218,0,0,0,0,1,0,169,40,0,21,60,1
Study 4,AMERICA,USA,Site 197,Subject 1718,Week 24 (1),Follow-Up,,,,,,,,,,55,394,0,,,,0,0,0,0,0,0,0,0,14,91,0,0,0,0,2,0,242,63,5,5,71,2
Study 4,AMERICA,USA,Site 197,Subject 1719,Unplanned Visit (3),Discontinued,,,,,,,,,,16,189,0,,,,0,0,0,0,0,0,0,0,13,46,159,1,0,0,1,0,112,31,0,0,31,0
Study 4,AMERICA,USA,Site 197,Subject 1720,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,11,3,0,0,3,0
Study 4,AMERICA,USA,Site 197,Subject 1721,Cycle 4 Week 1 (1),Discontinued,,,,,,,,,,13,114,0,,,,0,0,0,0,0,0,0,0,1,21,0,0,0,0,1,0,76,22,0,0,22,0
Study 4,AMERICA,USA,Site 197,Subject 1722,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,11,3,0,0,3,0
Study 4,AMERICA,USA,Site 198,Subject 1723,Post CYCLE 6 Visit 15 (1),On Trial,,,,,,,,,,42,403,0,,,,0,0,0,0,0,0,0,0,29,318,0,0,0,0,1,0,319,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1724,Cycle 3 Week 3 (1),Discontinued,,,,,,,,,,13,120,0,,,,0,0,0,0,0,0,0,0,4,28,0,0,0,0,0,0,97,0,0,0,0,0
Study 4,AMERICA,USA,Site 199,Subject 1725,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,46,359,0,,,,0,0,0,0,0,0,0,0,5,94,0,0,0,0,1,0,302,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1726,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,41,392,0,,,,0,0,0,0,0,0,0,0,16,107,0,0,0,0,1,0,326,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1727,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1728,Week 48 (1),Discontinued,,,,,,,,,,34,280,0,,,,0,0,0,0,0,0,0,0,4,66,0,0,0,0,2,0,232,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1729,Post CYCLE 6 Visit 14 (1),On Trial,,,,,,,,,,41,370,0,,,,0,0,0,0,0,0,0,0,15,129,0,0,0,0,0,0,315,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1730,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,359,0,,,,0,0,0,0,0,0,0,0,14,111,0,0,0,0,1,0,303,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1731,Unplanned Visit_CO (1),Discontinued,,,,,,,,,,50,394,0,,,,0,0,0,0,0,0,0,0,4,98,0,0,0,0,0,0,325,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1732,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,347,0,,,,0,0,0,0,0,0,0,0,15,114,0,0,0,0,1,0,296,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1733,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,38,283,0,,,,0,0,0,0,0,0,0,0,9,75,0,0,0,0,0,0,243,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1734,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,30,226,0,,,,0,0,0,0,0,0,0,0,4,51,0,0,0,0,0,0,182,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1735,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,291,0,,,,0,0,0,0,0,0,0,0,16,78,0,0,0,0,1,0,238,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1736,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,327,0,,,,0,0,0,0,0,0,0,0,15,96,0,0,0,0,0,0,276,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1737,Unplanned Visit (1),Discontinued,,,,,,,,,,30,234,0,,,,0,0,0,0,0,0,0,0,12,54,0,0,0,0,1,0,190,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1738,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,32,314,0,,,,0,0,0,0,0,0,0,0,21,102,0,0,0,0,1,0,249,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1739,Week 24 (1),Discontinued,,,,,,,,,,51,324,0,,,,1,2,0,0,0,0,0,3,11,57,0,0,0,0,0,0,265,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1740,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,304,0,,,,0,0,0,0,1,0,0,1,13,99,0,0,0,0,0,0,250,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1741,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,297,0,,,,0,0,0,0,0,0,0,0,16,109,0,0,0,0,2,0,237,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1742,Screening,Discontinued,,,,,,,,,,1,41,0,,,,0,0,0,0,0,0,0,0,2,9,0,0,0,0,1,0,38,0,0,0,0,0
Study 4,AMERICA,USA,Site 198,Subject 1743,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,49,0,,,,0,0,0,0,0,0,0,0,8,17,0,8,0,0,0,0,32,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1744,Long term FU 6 (1),Survival,,,,,,,,,,32,277,0,,,,0,0,0,0,0,0,0,0,16,222,0,0,0,0,3,0,223,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1745,Unplanned Visit (10),Discontinued,,,,,,,,,,30,303,0,,,,0,0,0,0,0,0,0,0,11,66,0,0,0,0,3,0,232,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1746,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1747,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,306,0,,,,0,0,0,10,0,0,0,10,8,103,0,0,0,0,2,0,255,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1748,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,337,0,,,,0,0,0,0,0,0,0,0,21,106,0,0,0,0,0,0,278,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1749,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1750,Week 48 (1),Survival,,,,,,,,,,32,224,0,,,,0,0,0,0,0,0,0,0,8,51,0,1,0,0,0,0,177,0,0,0,0,0
Study 4,AMERICA,USA,Site 200,Subject 1751,Unplanned Visit (1),Discontinued,,,,,,,,,,29,233,0,,,,0,0,0,0,0,0,0,0,10,71,0,2,0,0,0,0,178,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1752,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,30,295,0,,,,0,0,0,0,0,0,0,0,25,228,0,0,0,0,1,0,240,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1753,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1754,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1755,Week 24 (1),Survival,,,,,,,,,,29,204,0,,,,0,0,0,0,0,0,0,0,7,43,0,0,0,0,0,0,167,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1756,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1757,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1758,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,251,0,,,,4,0,0,0,0,0,0,4,8,74,0,0,0,0,1,0,216,0,0,0,0,0
Study 4,AMERICA,USA,Site 201,Subject 1759,Cycle 4 Week 5 (1),Discontinued,,,,,,,,,,18,162,0,,,,0,0,0,0,0,0,0,0,3,45,0,0,0,0,0,0,127,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1760,Cycle 3 Week 5 (1),Discontinued,,,,,,,,,,14,137,0,,,,0,0,0,0,0,0,0,0,5,111,0,0,0,0,3,0,107,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1761,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,12,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1762,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1763,Cycle 6 Week 6 (1),Discontinued,,,,,,,,,,27,184,0,,,,0,0,0,0,0,0,0,0,4,41,0,0,0,0,1,0,148,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1764,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,312,0,,,,2,0,0,0,0,0,0,2,10,88,0,0,0,0,2,0,250,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1765,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1766,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1767,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1768,Screening,Screen Failure,,,,,,,,,,1,20,0,,,,0,0,0,0,0,0,0,0,2,9,0,1,0,0,0,0,15,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1769,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,32,285,0,,,,0,0,0,0,0,0,0,0,5,73,0,0,0,0,2,0,231,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1770,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1771,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1772,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1773,Post CYCLE 6 Visit 7 (1),Discontinued,,,,,,,,,,33,274,0,,,,1,0,0,0,0,0,0,1,5,86,0,0,0,0,2,0,227,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1774,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1775,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1776,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,35,274,0,,,,0,1,0,0,0,0,0,1,7,72,0,0,0,0,7,0,221,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1777,Post CYCLE 6 Visit 2 (1),Discontinued,,,,,,,,,,29,235,0,,,,0,0,0,0,0,0,0,0,7,40,0,0,0,0,2,0,186,0,0,0,0,0
Study 4,AMERICA,USA,Site 202,Subject 1778,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,33,257,0,,,,0,0,0,0,0,0,0,0,6,71,0,0,0,0,1,0,211,0,0,0,0,0
Study 4,AMERICA,USA,Site 203,Subject 1779,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,26,0,,,,0,0,0,0,0,0,0,0,0,6,0,2,0,0,0,0,23,0,0,0,0,0
Study 4,AMERICA,USA,Site 204,Subject 1780,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,309,0,,,,0,0,0,0,0,0,0,0,1,257,0,0,0,0,0,0,218,43,0,0,43,0
Study 4,AMERICA,USA,Site 204,Subject 1781,Screening,Screen Failure,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,0,8,0,0,0,0,0,0,18,3,0,0,3,0
Study 4,AMERICA,USA,Site 204,Subject 1782,Post CYCLE 6 Visit 8 (1),Discontinued,,,,,,,,,,35,318,0,,,,0,0,0,0,0,0,0,0,1,89,0,0,0,0,1,0,227,41,4,0,43,2
Study 4,AMERICA,USA,Site 204,Subject 1783,Week 24 (1),Follow-Up,,,,,,,,,,56,389,0,,,,0,0,0,0,0,0,0,0,5,82,0,0,0,0,0,0,254,65,5,0,68,2
Study 4,AMERICA,USA,Site 204,Subject 1784,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 204,Subject 1785,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,265,0,,,,0,0,0,0,0,0,0,0,1,72,0,0,0,0,0,0,180,42,0,0,38,4
Study 4,AMERICA,USA,Site 205,Subject 1786,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,5,0,2,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 205,Subject 1787,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,31,249,0,,,,0,0,0,0,0,0,0,0,7,205,0,0,0,0,2,0,163,38,0,0,38,0
Study 4,AMERICA,USA,Site 205,Subject 1788,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,245,0,,,,0,0,0,0,0,0,0,0,8,73,0,0,0,0,0,0,161,42,0,0,42,0
Study 4,AMERICA,USA,Site 205,Subject 1789,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,31,236,0,,,,0,0,0,0,0,0,0,0,4,63,0,0,0,0,2,0,153,44,0,0,43,1
Study 4,AMERICA,USA,Site 206,Subject 1790,Unplanned Visit (3),Discontinued,,,,,,,,,,29,245,0,,,,0,0,0,0,0,0,0,0,11,186,205,0,0,0,1,0,161,37,0,0,37,0
Study 4,AMERICA,USA,Site 206,Subject 1791,Cycle 1 Week 2_CO (1),On Trial,,,,,,,,,,42,392,0,,,,5,1,0,0,0,0,0,6,18,120,269,0,0,0,1,0,315,16,0,0,11,5
Study 4,AMERICA,USA,Site 206,Subject 1792,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 206,Subject 1793,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,303,0,,,,0,0,0,0,0,0,0,0,4,96,234,0,0,0,1,0,194,44,9,9,47,15
Study 4,AMERICA,USA,Site 206,Subject 1794,Unplanned Visit (1),Discontinued,,,,,,,,,,1,47,0,,,,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,38,4,0,0,4,0
Study 4,AMERICA,USA,Site 206,Subject 1795,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 206,Subject 1796,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1797,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1798,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1799,Week 24 (1),Discontinued,,,,,,,,,,32,266,0,,,,0,0,0,0,0,0,0,0,7,69,229,0,0,0,1,0,157,43,2,18,63,0
Study 4,AMERICA,USA,Site 206,Subject 1800,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,3,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1801,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,339,0,,,,0,0,0,0,0,0,0,0,14,89,260,0,0,0,3,0,218,52,0,11,42,21
Study 4,AMERICA,USA,Site 206,Subject 1802,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,296,0,,,,0,0,0,0,0,0,0,0,7,94,224,1,0,0,0,0,180,49,0,14,45,18
Study 4,AMERICA,USA,Site 206,Subject 1803,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,277,0,,,,0,0,0,0,0,0,0,0,7,71,0,0,0,0,1,0,166,38,7,21,51,15
Study 4,AMERICA,USA,Site 206,Subject 1804,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,273,0,,,,1,0,0,0,0,0,0,1,14,85,0,0,0,0,0,0,163,42,0,20,47,15
Study 4,AMERICA,USA,Site 206,Subject 1805,Post CYCLE 6 Visit 3 (1),Discontinued,,,,,,,,,,30,240,0,,,,0,0,0,0,0,0,0,0,12,58,0,0,0,0,1,0,157,36,0,2,38,0
Study 4,AMERICA,USA,Site 206,Subject 1806,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1807,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1808,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,11,3,0,0,3,0
Study 4,AMERICA,USA,Site 206,Subject 1809,EOT1 (1),Survival,,,,,,,,,,30,251,0,,,,0,0,0,0,0,0,0,0,8,151,0,0,0,0,0,0,166,34,0,3,36,1
Study 4,AMERICA,USA,Site 207,Subject 1810,Long term FU 1 (1),Survival,,,,,,,,,,36,284,0,,,,1,0,0,0,1,0,0,2,16,216,0,1,0,0,1,0,225,9,0,0,9,0
Study 4,AMERICA,USA,Site 207,Subject 1811,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,269,0,,,,0,0,0,0,0,0,0,0,6,76,0,1,0,0,0,0,220,0,0,0,0,0
Study 4,AMERICA,USA,Site 207,Subject 1812,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 207,Subject 1813,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,11,0,0,0,0,0
Study 4,AMERICA,USA,Site 207,Subject 1814,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,407,0,,,,0,0,0,0,0,0,0,0,33,140,0,1,0,0,1,0,307,1,0,0,1,0
Study 4,AMERICA,USA,Site 207,Subject 1815,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,298,0,,,,0,0,0,0,0,0,0,0,13,95,0,5,0,0,2,0,236,0,0,0,0,0
Study 4,AMERICA,USA,Site 207,Subject 1816,Week 24 (1),Follow-Up,,,,,,,,,,32,274,0,,,,0,0,0,0,0,0,0,0,9,80,0,1,0,0,0,0,226,3,0,0,3,0
Study 4,AMERICA,USA,Site 207,Subject 1817,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,256,0,,,,1,0,0,0,0,0,0,1,3,82,0,0,0,0,1,0,213,0,0,0,0,0
Study 4,AMERICA,USA,Site 207,Subject 1818,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,31,322,0,,,,0,0,0,0,0,0,0,0,11,98,0,0,0,0,1,0,246,1,0,0,1,0
Study 4,AMERICA,USA,Site 207,Subject 1819,Screening,Discontinued,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,1,0,9,0,0,0,0,0
Study 4,AMERICA,USA,Site 208,Subject 1820,Long term FU 6 (1),Follow-Up,,,,,,,,,,37,449,0,,,,1,0,0,0,0,0,0,1,2,326,329,1,0,0,2,0,326,53,0,0,47,6
Study 4,AMERICA,USA,Site 208,Subject 1821,Week 24 (1),Follow-Up,,,,,,,,,,36,297,0,,,,2,0,0,0,0,0,0,2,5,97,0,1,0,0,0,0,196,58,0,0,55,3
Study 4,AMERICA,USA,Site 208,Subject 1822,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 208,Subject 1823,Unplanned Visit (10),Follow-Up,,,,,,,,,,37,323,0,,,,1,0,0,0,0,0,0,1,10,88,234,0,0,0,0,0,210,52,0,0,46,7
Study 4,AMERICA,USA,Site 209,Subject 1824,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,USA,Site 209,Subject 1825,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,297,0,,,,0,0,0,0,8,0,0,8,6,236,0,0,0,0,3,0,247,0,0,0,0,0
Study 4,AMERICA,USA,Site 209,Subject 1826,Long term FU 5 (1),Survival,,,,,,,,,,17,152,0,,,,0,0,0,0,0,0,0,0,2,60,0,0,0,0,4,0,131,0,0,0,0,0
Study 4,AMERICA,USA,Site 209,Subject 1827,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,274,0,,,,1,0,0,0,10,0,0,11,3,86,0,0,0,0,1,0,226,0,0,0,0,0
Study 4,AMERICA,USA,Site 210,Subject 1828,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 210,Subject 1829,EOT1 (1),Survival,,,,,,,,,,3,69,0,,,,0,0,0,0,0,0,0,0,2,44,0,0,0,0,1,0,54,8,0,0,8,0
Study 4,AMERICA,USA,Site 210,Subject 1830,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,11,2,0,0,2,0
Study 4,AMERICA,USA,Site 210,Subject 1831,Long term FU 1 (1),Survival,,,,,,,,,,27,208,0,,,,0,0,0,0,0,0,0,0,2,147,0,0,0,0,2,0,128,37,0,0,37,0
Study 4,AMERICA,USA,Site 210,Subject 1832,Unplanned Visit (2),Discontinued,,,,,,,,,,29,258,0,,,,0,0,0,0,0,0,0,0,8,93,0,0,0,0,2,0,147,33,13,1,45,2
Study 4,AMERICA,USA,Site 210,Subject 1833,Screening,Screen Failure,,,,,,,,,,1,29,0,,,,0,0,0,0,0,0,0,0,1,8,0,3,0,0,0,0,23,3,0,0,3,0
Study 4,AMERICA,USA,Site 195,Subject 1834,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,314,0,,,,0,0,0,5,0,0,0,5,22,218,0,0,0,0,0,0,245,8,0,0,0,8
Study 4,AMERICA,USA,Site 195,Subject 1835,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1836,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1837,Long term FU 2 (1),Survival,,,,,,,,,,37,373,0,,,,0,0,0,0,0,0,0,0,30,277,0,0,0,0,0,0,300,2,0,0,2,0
Study 4,AMERICA,USA,Site 211,Subject 1838,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,36,330,0,,,,0,0,0,0,0,0,0,0,5,90,0,0,0,0,3,0,277,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1839,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1840,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,328,0,,,,1,0,0,0,0,0,0,1,14,113,0,0,0,0,1,0,281,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1841,Week 48 (1),Discontinued,,,,,,,,,,33,271,0,,,,0,0,0,0,0,0,0,0,10,66,0,0,0,0,0,0,221,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1842,Unplanned Visit (6),Discontinued,,,,,,,,,,30,261,0,,,,0,0,0,0,0,0,0,0,6,74,0,0,0,0,0,0,210,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1843,EOT1 (1),Survival,,,,,,,,,,30,285,0,,,,0,0,0,0,0,0,0,0,17,84,0,0,0,0,0,0,238,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1844,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1845,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1846,Week 48 (1),Survival,,,,,,,,,,15,223,0,,,,0,0,0,0,0,0,0,0,20,53,0,0,0,0,2,0,172,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1847,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,31,373,0,,,,0,0,0,0,0,0,0,0,46,114,0,0,0,0,1,0,280,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1848,Unplanned Recist (1),Survival,,,,,,,,,,27,200,0,,,,0,0,0,0,0,0,0,0,8,49,0,0,0,0,0,0,157,0,0,0,0,0
Study 4,AMERICA,USA,Site 211,Subject 1849,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,248,0,,,,4,0,0,0,0,0,0,4,1,66,0,0,0,0,1,0,212,0,0,0,0,0
Study 4,AMERICA,USA,Site 212,Subject 1850,Post CYCLE 6 Visit 7 (1),Survival,,,,,,,,,,34,279,0,,,,0,0,0,0,0,0,0,0,2,233,0,0,0,0,1,0,198,41,0,0,41,0
Study 4,AMERICA,USA,Site 212,Subject 1851,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,308,0,,,,0,0,0,0,0,0,0,0,1,109,0,0,0,0,0,0,199,54,0,0,45,9
Study 4,AMERICA,USA,Site 212,Subject 1852,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,298,0,,,,0,0,0,0,0,0,0,0,1,92,0,0,0,0,2,0,199,54,0,0,43,11
Study 4,AMERICA,USA,Site 212,Subject 1853,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,53,342,0,,,,0,0,0,0,0,0,0,0,1,82,0,0,0,0,1,0,215,66,0,0,66,0
Study 4,AMERICA,USA,Site 212,Subject 1854,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,318,0,,,,0,0,0,0,0,0,0,0,1,98,0,0,0,0,4,0,208,57,0,0,46,11
Study 4,AMERICA,USA,Site 212,Subject 1855,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,343,0,,,,0,0,0,0,0,0,2,2,16,119,0,1,0,0,5,0,209,60,0,0,49,11
Study 4,AMERICA,USA,Site 212,Subject 1856,Unplanned Visit (4),Discontinued,,,,,,,,,,23,277,0,,,,0,0,0,0,0,0,0,0,1,96,0,0,0,0,3,0,169,36,0,0,36,0
Study 4,AMERICA,USA,Site 212,Subject 1857,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,351,0,,,,0,0,0,0,0,0,0,0,1,175,0,0,0,0,1,0,218,52,0,0,48,4
Study 4,AMERICA,USA,Site 212,Subject 1858,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 212,Subject 1859,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,309,0,,,,0,0,0,0,0,0,0,0,1,114,0,0,0,0,0,0,190,56,0,0,50,6
Study 4,AMERICA,USA,Site 212,Subject 1860,Week 48 (1),Survival,,,,,,,,,,32,235,0,,,,0,0,0,0,0,0,0,0,1,74,0,0,0,0,1,0,142,44,0,0,43,1
Study 4,AMERICA,USA,Site 212,Subject 1861,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,300,0,,,,1,0,0,0,0,0,0,1,6,105,0,0,0,0,0,0,183,52,0,0,45,7
Study 4,AMERICA,USA,Site 212,Subject 1862,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 213,Subject 1863,Unplanned Recist_CO (2),Discontinued,,,,,,,,,,32,298,0,,,,0,0,0,0,0,0,0,0,14,240,0,0,0,0,1,0,229,0,0,0,0,0
Study 4,AMERICA,USA,Site 213,Subject 1864,EOT1 (1),Survival,,,,,,,,,,38,341,0,,,,0,0,0,0,0,0,0,0,10,97,0,0,0,0,0,0,285,0,0,0,0,0
Study 4,AMERICA,USA,Site 213,Subject 1865,Post CYCLE 6 Visit 4 (1),Discontinued,,,,,,,,,,30,244,0,,,,1,0,0,0,0,0,0,1,14,66,0,0,0,0,0,0,188,0,0,0,0,0
Study 4,AMERICA,USA,Site 213,Subject 1866,Unplanned Visit (1),Survival,,,,,,,,,,1,56,0,,,,0,0,0,0,0,0,0,0,1,20,0,0,0,0,0,0,51,0,0,0,0,0
Study 4,AMERICA,USA,Site 213,Subject 1867,Screening,Discontinued,,,,,,,,,,1,44,0,,,,0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,40,0,0,0,0,0
Study 4,AMERICA,USA,Site 213,Subject 1868,Screening,Survival,,,,,,,,,,1,55,0,,,,0,0,0,0,0,0,0,0,1,22,0,0,0,0,0,0,51,0,0,0,0,0
Study 4,AMERICA,USA,Site 213,Subject 1869,Long term FU 1 (1),Discontinued,,,,,,,,,,27,218,0,,,,1,0,0,0,0,0,0,1,11,66,1,0,0,0,0,0,175,0,0,0,0,0
Study 4,AMERICA,USA,Site 214,Subject 1870,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,284,0,,,,1,0,0,0,0,0,0,1,1,240,0,0,0,0,2,0,244,0,0,0,0,0
Study 4,AMERICA,USA,Site 215,Subject 1871,Unplanned Visit (2),On Trial,,,,,,,,,,39,345,0,,,,0,0,0,0,0,0,0,0,44,246,0,0,0,0,1,0,209,64,0,0,50,14
Study 4,AMERICA,USA,Site 215,Subject 1872,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1873,EOT1 (1),Discontinued,,,,,,,,,,11,107,0,,,,0,0,0,0,0,0,0,0,1,30,0,0,0,0,3,0,75,18,0,0,18,0
Study 4,AMERICA,USA,Site 215,Subject 1874,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,36,358,0,,,,1,0,0,0,0,0,0,1,22,106,0,0,0,0,1,0,235,56,0,0,48,8
Study 4,AMERICA,USA,Site 215,Subject 1875,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,3,0,1,0,0,0,0,9,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1876,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,33,348,0,,,,14,0,0,0,0,0,0,14,12,95,0,0,0,0,0,0,241,52,0,0,46,6
Study 4,AMERICA,USA,Site 215,Subject 1877,EOT1 (1),Discontinued,,,,,,,,,,15,106,0,,,,0,0,0,0,0,0,0,0,2,16,0,0,0,0,0,0,64,19,3,0,22,0
Study 4,AMERICA,USA,Site 215,Subject 1878,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1879,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1880,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,343,0,,,,0,0,0,0,0,0,0,0,33,114,0,1,0,0,1,0,196,50,14,0,51,13
Study 4,AMERICA,USA,Site 215,Subject 1881,Long term FU 5 (1),Discontinued,,,,,,,,,,29,281,0,,,,0,0,0,0,0,0,0,0,7,92,0,0,0,0,4,0,189,43,0,0,43,0
Study 4,AMERICA,USA,Site 215,Subject 1882,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1883,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,422,0,,,,5,0,0,0,0,0,0,5,71,136,0,1,0,0,0,0,240,69,4,0,59,14
Study 4,AMERICA,USA,Site 215,Subject 1884,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,375,0,,,,0,0,0,0,1,0,0,1,45,124,0,0,0,0,0,0,226,55,11,0,64,2
Study 4,AMERICA,USA,Site 215,Subject 1885,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,32,347,0,,,,0,0,0,0,0,0,0,0,11,141,0,0,0,0,1,0,212,46,19,0,65,0
Study 4,AMERICA,USA,Site 215,Subject 1886,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,296,0,,,,0,0,0,0,0,0,0,0,12,91,0,0,0,0,1,0,192,48,0,0,48,0
Study 4,AMERICA,USA,Site 215,Subject 1887,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1888,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,239,0,,,,0,0,0,0,0,0,0,0,1,66,0,0,0,0,2,0,150,43,5,0,39,9
Study 4,AMERICA,USA,Site 215,Subject 1889,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,22,319,0,,,,1,0,0,0,0,0,0,1,28,87,0,0,0,0,0,0,173,74,1,0,64,11
Study 4,AMERICA,USA,Site 215,Subject 1890,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,20,306,0,,,,0,0,0,0,0,0,0,0,12,97,0,0,0,0,2,0,182,51,10,0,45,16
Study 4,AMERICA,USA,Site 215,Subject 1891,EOT1 (1),Discontinued,,,,,,,,,,27,262,0,,,,0,0,0,0,0,0,0,0,11,74,0,0,0,0,1,0,140,54,18,0,57,15
Study 4,AMERICA,USA,Site 215,Subject 1892,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,22,0,,,,0,0,0,0,0,0,0,0,0,4,0,3,0,0,0,0,17,3,0,0,3,0
Study 4,AMERICA,USA,Site 215,Subject 1893,Unplanned Visit (3),Follow-Up,,,,,,,,,,36,263,0,,,,0,0,0,0,2,0,0,2,9,70,0,2,0,0,3,0,160,57,1,0,50,8
Study 4,AMERICA,USA,Site 215,Subject 1894,Unplanned Visit (3),On Trial,,,,,,,,,,29,271,0,,,,0,0,0,0,0,0,0,0,14,73,0,0,0,0,0,0,169,47,1,0,43,5
Study 4,AMERICA,USA,Site 215,Subject 1895,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 215,Subject 1896,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,333,0,,,,0,0,0,0,0,0,0,0,39,89,0,0,0,0,1,0,200,53,16,0,60,9
Study 4,AMERICA,USA,Site 215,Subject 1897,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,30,310,0,,,,0,1,0,0,0,0,0,1,13,95,0,0,0,0,0,0,204,50,1,0,46,5
Study 4,AMERICA,USA,Site 216,Subject 1898,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,265,0,,,,0,0,0,0,0,0,0,0,8,220,0,0,0,0,0,0,173,48,0,0,42,6
Study 4,AMERICA,USA,Site 216,Subject 1899,Week 24 (1),Follow-Up,,,,,,,,,,32,267,0,,,,1,0,0,0,0,0,0,1,1,84,0,0,0,0,0,0,191,40,0,0,40,0
Study 4,AMERICA,USA,Site 216,Subject 1900,Week 48 (1),Follow-Up,,,,,,,,,,33,285,0,,,,0,0,0,0,0,0,0,0,33,61,0,1,0,0,0,0,167,44,2,0,42,4
Study 4,AMERICA,USA,Site 216,Subject 1901,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 216,Subject 1902,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 216,Subject 1903,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 216,Subject 1904,Screening,Discontinued,,,,,,,,,,1,46,0,,,,0,0,0,0,0,0,0,0,1,12,0,0,0,0,0,0,36,6,0,0,6,0
Study 4,AMERICA,USA,Site 216,Subject 1905,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,8,3,0,0,3,0
Study 4,AMERICA,USA,Site 216,Subject 1906,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,248,0,,,,0,0,0,0,0,0,0,0,4,81,0,0,0,0,0,0,169,39,0,0,39,0
Study 4,AMERICA,USA,Site 216,Subject 1907,Long term FU 2 (1),Follow-Up,,,,,,,,,,35,279,0,,,,0,0,0,0,0,0,0,0,5,89,0,0,0,0,0,0,185,54,0,0,42,12
Study 4,AMERICA,USA,Site 216,Subject 1908,Cycle 2 Week 1 (1),Discontinued,,,,,,,,,,4,108,0,,,,0,0,0,0,0,0,0,0,8,33,0,0,0,0,0,0,63,17,0,0,17,0
Study 4,AMERICA,USA,Site 217,Subject 1909,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,38,276,0,,,,0,0,0,0,0,0,0,0,1,234,0,1,0,0,2,0,228,0,0,0,0,0
Study 4,AMERICA,USA,Site 217,Subject 1910,Week 48 (1),Follow-Up,,,,,,,,,,57,379,0,,,,6,2,0,0,0,0,0,8,1,83,0,2,0,0,1,0,301,4,0,0,4,0
Study 4,AMERICA,USA,Site 217,Subject 1911,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,291,0,,,,2,0,0,0,0,0,0,2,1,91,0,1,0,0,1,0,246,0,0,0,0,0
Study 4,AMERICA,USA,Site 217,Subject 1912,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 217,Subject 1913,Post CYCLE 6 Visit 2 (1),Discontinued,,,,,,,,,,29,220,0,,,,0,0,0,0,0,0,0,0,1,60,0,0,0,0,1,0,179,0,0,0,0,0
Study 4,AMERICA,USA,Site 217,Subject 1914,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 217,Subject 1915,Post CYCLE 6 Visit 1 (1),Discontinued,,,,,,,,,,28,264,0,,,,0,0,0,0,0,0,0,0,1,75,0,0,0,0,1,0,208,0,0,0,0,0
Study 4,AMERICA,USA,Site 218,Subject 1916,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 218,Subject 1917,Screening,Discontinued,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,7,2,0,0,2,0
Study 4,AMERICA,USA,Site 218,Subject 1918,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,278,0,,,,0,0,0,0,0,0,0,0,4,91,0,0,0,0,0,0,183,52,0,0,40,12
Study 4,AMERICA,USA,Site 218,Subject 1919,EOT1 (1),Discontinued,,,,,,,,,,11,142,0,,,,0,1,0,0,0,0,0,1,6,42,0,0,0,0,0,0,86,22,0,0,22,0
Study 4,AMERICA,USA,Site 218,Subject 1920,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,241,0,,,,0,0,0,0,0,0,0,0,3,192,0,0,0,0,0,0,161,39,0,0,39,0
Study 4,AMERICA,USA,Site 218,Subject 1921,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,302,0,,,,0,0,0,0,0,0,0,0,4,123,0,0,0,0,0,0,197,44,0,0,44,0
Study 4,AMERICA,USA,Site 218,Subject 1922,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,265,0,,,,4,2,0,0,0,0,0,6,22,65,0,0,0,0,0,0,158,52,0,0,40,12
Study 4,AMERICA,USA,Site 219,Subject 1923,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,293,0,,,,1,0,0,0,0,0,0,1,19,229,0,0,0,0,0,0,237,0,0,0,0,0
Study 4,AMERICA,USA,Site 219,Subject 1924,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,307,0,,,,1,0,0,0,0,0,0,1,24,94,0,0,0,0,0,0,249,1,0,0,1,0
Study 4,AMERICA,USA,Site 220,Subject 1925,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 220,Subject 1926,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 221,Subject 1927,EOT1 (1),Discontinued,,,,,,,,,,27,268,0,,,,0,0,0,0,8,0,0,8,21,212,0,0,0,0,3,0,206,3,0,0,3,0
Study 4,AMERICA,USA,Site 221,Subject 1928,Screening,Screen Failure,,,,,,,,,,0,11,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,USA,Site 221,Subject 1929,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,389,0,,,,0,0,0,0,0,0,0,0,45,147,0,0,0,0,0,0,295,0,0,0,0,0
Study 4,AMERICA,USA,Site 221,Subject 1930,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,30,282,0,,,,2,0,0,0,7,0,0,9,19,79,0,0,0,0,0,0,234,3,0,0,3,0
Study 4,AMERICA,USA,Site 221,Subject 1931,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,29,284,0,,,,1,0,0,0,0,0,0,1,3,77,0,0,0,0,0,0,240,1,0,0,1,0
Study 4,AMERICA,USA,Site 221,Subject 1932,Long term FU 1 (1),Survival,,,,,,,,,,5,79,0,,,,0,0,0,0,0,0,0,0,2,22,0,0,0,0,1,0,70,0,0,0,0,0
Study 4,AMERICA,USA,Site 221,Subject 1933,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,262,0,,,,3,0,0,0,5,0,0,8,9,74,0,0,0,0,1,0,220,0,0,0,0,0
Study 4,AMERICA,USA,Site 221,Subject 1934,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,297,0,,,,0,0,0,0,1,0,0,1,20,102,0,0,0,0,0,0,244,0,0,0,0,0
Study 4,AMERICA,USA,Site 221,Subject 1935,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,298,0,,,,0,0,0,0,1,0,0,1,20,87,0,0,0,0,0,0,236,4,0,0,0,4
Study 4,AMERICA,USA,Site 222,Subject 1936,Week 48 (1),Survival,,,,,,,,,,34,251,0,,,,3,0,0,0,0,0,0,3,10,207,0,0,0,0,0,0,162,41,1,3,43,2
Study 4,AMERICA,USA,Site 222,Subject 1937,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,281,0,,,,0,0,0,0,0,0,0,0,5,84,0,0,0,0,0,0,178,41,3,12,45,11
Study 4,AMERICA,USA,Site 222,Subject 1938,Week 48 (1),Survival,,,,,,,,,,29,236,0,,,,0,1,0,0,0,0,0,1,5,82,0,0,0,0,3,0,154,39,0,4,41,2
Study 4,AMERICA,USA,Site 222,Subject 1939,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,349,0,,,,15,0,0,0,0,0,9,24,28,111,0,1,0,0,1,0,196,46,26,13,50,35
Study 4,AMERICA,USA,Site 222,Subject 1940,Week 24 (1),Discontinued,,,,,,,,,,23,178,0,,,,2,0,0,0,0,0,0,2,12,46,0,0,0,0,0,0,103,29,2,3,34,0
Study 4,AMERICA,USA,Site 222,Subject 1941,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,280,0,,,,0,0,0,0,0,0,0,0,4,79,0,0,0,0,0,0,164,43,20,7,55,15
Study 4,AMERICA,USA,Site 222,Subject 1942,Week 48 (1),Discontinued,,,,,,,,,,23,208,0,,,,0,0,0,0,0,0,0,0,11,68,0,17,0,0,2,0,128,30,7,2,37,2
Study 4,AMERICA,USA,Site 222,Subject 1943,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,251,0,,,,0,0,0,0,0,0,0,0,9,74,0,0,0,0,0,0,142,41,19,10,48,22
Study 4,AMERICA,USA,Site 222,Subject 1944,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,266,0,,,,0,0,0,0,0,0,0,0,12,90,0,0,0,0,0,0,146,50,6,16,42,30
Study 4,AMERICA,USA,Site 223,Subject 1945,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 218,Subject 1946,Post CYCLE 6 Visit 4 (1),Survival,,,,,,,,,,31,222,0,,,,1,0,0,0,0,0,0,1,6,175,0,0,0,0,0,0,139,45,2,0,46,1
Study 4,AMERICA,USA,Site 223,Subject 1947,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,257,0,,,,2,1,0,0,0,0,0,3,6,85,0,0,0,0,1,0,180,40,0,0,40,0
Study 4,AMERICA,USA,Site 224,Subject 1948,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,389,0,,,,0,0,0,0,0,0,0,0,46,299,0,0,0,0,3,0,307,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1949,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,11,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1950,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,29,376,0,,,,0,0,0,0,0,0,0,0,50,121,0,0,0,0,1,0,282,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1951,Long term FU 1 (1),Survival,,,,,,,,,,13,133,0,,,,0,0,0,0,0,0,0,0,2,21,0,0,0,0,1,0,114,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1952,EOT 2 (1),Discontinued,,,,,,,,,,51,514,0,,,,0,0,0,0,0,0,0,0,30,117,0,1,0,0,3,0,400,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1953,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1954,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,30,338,0,,,,0,0,0,0,0,0,0,0,11,100,0,0,0,0,0,0,284,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1955,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,353,0,,,,0,0,0,0,0,0,0,0,31,108,0,0,0,0,0,0,279,0,0,0,0,0
Study 4,AMERICA,USA,Site 224,Subject 1956,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,32,309,0,,,,0,1,0,0,0,0,0,1,30,95,0,0,0,0,1,0,236,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1957,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,321,0,,,,0,0,0,0,0,0,0,0,13,255,0,0,0,0,1,0,273,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1958,EOT1 (1),Discontinued,,,,,,,,,,29,220,0,,,,0,0,0,0,0,0,0,0,5,59,0,1,0,0,1,0,176,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1959,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,349,0,,,,0,0,0,0,0,0,0,0,19,100,0,0,0,0,4,0,278,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1960,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,319,0,,,,0,0,0,0,0,0,0,0,14,107,0,0,0,0,0,0,270,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1961,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1962,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1963,Week 24 (1),Discontinued,,,,,,,,,,31,233,0,,,,0,0,0,0,0,0,0,0,8,63,0,0,0,0,3,0,191,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1964,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,276,0,,,,0,0,0,0,0,0,0,0,22,79,0,0,0,0,1,0,221,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1965,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1966,Week 24 (1),Survival,,,,,,,,,,29,232,0,,,,0,0,0,0,0,0,0,0,7,51,0,0,0,0,1,0,194,0,0,0,0,0
Study 4,AMERICA,USA,Site 225,Subject 1967,Week 24 (1),Discontinued,,,,,,,,,,30,246,0,,,,0,0,0,0,0,0,0,0,14,62,0,0,0,0,0,0,192,0,0,0,0,0
Study 4,AMERICA,USA,Site 226,Subject 1968,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,276,0,,,,0,0,0,0,0,0,0,0,2,236,0,0,0,0,0,0,237,0,0,0,0,0
Study 4,AMERICA,USA,Site 226,Subject 1969,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,272,0,,,,0,0,0,0,0,0,0,0,9,94,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,AMERICA,USA,Site 226,Subject 1970,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,274,0,,,,0,0,0,0,0,0,0,0,5,82,0,0,0,0,0,0,231,0,0,0,0,0
Study 4,AMERICA,USA,Site 226,Subject 1971,Long term FU 5 (1),Follow-Up,,,,,,,,,,36,250,0,,,,3,0,0,0,0,0,0,3,2,71,0,1,0,0,0,0,214,0,0,0,0,0
Study 4,AMERICA,USA,Site 227,Subject 1972,Week 24 (1),Discontinued,,,,,,,,,,21,286,0,,,,0,0,0,0,3,0,0,3,17,219,0,4,0,0,2,0,152,41,11,3,55,0
Study 4,AMERICA,USA,Site 227,Subject 1973,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,24,227,0,,,,0,0,0,0,3,0,0,3,3,61,0,1,0,0,2,0,127,41,12,8,46,15
Study 4,AMERICA,USA,Site 228,Subject 1974,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1975,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1976,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1977,EOT1 (1),Discontinued,,,,,,,,,,18,213,0,,,,0,0,0,0,0,0,0,0,13,174,0,0,0,0,2,0,158,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1978,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,309,0,,,,0,0,0,0,0,0,0,0,14,107,0,0,0,0,0,0,244,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1979,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,283,0,,,,0,0,0,0,0,0,0,0,12,74,0,0,0,0,0,0,240,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1980,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1981,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,305,0,,,,2,0,0,0,0,0,0,2,27,91,0,0,0,0,0,0,244,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1982,Week 24 (1),Discontinued,,,,,,,,,,34,308,0,,,,0,0,0,0,0,0,0,0,13,109,0,1,0,0,0,0,247,0,0,0,0,0
Study 4,AMERICA,USA,Site 228,Subject 1983,Cycle 1 Week 2_CO (1),On Trial,,,,,,,,,,37,357,0,,,,3,0,0,0,0,0,0,3,51,82,0,0,0,0,1,0,276,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1984,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,5,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1985,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1986,Long term FU 1 (1),Discontinued,,,,,,,,,,20,199,0,,,,0,0,0,0,0,0,0,0,1,157,0,0,0,0,0,0,155,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1987,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1988,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1989,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1990,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,280,0,,,,1,0,0,0,0,0,0,1,1,117,0,0,0,0,1,0,223,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1991,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1992,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 229,Subject 1993,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,280,0,,,,0,0,0,0,0,0,0,0,1,96,0,0,0,0,0,0,236,0,0,0,0,0
Study 4,AMERICA,USA,Site 230,Subject 1994,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,6,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 230,Subject 1995,Screening,Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 230,Subject 1996,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,291,0,,,,0,0,0,0,0,0,0,0,4,249,0,0,0,0,0,0,238,0,0,0,0,0
Study 4,AMERICA,USA,Site 230,Subject 1997,EOT1 (1),Discontinued,,,,,,,,,,28,221,0,,,,0,0,0,0,0,0,0,0,1,58,0,0,0,0,1,0,176,0,0,0,0,0
Study 4,AMERICA,USA,Site 199,Subject 1998,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 199,Subject 1999,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,5,78,0,,,,0,0,0,0,0,0,0,0,4,25,0,0,0,0,0,0,67,0,0,0,0,0
Study 4,AMERICA,USA,Site 199,Subject 2000,EOT 2 (1),Survival,,,,,,,,,,44,300,0,,,,0,0,0,0,0,0,0,0,5,68,0,0,0,0,0,0,248,0,0,0,0,0
Study 4,AMERICA,USA,Site 199,Subject 2001,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,272,0,,,,0,0,0,0,0,0,0,0,10,195,0,0,0,0,1,0,225,0,0,0,0,0
Study 4,AMERICA,USA,Site 199,Subject 2002,Long term FU 1 (1),Follow-Up,,,,,,,,,,34,308,0,,,,0,0,0,0,0,0,0,0,26,92,0,0,0,0,0,0,246,0,0,0,0,0
Study 4,AMERICA,USA,Site 231,Subject 2003,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,36,288,0,,,,1,0,0,0,1,0,0,2,3,238,0,0,0,0,0,0,199,45,1,0,41,5
Study 4,AMERICA,USA,Site 231,Subject 2004,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,282,0,,,,0,0,0,0,1,0,0,1,4,93,0,0,0,0,1,0,189,41,3,0,44,0
Study 4,AMERICA,USA,Site 231,Subject 2005,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,35,269,0,,,,1,0,0,1,1,0,0,3,1,67,0,0,0,0,0,0,187,41,1,0,42,0
Study 4,AMERICA,USA,Site 231,Subject 2006,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,285,0,,,,1,0,0,0,1,0,0,2,2,98,0,0,0,0,1,0,205,40,2,0,42,0
Study 4,AMERICA,USA,Site 231,Subject 2007,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 231,Subject 2008,Week 48 (1),Follow-Up,,,,,,,,,,60,383,0,,,,1,0,0,0,0,0,0,1,1,76,0,1,0,0,1,0,245,68,2,0,68,2
Study 4,AMERICA,USA,Site 231,Subject 2009,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,268,0,,,,0,0,0,0,1,0,0,1,2,71,0,0,0,0,1,0,188,39,2,0,41,0
Study 4,AMERICA,USA,Site 231,Subject 2010,Long term FU 6 (1),Follow-Up,,,,,,,,,,36,288,0,,,,0,0,0,0,0,0,0,0,1,102,217,2,0,0,1,0,203,44,0,0,44,0
Study 4,AMERICA,USA,Site 231,Subject 2011,Screening,Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,9,2,0,0,2,0
Study 4,AMERICA,USA,Site 231,Subject 2012,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 231,Subject 2013,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,298,0,,,,1,0,0,0,2,0,0,3,6,109,0,0,0,0,1,0,195,41,9,0,42,8
Study 4,AMERICA,USA,Site 231,Subject 2014,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,252,0,,,,1,0,0,0,1,0,0,2,2,64,0,0,0,0,0,0,164,50,0,0,39,11
Study 4,AMERICA,USA,Site 231,Subject 2015,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,283,0,,,,0,0,0,0,1,0,0,1,4,108,0,0,0,0,0,0,188,48,0,0,40,8
Study 4,AMERICA,USA,Site 231,Subject 2016,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 231,Subject 2017,Week 48 (1),Discontinued,,,,,,,,,,20,162,0,,,,0,0,0,0,0,0,0,0,1,41,0,4,0,0,0,0,102,26,0,0,26,0
Study 4,AMERICA,USA,Site 231,Subject 2018,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 231,Subject 2019,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,250,0,,,,0,0,0,0,1,0,0,1,2,65,0,0,0,0,0,0,165,48,0,0,37,11
Study 4,AMERICA,USA,Site 232,Subject 2020,EOT 2 (1),Discontinued,,,,,,,,,,32,257,0,,,,0,0,0,0,0,0,0,0,3,215,0,1,0,0,1,0,168,46,5,0,51,0
Study 4,AMERICA,USA,Site 233,Subject 2021,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 233,Subject 2022,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,27,241,0,,,,0,0,0,0,0,0,0,0,8,201,0,0,0,0,4,0,158,36,0,4,40,0
Study 4,AMERICA,USA,Site 234,Subject 2023,Week 48 (1),Survival,,,,,,,,,,34,272,0,,,,0,0,0,0,0,0,0,0,5,231,0,0,0,0,2,0,219,0,0,0,0,0
Study 4,AMERICA,USA,Site 234,Subject 2024,Long term FU 7 (1),Follow-Up,,,,,,,,,,34,274,0,,,,0,0,0,0,0,0,0,0,6,107,0,0,0,0,0,0,217,0,0,0,0,0
Study 4,AMERICA,USA,Site 234,Subject 2025,Post CYCLE 6 Visit 1 (1),Survival,,,,,,,,,,28,211,0,,,,0,0,0,0,0,0,0,0,1,68,0,0,0,0,0,0,165,0,0,0,0,0
Study 4,AMERICA,USA,Site 234,Subject 2026,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 234,Subject 2027,Cycle 6 Week 6 (1),Survival,,,,,,,,,,26,229,0,,,,0,0,0,0,0,0,0,0,4,66,0,0,0,0,0,0,183,0,0,0,0,0
Study 4,AMERICA,USA,Site 235,Subject 2028,Post CYCLE 6 Visit 4 (1),Discontinued,,,,,,,,,,27,244,0,,,,0,0,0,0,0,0,0,0,5,203,0,0,0,0,3,0,153,37,6,1,44,0
Study 4,AMERICA,USA,Site 236,Subject 2029,30-DAY SAFETY FOLLOW UP_CO (1),Follow-Up,,,,,,,,,,50,466,0,,,,0,0,0,0,0,0,0,0,32,141,0,0,0,0,2,0,200,48,10,111,62,107
Study 4,AMERICA,USA,Site 236,Subject 2030,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,410,0,,,,0,0,0,0,0,0,0,0,15,191,0,0,0,0,0,0,210,58,0,42,56,44
Study 4,AMERICA,USA,Site 236,Subject 2031,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,33,363,0,,,,0,0,0,0,0,0,0,0,19,152,0,0,0,0,0,0,208,49,0,27,51,25
Study 4,AMERICA,USA,Site 236,Subject 2032,Long term FU 9 (1),Follow-Up,,,,,,,,,,28,288,0,,,,1,0,0,0,0,0,0,1,6,117,1,0,0,0,2,0,163,48,0,15,47,16
Study 4,AMERICA,USA,Site 236,Subject 2033,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,344,0,,,,0,0,0,0,0,0,0,0,11,139,0,0,0,0,0,0,195,47,2,26,49,26
Study 4,AMERICA,USA,Site 236,Subject 2034,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,31,406,0,,,,1,0,0,0,0,0,0,1,43,167,0,0,0,0,0,0,206,56,30,10,62,34
Study 4,AMERICA,USA,Site 236,Subject 2035,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 236,Subject 2036,Cycle 3 Week 3 (1),Discontinued,,,,,,,,,,13,138,0,,,,0,0,0,0,0,0,0,0,1,51,0,0,0,0,0,0,80,21,1,4,26,0
Study 4,AMERICA,USA,Site 236,Subject 2037,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,27,287,0,,,,0,0,0,0,0,0,0,0,1,108,0,0,0,0,1,0,177,42,2,2,46,0
Study 4,AMERICA,USA,Site 236,Subject 2038,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 236,Subject 2039,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,31,403,0,,,,0,0,0,0,0,0,0,0,5,141,0,0,0,0,1,0,245,46,19,7,60,12
Study 4,AMERICA,USA,Site 236,Subject 2040,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,31,307,0,,,,0,0,0,0,0,0,0,0,18,125,0,0,0,0,0,0,166,55,1,13,45,24
Study 4,AMERICA,USA,Site 236,Subject 2041,30-DAY SAFETY FOLLOW UP (1),Survival,,,,,,,,,,27,416,0,,,,2,0,0,0,0,0,0,2,8,126,0,0,0,0,1,0,235,33,9,60,49,53
Study 4,AMERICA,USA,Site 236,Subject 2042,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,1,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 236,Subject 2043,Post CYCLE 6 Visit 2 (1),Survival,,,,,,,,,,24,226,0,,,,0,0,0,0,0,0,0,0,2,82,0,0,0,0,0,0,130,37,2,14,47,6
Study 4,AMERICA,USA,Site 236,Subject 2044,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,32,403,0,,,,0,0,0,0,0,0,0,0,2,161,0,0,0,0,1,0,215,56,12,18,68,18
Study 4,AMERICA,USA,Site 236,Subject 2045,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 236,Subject 2046,Unplanned Visit (1),Discontinued,,,,,,,,,,20,210,0,,,,0,0,0,0,0,0,0,0,20,64,0,0,0,0,0,0,108,30,20,2,51,1
Study 4,AMERICA,USA,Site 236,Subject 2047,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,31,260,0,,,,0,0,0,0,0,0,0,0,17,69,0,0,0,0,0,0,149,39,0,20,40,19
Study 4,AMERICA,USA,Site 236,Subject 2048,Week 24 (1),Follow-Up,,,,,,,,,,32,248,0,,,,0,0,0,0,0,0,0,0,5,60,0,0,0,0,0,0,167,35,3,7,40,5
Study 4,AMERICA,USA,Site 236,Subject 2049,Unplanned Recist (1),Discontinued,,,,,,,,,,17,254,0,,,,0,0,0,0,0,0,0,0,25,95,0,0,0,0,0,0,141,41,3,2,46,0
Study 4,AMERICA,USA,Site 236,Subject 2050,Week 24 (1),Follow-Up,,,,,,,,,,27,270,0,,,,0,1,0,0,0,0,0,1,15,76,0,0,0,0,1,0,166,43,7,2,44,8
Study 4,AMERICA,USA,Site 236,Subject 2051,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,29,369,0,,,,0,0,0,0,0,0,0,0,31,89,0,0,0,0,1,0,218,48,5,24,42,35
Study 4,AMERICA,USA,Site 236,Subject 2052,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,31,361,0,,,,0,1,0,0,0,0,0,1,38,84,0,0,0,0,0,0,208,48,4,20,40,32
Study 4,AMERICA,USA,Site 236,Subject 2053,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 236,Subject 2054,Cycle 5 Week 1 (1),Survival,,,,,,,,,,8,207,0,,,,0,0,0,0,0,0,0,0,43,28,0,0,0,0,0,0,125,33,4,5,42,0
Study 4,AMERICA,USA,Site 235,Subject 2055,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 235,Subject 2056,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 235,Subject 2057,Screening,Screen Failure,,,,,,,,,,1,23,0,,,,0,0,0,0,0,0,0,0,1,6,0,4,0,0,0,0,18,3,0,0,3,0
Study 4,AMERICA,USA,Site 235,Subject 2058,EOT 2 (1),Discontinued,,,,,,,,,,39,292,0,,,,0,0,0,0,0,0,0,0,1,74,0,0,0,0,1,0,186,45,1,14,60,0
Study 4,AMERICA,USA,Site 235,Subject 2059,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 235,Subject 2060,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,36,291,0,,,,1,0,0,0,0,0,0,1,14,224,0,0,0,0,1,0,167,40,9,23,41,31
Study 4,AMERICA,USA,Site 235,Subject 2061,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 235,Subject 2062,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 235,Subject 2063,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,275,0,,,,1,0,0,0,0,0,0,1,13,82,0,0,0,0,0,0,145,42,11,28,48,33
Study 4,AMERICA,USA,Site 237,Subject 2064,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 237,Subject 2065,Screening,Screen Failure,,,,,,,,,,1,17,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,12,3,0,0,3,0
Study 4,AMERICA,USA,Site 237,Subject 2066,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,270,0,,,,0,0,0,0,0,0,0,0,2,110,0,0,0,0,2,0,168,38,4,21,43,20
Study 4,AMERICA,USA,Site 237,Subject 2067,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 237,Subject 2068,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 237,Subject 2069,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,270,0,,,,0,0,0,0,0,0,0,0,1,82,0,0,0,0,0,0,158,43,4,28,58,17
Study 4,AMERICA,USA,Site 237,Subject 2070,EOT1 (1),Survival,,,,,,,,,,30,277,0,,,,0,0,0,0,0,0,0,0,9,83,0,0,0,0,1,0,151,37,1,36,42,32
Study 4,AMERICA,USA,Site 237,Subject 2071,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,19,145,0,,,,0,1,0,0,0,0,0,1,8,113,0,0,0,0,0,0,90,22,1,10,28,5
Study 4,AMERICA,USA,Site 237,Subject 2072,EOT1 (1),Discontinued,,,,,,,,,,25,194,0,,,,0,0,0,0,0,0,0,0,3,50,0,0,0,0,1,0,123,30,0,5,35,0
Study 4,AMERICA,USA,Site 238,Subject 2073,Long term FU 1 (1),Discontinued,,,,,,,,,,31,222,0,,,,0,0,0,0,0,0,0,0,1,183,0,0,0,0,1,0,180,0,0,0,0,0
Study 4,AMERICA,USA,Site 214,Subject 2074,Long term FU 1 (1),Survival,,,,,,,,,,28,257,1,,,,3,1,0,0,0,0,0,4,1,80,0,0,0,0,0,0,206,1,0,0,1,0
Study 4,AMERICA,USA,Site 238,Subject 2075,Long term FU 5 (1),Survival,,,,,,,,,,40,337,0,,,,1,0,0,0,0,0,0,1,2,115,0,0,0,0,0,0,290,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2076,Screening,Discontinued,,,,,,,,,,1,25,0,,,,0,0,0,0,0,0,0,0,1,14,0,1,0,0,0,0,16,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2077,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2078,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,300,0,,,,0,0,0,0,0,0,0,0,2,84,0,0,0,0,0,0,252,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2079,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,273,0,,,,0,0,0,0,0,0,0,0,2,87,0,0,0,0,0,0,228,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2080,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2081,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,310,0,,,,0,0,0,0,0,0,0,0,9,79,0,0,0,0,1,0,255,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2082,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,34,329,0,,,,0,0,0,0,0,0,0,0,9,78,0,0,0,0,2,0,273,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2083,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,253,0,,,,0,0,0,0,0,0,0,0,8,72,0,0,0,0,0,0,210,0,0,0,0,0
Study 4,AMERICA,USA,Site 238,Subject 2084,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,291,0,,,,1,0,0,0,0,0,0,1,1,85,0,0,0,0,1,0,249,0,0,0,0,0
Study 4,AMERICA,USA,Site 231,Subject 2085,EOT1 (1),Discontinued,,,,,,,,,,31,242,0,,,,0,0,0,0,0,0,0,0,1,72,0,1,0,0,2,0,163,38,0,0,38,0
Study 4,AMERICA,USA,Site 238,Subject 2086,Screening,Screen Failure,,,,,,,,,,1,26,0,,,,0,0,0,0,0,0,0,0,1,10,0,2,0,0,0,0,18,0,0,0,0,0
Study 4,AMERICA,USA,Site 239,Subject 2087,30-DAY SAFETY FOLLOW UP (1),Follow-Up,,,,,,,,,,35,289,0,,,,0,0,0,4,0,0,0,4,15,237,0,1,0,0,2,0,197,41,4,0,45,0
Study 4,AMERICA,USA,Site 239,Subject 2088,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 239,Subject 2089,Screening,Screen Failure,,,,,,,,,,0,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 239,Subject 2090,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,282,0,,,,5,0,0,1,0,0,0,6,7,83,0,3,0,0,1,0,193,46,1,0,45,2
Study 4,AMERICA,USA,Site 239,Subject 2091,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,289,0,,,,1,0,0,4,7,0,0,12,6,83,0,3,0,0,2,0,198,44,0,0,40,4
Study 4,AMERICA,USA,Site 239,Subject 2092,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 239,Subject 2093,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,306,0,,,,0,0,0,1,0,0,0,1,22,91,0,4,0,0,1,0,204,51,0,0,46,5
Study 4,AMERICA,USA,Site 239,Subject 2094,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 239,Subject 2095,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,269,0,,,,0,0,0,1,0,0,0,1,12,68,0,0,0,0,0,0,182,44,0,0,39,5
Study 4,AMERICA,USA,Site 239,Subject 2096,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,31,289,0,,,,0,0,0,1,0,0,0,1,23,79,0,0,0,0,0,0,197,39,4,0,43,0
Study 4,AMERICA,USA,Site 239,Subject 2097,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,274,0,,,,1,0,0,3,0,0,0,4,24,54,0,0,0,0,1,0,165,49,12,0,52,9
Study 4,AMERICA,USA,Site 239,Subject 2098,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 240,Subject 2099,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,377,0,,,,0,0,0,0,0,0,0,0,26,310,0,0,0,0,0,0,282,1,0,0,1,0
Study 4,AMERICA,USA,Site 240,Subject 2100,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,297,0,,,,1,0,0,2,0,0,1,4,19,73,0,0,0,0,0,0,230,11,0,0,4,7
Study 4,AMERICA,USA,Site 240,Subject 2101,Screening,Discontinued,,,,,,,,,,1,40,0,,,,0,0,0,0,0,0,0,0,1,7,0,0,0,0,1,0,36,0,0,0,0,0
Study 4,AMERICA,USA,Site 240,Subject 2102,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 240,Subject 2103,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 240,Subject 2104,Screening,Screen Failure,,,,,,,,,,1,18,0,,,,0,0,0,0,0,0,0,0,0,10,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 240,Subject 2105,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 240,Subject 2106,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,256,0,,,,0,1,0,0,0,0,0,1,1,84,0,0,0,0,1,0,208,1,0,0,1,0
Study 4,AMERICA,USA,Site 240,Subject 2107,Long term FU 7 (1),Discontinued,,,,,,,,,,26,206,0,,,,0,0,0,0,0,0,0,0,37,39,0,0,0,0,0,0,185,0,0,0,0,0
Study 4,AMERICA,USA,Site 241,Subject 2108,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,289,0,,,,0,1,0,0,0,0,0,1,4,247,0,0,0,0,1,0,231,0,0,0,0,0
Study 4,AMERICA,USA,Site 241,Subject 2109,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 241,Subject 2110,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 241,Subject 2111,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,286,0,,,,0,0,0,0,0,0,0,0,1,92,0,0,0,0,1,0,233,0,0,0,0,0
Study 4,AMERICA,USA,Site 242,Subject 2112,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,24,241,0,,,,1,0,0,0,0,0,0,1,15,183,0,1,0,0,2,0,118,36,14,35,50,35
Study 4,AMERICA,USA,Site 242,Subject 2113,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,242,0,,,,0,0,0,0,0,0,0,0,18,64,0,1,0,0,0,0,98,29,2,72,62,41
Study 4,AMERICA,USA,Site 242,Subject 2114,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,31,264,0,,,,0,0,0,0,0,0,1,1,18,66,0,0,0,0,0,0,132,45,9,32,49,37
Study 4,AMERICA,USA,Site 243,Subject 2115,Post CYCLE 6 Visit 13 (1),On Trial,,,,,,,,,,40,381,0,,,,0,0,0,0,0,0,0,0,13,324,0,0,0,0,2,0,249,53,9,0,50,12
Study 4,AMERICA,USA,Site 243,Subject 2116,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,39,377,0,,,,0,0,0,0,0,0,0,0,23,142,0,0,0,0,1,0,245,55,1,0,52,4
Study 4,AMERICA,USA,Site 243,Subject 2117,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 243,Subject 2118,Post CYCLE 6 Visit 12 (1),On Trial,,,,,,,,,,38,338,0,,,,0,0,0,0,0,0,0,0,11,103,0,0,0,0,0,0,221,53,0,7,49,11
Study 4,AMERICA,USA,Site 243,Subject 2119,EOT 2 (1),Discontinued,,,,,,,,,,52,440,0,,,,0,0,0,0,0,0,0,0,16,125,0,3,0,0,3,0,285,64,8,0,68,4
Study 4,AMERICA,USA,Site 243,Subject 2120,Unplanned Visit (1),On Trial,,,,,,,,,,37,296,0,,,,0,0,0,0,0,0,0,0,8,80,0,0,0,0,1,0,190,59,0,0,43,16
Study 4,AMERICA,USA,Site 243,Subject 2121,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,328,0,,,,0,0,0,0,0,0,0,0,18,111,0,0,0,0,0,0,206,45,12,0,46,11
Study 4,AMERICA,USA,Site 243,Subject 2122,EOT 2 (1),Discontinued,,,,,,,,,,57,449,0,,,,0,0,0,0,0,0,0,0,28,108,0,0,0,0,1,0,281,69,5,2,74,2
Study 4,AMERICA,USA,Site 243,Subject 2123,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 243,Subject 2124,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,28,214,0,,,,0,0,0,0,0,0,0,0,5,53,0,0,0,0,1,0,137,36,0,0,36,0
Study 4,AMERICA,USA,Site 243,Subject 2125,Post CYCLE 6 Visit 5 (1),Discontinued,,,,,,,,,,31,328,0,,,,0,1,0,0,0,0,0,1,17,131,0,1,0,0,0,0,194,43,12,2,57,0
Study 4,AMERICA,USA,Site 243,Subject 2126,Unplanned Recist (1),Discontinued,,,,,,,,,,8,119,0,,,,0,0,0,0,0,0,0,0,8,34,0,0,0,0,2,0,74,17,0,0,17,0
Study 4,AMERICA,USA,Site 244,Subject 2127,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 244,Subject 2128,Long term FU 1 (1),Follow-Up,,,,,,,,,,35,297,0,,,,0,0,0,0,0,0,0,0,11,122,0,0,0,0,1,0,251,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2129,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,7,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2130,Post CYCLE 6 Visit 11 (1),On Trial,,,,,,,,,,37,337,0,,,,0,0,0,0,0,0,0,0,24,259,0,0,0,0,2,0,273,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2131,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2132,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,321,0,,,,0,0,0,0,0,0,0,0,7,123,0,0,0,0,1,0,270,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2133,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,311,0,,,,0,0,0,0,0,0,0,0,7,96,0,0,0,0,2,0,258,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2134,EOT1 (1),Discontinued,,,,,,,,,,10,108,0,,,,0,0,0,0,0,0,0,0,4,60,0,0,0,0,1,0,87,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2135,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2136,EOT1 (1),Discontinued,,,,,,,,,,12,131,0,,,,0,0,0,0,0,0,0,0,7,33,0,0,0,0,1,0,103,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2137,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,303,0,,,,0,0,0,0,0,0,0,0,15,102,0,0,0,0,1,0,245,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2138,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2139,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2140,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,32,315,0,,,,0,0,0,0,0,0,0,0,19,120,0,0,0,0,1,0,228,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2141,Cycle 1 Week 3_CO (1),On Trial,,,,,,,,,,42,331,0,,,,6,0,0,0,0,0,0,6,21,85,0,0,0,0,2,0,274,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2142,EOT1 (1),Discontinued,,,,,,,,,,30,280,0,,,,0,0,0,0,0,0,0,0,13,99,0,0,0,0,0,0,211,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2143,EOT1 (1),Discontinued,,,,,,,,,,31,232,0,,,,0,0,0,0,0,0,0,0,3,56,0,0,0,0,0,0,193,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2144,Long term FU 2 (1),Follow-Up,,,,,,,,,,34,309,0,,,,0,0,0,0,0,0,0,0,23,109,0,0,0,0,0,0,236,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2145,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,34,303,0,,,,0,0,0,0,0,0,0,0,9,114,0,0,0,0,0,0,245,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2146,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,274,0,,,,0,0,0,0,0,0,0,0,3,78,0,0,0,0,1,0,230,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2147,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,43,326,0,,,,0,0,0,0,0,0,0,0,13,81,0,0,0,0,0,0,258,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2148,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,32,320,0,,,,0,0,0,0,0,0,0,0,20,126,0,0,0,0,0,0,251,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2149,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,284,0,,,,0,0,0,0,0,0,0,0,12,85,0,0,0,0,2,0,232,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2150,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,33,261,0,,,,0,0,0,0,0,0,0,0,7,80,0,0,0,0,0,0,212,0,0,0,0,0
Study 4,AMERICA,USA,Site 245,Subject 2151,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 246,Subject 2152,EOT1 (1),Discontinued,,,,,,,,,,16,135,0,,,,1,0,0,0,0,0,0,1,1,110,0,0,0,0,0,0,81,20,2,2,23,1
Study 4,AMERICA,USA,Site 246,Subject 2153,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,10,3,0,0,3,0
Study 4,AMERICA,USA,Site 246,Subject 2154,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,11,3,0,0,3,0
Study 4,AMERICA,USA,Site 246,Subject 2155,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,253,0,,,,0,0,0,0,0,0,0,0,3,80,0,0,0,0,0,0,127,36,11,34,48,33
Study 4,AMERICA,USA,Site 246,Subject 2156,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,251,0,,,,0,0,0,0,0,0,0,0,3,80,0,0,0,0,0,0,132,46,1,28,43,32
Study 4,AMERICA,USA,Site 246,Subject 2157,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,276,0,,,,1,0,0,0,0,0,0,1,3,188,0,0,0,0,0,0,156,48,3,25,41,35
Study 4,AMERICA,USA,Site 247,Subject 2158,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,35,287,0,,,,0,0,0,0,0,0,0,0,7,232,0,0,0,0,1,0,192,43,0,0,43,0
Study 4,AMERICA,USA,Site 247,Subject 2159,Week 24 (1),Follow-Up,,,,,,,,,,57,348,0,,,,0,0,0,0,0,0,0,0,1,57,0,0,0,0,0,0,227,63,0,0,63,0
Study 4,AMERICA,USA,Site 247,Subject 2160,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 248,Subject 2161,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 248,Subject 2162,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 248,Subject 2163,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,2,0,0,1,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 249,Subject 2164,EOT1 (1),Follow-Up,,,,,,,,,,34,356,0,,,,4,1,0,0,0,0,0,5,40,267,0,1,0,0,0,0,262,3,0,0,3,0
Study 4,AMERICA,USA,Site 249,Subject 2165,Unplanned Visit (1),Discontinued,,,,,,,,,,27,213,0,,,,0,0,0,0,0,0,0,0,7,50,0,0,0,0,0,0,172,0,0,0,0,0
Study 4,AMERICA,USA,Site 250,Subject 2166,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 250,Subject 2167,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,14,0,0,0,0,0
Study 4,AMERICA,USA,Site 250,Subject 2168,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,37,315,0,,,,0,0,0,0,0,0,0,0,6,264,0,0,0,0,2,0,251,7,0,0,7,0
Study 4,AMERICA,USA,Site 250,Subject 2169,Post CYCLE 6 Visit 10 (1),On Trial,,,,,,,,,,35,307,0,,,,8,3,0,0,0,0,0,11,1,121,0,0,0,0,3,0,247,2,0,0,2,0
Study 4,AMERICA,USA,Site 250,Subject 2170,Screening,Screen Failure,,,,,,,,,,1,11,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 250,Subject 2171,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,286,0,,,,1,0,0,0,0,0,0,1,1,90,0,0,0,0,1,0,232,1,0,0,1,0
Study 4,AMERICA,USA,Site 250,Subject 2172,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 251,Subject 2173,Unplanned Visit (1),Screen Failure,,,,,,,,,,1,21,0,,,,0,0,0,0,0,0,0,0,1,4,0,3,0,0,1,0,15,3,0,0,3,0
Study 4,AMERICA,USA,Site 251,Subject 2174,Screening,Screen Failure,,,,,,,,,,1,13,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,8,3,0,0,3,0
Study 4,AMERICA,USA,Site 251,Subject 2175,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 251,Subject 2176,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,7,3,0,0,3,0
Study 4,AMERICA,USA,Site 251,Subject 2177,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,341,0,,,,4,0,0,0,0,0,0,4,15,71,0,1,0,0,0,0,174,51,7,53,49,62
Study 4,AMERICA,USA,Site 251,Subject 2178,Unplanned Visit (9),On Trial,,,,,,,,,,31,325,0,,,,3,0,0,5,0,0,0,8,5,78,0,0,0,0,0,0,175,49,16,25,47,43
Study 4,AMERICA,USA,Site 251,Subject 2179,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,297,0,,,,0,0,0,3,0,0,0,3,3,79,0,0,0,0,0,0,168,39,20,12,39,32
Study 4,AMERICA,USA,Site 251,Subject 2180,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,11,3,0,0,3,0
Study 4,AMERICA,USA,Site 251,Subject 2181,Long term FU 4 (1),Survival,,,,,,,,,,12,103,0,,,,0,0,0,1,0,0,0,1,7,24,85,0,0,0,0,0,61,17,3,6,21,5
Study 4,AMERICA,USA,Site 251,Subject 2182,Screening,Screen Failure,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,6,2,0,0,2,0
Study 4,AMERICA,USA,Site 252,Subject 2183,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,340,0,,,,0,0,0,0,0,0,0,0,4,299,0,0,0,0,0,0,266,0,0,0,0,0
Study 4,AMERICA,USA,Site 252,Subject 2184,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 252,Subject 2185,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,320,1,,,,0,0,0,0,0,0,0,0,1,125,0,0,0,0,0,0,245,0,0,0,0,0
Study 4,AMERICA,USA,Site 252,Subject 2186,Week 24 (1),Follow-Up,,,,,,,,,,33,286,0,,,,0,0,0,0,0,0,0,0,1,101,0,0,0,0,2,0,228,0,0,0,0,0
Study 4,AMERICA,USA,Site 252,Subject 2187,Post CYCLE 6 Visit 6 (1),On Trial,,,,,,,,,,32,265,0,,,,0,0,0,0,0,0,0,0,1,85,0,0,0,0,0,0,225,0,0,0,0,0
Study 4,AMERICA,USA,Site 252,Subject 2188,Long term FU 6 (1),Follow-Up,,,,,,,,,,25,191,0,,,,0,0,0,0,0,0,0,0,2,68,0,0,0,0,0,0,163,0,0,0,0,0
Study 4,AMERICA,USA,Site 252,Subject 2189,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 253,Subject 2190,Screening,Discontinued,,,,,,,,,,1,10,0,,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,9,0,0,0,0,0
Study 4,AMERICA,USA,Site 253,Subject 2191,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 253,Subject 2192,Unplanned Visit (1),Follow-Up,,,,,,,,,,33,245,0,,,,0,0,0,0,0,0,0,0,14,191,4,0,0,0,0,0,203,0,0,0,0,0
Study 4,AMERICA,USA,Site 253,Subject 2193,Week 24 (1),Follow-Up,,,,,,,,,,34,300,0,,,,1,0,0,0,0,0,0,1,5,90,2,0,0,0,2,0,257,0,0,0,0,0
Study 4,AMERICA,USA,Site 253,Subject 2194,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,235,0,,,,0,0,0,0,0,0,0,0,1,58,1,0,0,0,1,0,199,0,0,0,0,0
Study 4,AMERICA,USA,Site 254,Subject 2195,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,33,261,0,,,,0,0,0,0,0,0,0,0,8,216,11,0,0,0,1,0,151,41,11,15,45,22
Study 4,AMERICA,USA,Site 254,Subject 2196,Week 48 (1),Survival,,,,,,,,,,30,257,0,,,,0,0,0,0,0,0,0,0,4,58,6,0,0,0,5,0,150,41,2,21,62,2
Study 4,AMERICA,USA,Site 254,Subject 2197,Long term FU 1 (1),Follow-Up,,,,,,,,,,34,289,0,,,,5,0,0,0,0,0,0,5,6,97,11,0,0,0,0,0,158,36,16,36,43,45
Study 4,AMERICA,USA,Site 254,Subject 2198,Week 24 (1),Discontinued,,,,,,,,,,30,268,0,,,,0,0,0,0,0,0,0,0,16,70,11,0,0,0,0,0,155,39,2,11,51,1
Study 4,AMERICA,USA,Site 254,Subject 2199,EOT1 (1),Discontinued,,,,,,,,,,2,56,0,,,,0,0,0,0,0,0,0,0,3,20,4,0,0,0,0,0,38,7,0,0,7,0
Study 4,AMERICA,USA,Site 255,Subject 2200,Unplanned Visit (34),Discontinued,,,,,,,,,,28,424,0,,,,0,0,0,0,0,0,0,0,1,357,0,28,0,0,0,0,358,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2201,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2202,Unplanned Visit (39),On Trial,,,,,,,,,,35,526,0,,,,0,0,0,0,0,0,0,0,1,108,0,24,0,0,0,0,440,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2203,Screening,Screen Failure,,,,,,,,,,0,10,0,,,,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2204,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2205,Unplanned Visit (49),On Trial,,,,,,,,,,34,621,0,,,,2,0,0,0,0,0,0,2,1,129,0,21,0,1,1,0,514,1,0,0,1,0
Study 4,AMERICA,USA,Site 255,Subject 2206,Unplanned Visit (40),On Trial,,,,,,,,,,34,562,0,,,,0,0,0,0,0,0,0,0,1,109,0,22,0,0,3,0,473,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2207,EOT1 (1),Discontinued,,,,,,,,,,11,157,0,,,,0,0,0,0,0,0,0,0,1,22,0,10,0,1,3,0,128,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2208,30-DAY SAFETY FOLLOW UP_CO (1),Discontinued,,,,,,,,,,42,617,0,,,,0,0,0,0,0,0,0,0,1,96,0,22,0,0,5,0,501,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2209,Unplanned Visit (42),On Trial,,,,,,,,,,35,570,0,,,,0,0,0,0,0,0,0,0,1,103,0,5,0,0,1,0,473,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2210,Unplanned Visit (35),On Trial,,,,,,,,,,34,534,0,,,,1,0,0,0,0,0,0,1,1,132,0,18,0,0,0,0,438,0,0,0,0,0
Study 4,AMERICA,USA,Site 212,Subject 2211,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,32,466,0,,,,0,0,0,0,0,0,0,0,8,94,0,18,0,0,1,0,329,54,0,0,44,10
Study 4,AMERICA,USA,Site 255,Subject 2212,Week 24 (1),Follow-Up,,,,,,,,,,33,551,0,,,,0,0,0,0,0,0,0,0,3,85,0,20,0,0,0,0,461,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2213,Unplanned Visit (37),On Trial,,,,,,,,,,35,532,0,,,,0,0,0,0,0,0,0,0,1,103,0,12,0,0,0,0,446,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2214,Screening,Screen Failure,,,,,,,,,,1,14,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2215,Post CYCLE 6 Visit 2 (1),Discontinued,,,,,,,,,,28,409,0,,,,0,0,0,0,0,0,0,0,1,75,0,8,0,0,1,0,330,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2216,Unplanned Visit (36),On Trial,,,,,,,,,,34,537,0,,,,0,1,0,0,0,0,0,1,9,127,0,5,0,0,1,0,434,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2217,Unplanned Visit (30),Discontinued,,,,,,,,,,17,344,0,,,,0,0,0,0,0,0,0,0,1,58,0,0,0,0,2,0,276,0,0,0,0,0
Study 4,AMERICA,USA,Site 255,Subject 2218,Unplanned Visit (30),On Trial,,,,,,,,,,32,476,0,,,,0,0,0,0,0,0,0,0,12,93,0,0,0,0,3,0,401,0,0,0,0,0
Study 4,AMERICA,USA,Site 256,Subject 2219,Post CYCLE 6 Visit 9 (1),On Trial,,,,,,,,,,36,317,0,,,,0,0,0,0,0,0,0,0,2,268,5,0,0,0,2,0,260,0,0,0,0,0
Study 4,AMERICA,USA,Site 256,Subject 2220,Screening,Screen Failure,,,,,,,,,,1,15,0,,,,0,0,0,0,0,0,0,0,1,4,0,1,0,0,1,0,13,0,0,0,0,0
Study 4,AMERICA,USA,Site 256,Subject 2221,Screening,Screen Failure,,,,,,,,,,1,16,0,,,,0,0,0,0,0,0,0,0,0,4,1,0,0,0,0,0,15,0,0,0,0,0
Study 4,AMERICA,USA,Site 256,Subject 2222,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,275,0,,,,0,0,0,0,0,0,0,0,17,83,10,0,0,0,1,0,219,0,0,0,0,0
Study 4,AMERICA,USA,Site 257,Subject 2223,Post CYCLE 6 Visit 8 (1),On Trial,,,,,,,,,,35,321,0,,,,0,0,0,0,0,0,0,0,18,265,21,0,0,0,1,0,250,0,0,0,0,0
Study 4,AMERICA,USA,Site 257,Subject 2224,Screening,Screen Failure,,,,,,,,,,1,12,0,,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,10,0,0,0,0,0
Study 4,AMERICA,USA,Site 257,Subject 2225,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,305,0,,,,0,0,0,4,1,0,0,5,32,90,21,1,0,0,0,0,236,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2226,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,30,255,0,,,,0,0,0,0,0,0,0,0,1,214,14,0,0,0,0,0,192,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2227,Week 24 (1),Discontinued,,,,,,,,,,29,217,0,,,,0,0,0,0,0,0,0,0,1,52,7,1,0,0,0,0,174,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2228,Post CYCLE 6 Visit 9 (1),Survival,,,,,,,,,,35,366,0,,,,0,0,0,0,0,0,0,0,1,155,37,0,0,0,0,0,294,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2229,Week 48 (1),Survival,,,,,,,,,,33,347,0,,,,0,0,0,0,0,0,0,0,1,164,45,0,0,0,1,0,255,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2230,30-DAY SAFETY FOLLOW UP (1),Discontinued,,,,,,,,,,31,244,0,,,,0,0,0,0,0,0,0,0,0,86,18,0,0,0,0,0,192,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2231,Screening,Screen Failure,,,,,,,,,,1,9,0,,,,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,8,0,0,0,0,0
Study 4,AMERICA,USA,Site 258,Subject 2232,Post CYCLE 6 Visit 7 (1),On Trial,,,,,,,,,,34,327,0,,,,0,0,0,0,0,0,0,0,1,150,35,0,0,0,0,0,243,0,0,0,0,0
,,,169,1554,Total:,,,,,,,,,,,38214,343264,39,,,,447,115,0,194,119,0,19,894,12009,123627,9581,817,,,,,258872,19606,1776,Site 1806,19779,4833
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
